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Abstract 
The class kinetoplastida include parasites responsible for devastating diseases like 
African sleeping sickness, Chagas’s disease and Leishmaniases, mainly effecting 
people in the developing world. Current treatments are highly toxic and inefficient, 
leading to an urgent need of novel anti-parasitic compounds. This thesis focuses on 
the structural characterisation of potential drug targets against these parasites, 
namely adenosine kinase from Trypanosoma brucei (TbAK), thymidine kinases from 
T. brucei (TbTK) and Leishmania major (LmTK) and the leucyl aminopeptidases from 
T. brucei (TbLAP-A), T. cruzi (TcLAP-A) and L. major (LmLAP-A).   
Structures of TbAK were solved in two conformations, open (apo) and closed (in 
complex with adenosine and ADP), both to 2.6 Å. Comprised of a big α/β-domain 
and a small lid domain, the structures confirm the large conformational change of 
the lid domain upon substrate binding. The structures of C-terminally truncated 
versions of LmTK and TbTK were determined as ligand-bound complexes with 
resolutions up to 2.4 Å and 2.2 Å, respectively. They show high similarity to 
structures of homologues in the PDB. The structures solved in this thesis give 
valuable information about ligand binding and aid rational drug design. 
Leucyl aminopeptidase (LAP-A) was evaluated as a potential drug target in T. brucei 
parasites. It is not essential for T. brucei parasites grown in vitro, shown by 
generation and analysis of LAP-A-depleted parasites. Although this does not support 
LAP-A as a drug target in T. brucei, no conclusions can be drawn about the potential 
in T. cruzi and L. major. Several structures of the LAP-As were solved, the highest 
resolution ones to 2.3 Å, 2.3 Å and 2.5 Å for TbLAP-A, TcLAP-A and LmLAP-A, 
respectively. These enzymes are hexameric and show the typical two-domain 
architecture of M17 LAPs. Although the physiological function remains elusive, the 
work in this thesis provides a firm basis for future studies. 
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into the rabbit and the extraction of the blood were done in collaboration 
with the staff of the Instituto de Parasitologia y Biomedicina “Lopez-Neyra” 
in Granada, Spain.  
 The data of ESI-MS mentioned in Chapter 3 and SEC-MALLS in Chapter 5 
were collected by the staff of the Technology Facility at the University of 
York.  
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Chapter 1 Introduction 
1.1 Neglected tropical diseases  
Neglected tropical diseases (NTDs) are a medically diverse group mainly affecting 
people in the low-income populations in the developing world. They have been 
largely overlooked partly due to general disregard of the developing world and 
focus on the big three infectious diseases: HIV/AIDS, tuberculosis and malaria 
(Feasey et al., 2010). NTDs defined by the World Health Organisation (WHO) include 
devastating diseases caused by a variety of different pathogens, including viruses 
(e.g. dengue/severe dengue and rabies), bacteria (e.g. buruli ulcer, leprosy, 
trachoma and yaws), protozoa (Chagas’ disease, Human African trypanosomiasis 
and Leishmaniases) and helminths (e.g. cysticercosis/taeniasis, dracunculiasis, 
echinococcosis, foodborne trematodiases, lymphatic filariasis, onchocerciasis, 
schistosomiasis and soil-transmitted helminthiases). Recently, the problem of NTDs 
has been addressed more extensively, e.g. by foundation of a specific department 
within the World Health Organisation (World Health Organisation, 2014b), the 
Global Network for Neglected Tropical Diseases Control at the Sabin Vaccine 
institute (http://www.globalnetwork.org) and the open access journal PLoS 
Neglected Tropical Diseases (http://www.plosntds.org).  
  
1.2 Kinetoplastids and the TriTryps 
Kinetoplastids are unicellular flagellate protozoa of the class kinetoplastida. They 
have either one or two flagella and therefore are divided into two groups, the 
uniflagellate trypanosomatida and the biflagellate bodonina. Some kinetoplastids 
are parasitic, targeting humans, animals or plants, while others are free-living, 
feeding on bacteria. Alongside the universal eukaryotic organelles, e.g. nucleus, 
mitochondrion, endoplasmic reticulum and Golgi apparatus and flagella, they also 
show many unique morphological features (Figure 1-1).  
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Figure 1-1: Schematic representation of kinetoplastid cell morphology. 
 
One of the features is the kinetoplast, which contains the extensive genome of the 
single mitochondrion in the form of circular DNA molecules, structural proteins and 
polymerases. It is situated at the base of the flagellum associated with the flagella’s 
basal body. The flagellum, containing a structure called the para-flagellar rod, starts 
from the flagellar pocket, the only site of endo- and exocytosis, and is sometimes 
attached to the cell body forming an undulating membrane. Kinetoplastids have 
only a single disc-shaped lysosome instead of the multiple lysosomes seen in other 
eukaryotes, and glycolysis takes place in specialised organelles called glycosomes. 
The cytoskeleton comprises mainly microtubules forming a regular structure under 
the cell’s surface, the sub-pellicular microtubule array.  
Parasitic kinetoplastids often have complex life cycles involving one or more hosts 
and show several different morphological forms, depending on their life cycle stage, 
e.g. trypomastigotes, epimastigotes, promastigotes and amastigotes (Figure 1-2). 
The different morphological forms can be distinguished by the length and 
attachment of the flagellum and by the position of the kinetoplast relative to the 
nucleus. In addition, these forms have differences in their metabolism adapting to 
their environment.   
 19 
 
Figure 1-2: Positioning of nucleus, kinetoplast and flagellum.  
Shown are the organelle positions in the different morphological forms during the kinetoplast life cycle. kDNA 
= kinetoplast in purple, FP = flagellar pocket in orange. Figure from (Field & Carrington, 2009). 
 
The class kinetoplastida contains parasitic species causing devastating diseases in 
humans. The term “TriTryps” describes the human infectious kinetoplastida 
Trypanosoma brucei, causative agent of African sleeping sickness, T. cruzi, 
responsible for Chagas’ disease, and Leishmania spp., causing leishmaniases. 
Genome sequences, information on initial proteomic studies and some biological 
data can be found in a specialised database, TriTrypDB (Aslett et al., 2010). 
 
1.3 Trypanosoma brucei 
T. brucei has the typical morphological features defining the kinetoplastida. There 
are three subspecies, T. b. brucei, T. b. gambiense and T. b. rhodesiense, which are 
morphologically almost indistinguishable, but vector preferences, drug sensitivity 
and the position of the nucleus in some T. b. rhodesiense cells (further towards the 
posterior end) made it possible to differentiate T. b. gambiense and 
T. b. rhodesiense (Gibson, 1986). Except for human infectivity, distinguishing 
T. b. brucei and T. b. rhodesiense is more difficult because of their similarity in 
endemicity and animal hosts and the high level of genetic heterogeneity in 
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T. b. rhodesiense from different geographical areas. The geographical distribution of 
the T. brucei subspecies is distinct and determined by their preferred insect vector 
species. T. b. gambiense and its main vector Glossina palpalis are endemic in 
western and central Africa (Figure 1-3), close to rivers and lakes. It is a mainly 
anthroponotic parasite with little involvement of animal vectors. T. b. rhodesiense 
and its main vector G. morsitans on the other hand are endemic in east Africa 
(Figure 1-4), preferentially in dry bush and woodland. Unlike T. b. gambiense it is a 
zoonotic disease, mainly infecting wild and domestic animals and being transmitted 
from animals to humans. T. b. brucei shares its main insect vector and therefore 
endemic area with T. b. rhodesiense.  
 
 
Figure 1-3: Geographic endemicity of HAT caused by T. brucei gambiense, 2013. 
The colour (green) indicating the number of cases reported in 2013. Figure modified from WHO (World Health 
Organisation, 2013). 
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Figure 1-4: Geographic endemicity of HAT caused by T. brucei rhodesiense, 2013. 
The colour (green) indicating the number of cases reported in 2013. Figure modified from WHO (World Health 
Organisation, 2013). 
 
While T. b. brucei cannot infect humans because of the presence of the serum 
complexes TLF-1 and TLF-2 (named from trypanosome lytic factors) containing the 
trypanolytic protein APOL1, the other two subspecies developed resistance to 
APOL1/TLF becoming human infective (Raper et al., 2001). In T. b. rhodesiense a 
single gene, the human-serum-resistance-associated (SRA) gene, which encodes a 
truncated version of a variant surface glycoprotein, confers resistance (De Greef & 
Hamers, 1994, Xong et al., 1998). Genetic exchange can occur between 
T. b. rhodesiense and T. b. brucei (Gibson, 1989) making it possible that the SRA 
gene may be transferred to other not-yet resistant T. b. brucei resulting in 
T. b. rhodesiense with other genetic backgrounds. This supports the definition of 
T. b. rhodesiense as a simple host-range variant of T. b. brucei (Tait et al., 1985). In 
T. b. gambiense multiple factors play a role in resistance. First, a gene called 
T. gambiense-specific glycoprotein (TgsGP) mediates the APOL1/TLF resistance 
(Uzureau et al., 2013), and second, differences in the TLF-1 receptor TbHpHbR in 
T. b. gambiense were found to be significant (Vanhollebeke et al., 2008). 
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1.3.1 T. brucei cell cycle 
As in other eukaryotes, the cell cycle of T. brucei, Figure 1-5 (reviewed in (Ooi & 
Bastin, 2013), is divided into G1/G0-, S-, M- and G2-phases and DNA replication, 
segregation of the organelles and cytokinesis are taking place at specific time 
points. 
 
Figure 1-5: Cell cycle of procyclic T. brucei. 
 (I.) G1/G0-phase with 1N1K(1F). (II.) S-phase with 1N1K(1F). (III.) G2-phase with 1N2K(2F). (IV.) M-phase with 
2N2K(2F). (V.) Cytokinesis.  N = nucleus, K = kinetoplast, F = flaggelum, BB = basal body. More details in the 
main text. Figure modified from (Ooi & Bastin, 2013). 
 
Single cells are in G1-phase (Figure 1-5 I.), called G0 in cell cycle arrested cells, which 
is characterised by the presence of one nucleus (N), with one copy of the genome, 
one kinetoplast (K) and one flagellum (F) and therefore referred to as 1N1K(1F). 
Cells enter the S-phase (Figure 1-5 II.) with the initiation of DNA replication in the 
nucleus and the kinetoplast, both changing shape as a result of the increased DNA 
content. The basal body (BB) of the flagellum matures and forms a daughter basal 
body during this phase. The end of the S-phase and beginning of G2-phase (Figure 
1-5 III.) are marked by the presence of one nucleus, with more than one copy of the 
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genome, two kinetoplasts and two flagella attached to one another, referred to as 
1N2K(2F). When DNA replication and nuclear segregation are complete, the cells 
enter the M-phase (Figure 1-5 IV.), with two nuclei, two kinetoplasts and two 
flagella, 2N2K(2F). This is followed by cytokinesis starting from the anterior end of 
the cell following the longitudinal axis (Figure 1-5 V.) and ultimately resulting in two 
daughter cells. 
 
1.3.2 T. brucei life cycle 
T. brucei has a complex life cycle involving differentiation processes within its 
human host and the tsetse fly (Glossina spp.) vector (Figure 1-6, reviewed in 
(Vickerman, 1985, Ooi & Bastin, 2013). All three subspecies show the same life cycle 
stages.  
 
Figure 1-6: Life cycle stages of T. brucei. 
I. Metacyclic trypomastigotes, II. Long slender trypomastigotes (= bloodstream form), III. Short stumpy 
trypomastigotes, IV. Procyclic trypomastigotes, V-VII. Epimastigote forms. More details in the main text. 
 
At the moment of infection by the bite of the tsetse fly, T. brucei parasites are in 
their metacyclic trypomastigote form (Figure 1-6 I.), showing the classic 
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trypomastigote morphology with the nucleus in the centre of the cell, the 
kinetoplast at the posterior end and the flagellum starting at the posterior end 
being attached along the cell body forming an undulating membrane. As they are 
extracellular in the bloodstream (Figure 1-6 II.), exposed to the mammalian host’s 
immune system, they undergo antigenic variation in the form of expression of one 
of the many variable surface glycoproteins (VSGs) encoded in their genome. The 
blood contains high levels of glucose, so the parasites’ metabolism is fuelled mainly 
by glycolysis and no oxidative phosphorylation within the mitochondrion occurs. 
Therefore, the mitochondrion shows only little electron transport activity and lacks 
the typical cristae. While in the bloodstream the parasites are in a long slender form 
and replicate asexually by binary fission along the long axis of the cell. They 
differentiate into short, stumpy parasites (Figure 1-6 III.), which do not replicate and 
reactivate the mitochondria in preparation for the transfer into the tsetse fly. Some 
of the parasites cross the blood brain barrier, which marks the second stage of the 
disease. The remaining parasites in the blood stream are ready to be taken up by a 
tsetse fly. 
When a tsetse fly ingests a blood meal, the bloodstream trypomastigotes within the 
fly’s midgut differentiate into procyclic trypomastigotes (Figure 1-6 IV.). These 
parasites do not express VSGs and due to the low glucose levels within the fly’s 
midgut, the parasites switch to an amino acid-based metabolism, showing high 
levels of oxidative phosphorylation within the mitochondrion. The main energy 
source at that stage is proline. Cristae develop in the mitochondrion and its electron 
transport activity is high. Procyclic parasites have a long, slender shape and 
replicate by binary fission. These parasites penetrate the ectoperitrophic space 
changing morphologically to become longer and the mitochondrion regresses.  
Reaching the salivary glands, probably by following the digestive system backwards, 
the parasites differentiate into epimastigotes (Figure 1-6 V.), attaching to the 
epithelial cells via their flagella, which are starting from the middle of the cell, 
forming just a short undulating membrane. The nucleus is centrally located and the 
kinetoplast is closer, usually anterior, to the nucleus. Epimastigotes replicate further 
and eventually differentiate, via two intermediate stages (Figure 1-6 VI-VII.), into 
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mature metacyclic trypomastigotes. These metacyclics are not attached to the 
epithelium, show VSG expression and the mitochondrion is acristate. During the 
next blood meal, the tsetse fly transfers these parasites to the new host. 
While in the tsetse fly T. brucei can undergo meiotic stages, exchanging genetic 
information between different parasites (Peacock et al., 2008, Peacock et al., 2011). 
In the laboratory two T. brucei forms are cultured, the slender metacyclic 
trypomastigote (Figure 1-6 II.), often referred to as bloodstream form, and the 
procyclic trypomastigote form (Figure 1-6 IV.). Different laboratory strains are used, 
some of which can easily differentiate, while others do not. 
 
1.3.3 Antigenic variation  
T. brucei is a parasite residing in the blood stream of its mammalian host, which 
exposes it to the host’s immune system. The immune system raises antibodies 
against the parasites, leading to their elimination. This results in strong fluctuation 
of parasitaemia during the course of an infection and the parasites in successive 
peaks display variant antigenic types (VATs). These VATs are the result of the 
expression of variant surface glycoproteins (VSGs), covering the parasite’s surface 
as a thick coat and therefore providing the only antigen exposed to the host’s 
immune system (Horn & McCulloch, 2010). The VSGs have a highly variable N-
terminal domain, which covers the conserved C-terminal domain, and a GPI anchor 
attaches it to the parasite’s plasma membrane. 
The genome of T. brucei encodes for more than 1000 different VSGs, located mainly 
in subtelomeric regions, but also close to the telomeres of minichromosomes and 
very few at expression sites. Only one of these VSGs is expressed at a time by an 
individual parasite, so the host’s immune system only raises antibodies against that 
one. The VSG expression is switched to another gene by in situ activation, telomere 
exchange or gene conversion. In situ activation occurs mainly in the beginning of an 
infection with the expression site of the original VSG being switched off, while a 
new one is switched on.  In telomere exchange the telomere of the actively 
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expressed VSG is exchanged for an inactive one or one of the minichromosome and 
in case of the gene conversion an inactive VSG is copied into the site of the active 
VSG replacing it. Additional to the VSG genes, the T. brucei genome encodes for 
pseudogenes of VSGs containing frame shifts errors and in frame stop-codons. 
These sites undergo recombination resulting in novel and functional VSGs, which 
can be activated by gene conversion.  
Switching expression of the VSG hides the parasites from the host’s immune 
response developed against the previous VSG and the parasites with the new VSG 
multiply until the immune system raises a response against that one. 
 
1.3.4 Human African Trypanosomiasis (HAT) 
HAT, also called African sleeping sickness, is caused by T. brucei parasites and is 
ultimately fatal if left untreated. The disease was nearly eliminated by the late 
1960s through systematic screening, treatment, patient follow-up and partial vector 
control, but negligence in subsequent years led to re-emergence of HAT in the 
1980s (Simarro, Franco, Cecchi, et al., 2012). After a big increase in the number of 
cases during the 1990s, the number of infections has been reduced over the past 20 
years and the WHO estimates approximately 30 000 current infections with 7139 
new cases reported in 2010 (World Health Organisation, 2014a). In addition to 
being a threat to human populations in endemic areas, T. brucei together with 
T. vivax and T. congolense, have big impacts on agriculture, causing a disease called 
nagana in cattle and other domestic and wild animals. 
The clinical course of HAT is divided in two stages. During the first, haemolymphatic, 
stage, the parasites are found in the peripheral circulation, causing fever, strong 
headache, fatigue, aching muscles and joints, irritability and swollen lymph nodes 
among other symptoms (Centers for Disease Control and Prevention, 2014b). The 
symptoms are very similar to malaria and often misdiagnosed as such. In travellers 
the symptoms differ from people from endemic countries (Brun et al., 2010). 
Travellers suffer high fever, severe haematological disorders, impaired kidney 
function, electrolyte disturbances, high concentrations of C-reactive protein and 
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liver enzymes, and a chancre at the site of the infective bite and trypanosomal rash 
are seen more frequently. In the second, or encephalitic, stage the parasites cross 
the blood brain barrier, entering the central nervous system, and patients suffer 
progressive confusion, changes in personality and other neurologic disorders, like 
alteration of the sleeping pattern with sleepiness in daytime and sleep disturbance 
at night. Depending on the subspecies the rate of disease onset and progression 
differs, but generally the symptoms are very similar for both subspecies. Coma and 
death will follow, if the disease remains untreated. 
T. brucei rhodesiense is the causative agent of the acute form of HAT, which 
progresses rapidly. First symptoms occur within 1-3 weeks after the infective bite, 
the symptoms are severe and death follows months later, unless the disease is 
treated. These parasites, while mainly human infective, also infect domestic and 
wild animals, which serve as important reservoirs.  
T. brucei gambiense causes the chronic form of HAT, with initially mild symptoms 
and which progresses slowly. First symptoms can occur several weeks or months 
after the infective bite and involvement of the central nervous system becomes 
apparent after 1-2 years. In most cases, the untreated disease kills within 3 years, 
but in some it can take up to 6-7 years before death. This parasite is anthroponotic 
and domestic and wild animals are rarely infected. In this case infective humans are 
the main reservoir. 
 
1.3.5 Diagnosis and Current treatment of HAT 
The clinical manifestations of HAT, especially during the first stage, are not 
sufficiently specific for diagnosis, so laboratory methods have to be applied. Most 
diagnoses are based on the detection of the parasites in the blood or lymph node 
aspirates via microscopic techniques (Centers for Disease Control and Prevention, 
2014b). To address low parasitaemia in T. brucei gambiense infections and increase 
the chance of finding the parasite in the blood samples, blood concentration 
techniques are used. T. brucei rhodesiense infections show higher parasitaemia and 
detection of parasites is easier. Serological tests, e.g. the card agglutination test for 
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trypanosomiasis (CATT), immunofluorescence and enzyme-linked immunosorbent 
assays (ELISAs) are available for detection of T. brucei gambiense, but not for 
T. brucei rhodesiense (Brun et al., 2010). None of the diagnostic techniques is 100 % 
sensitive, which requires physicians to pay close attention to clinical symptoms and 
the possibility of exposure. 
After detection of parasites in the patient, the disease stage needs to be 
determined. For this the cerebro-spinal fluid is examined for the presence of 
parasites or more than five white blood cells per μL. Parasite invasion of the central 
nervous system increases the complications and different drugs have to be used for 
the treatment of second stage HAT compared to the first stage. 
Drugs currently available for treatment of HAT (Figure 1-7) are highly toxic inducing 
a variety of severe side effects. Additionally, limited efficiency, high costs, long and 
complicated administration regimens and inadequate availability worsens the 
situation. The mechanism of action (MOA) of some of these drugs is poorly 
understood.  
 
 
Figure 1-7: Anti-parasitic compounds used for treatment of HAT.  
Details in the main text. Figure made with MarvinSketch (ChemAxon). 
 
 29 
First stage HAT is treated with one of two drugs, either pentamidine or suramin. 
Treatment of second stage HAT is more complicated as the drugs are required to 
cross the blood brain barrier. The available drugs for second stage HAT are 
melarsoprol and eflornithine. Combinational therapy of eflornithine with 
nifurtimox, a drug registered for treatment of Chagas’ disease, shows an increased 
efficiency and fewer side effects compared to eflornithine monotherapy (Simarro, 
Franco, Diarra, et al., 2012).  
 
1.4 Trypanosoma cruzi 
T. cruzi, the causative agent of Chagas’ disease in humans, is endemic in Central and 
South America (Figure 1-8).  
 
 
Figure 1-8: Geographic endemicity of Chagas’ disease, 2006-2009.  
The size of the circle indicating the number of cases reported, blue indicating endemicity. The data are based 
on official estimates and status of vector transmission by the WHO (World Health Organisation, 2013).  
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The T. cruzi genome shows a high degree of diversity and multiplicity. There are six 
discrete typing units (DTU), called TcI-TcVI, which show different geographical and 
environmental distributions (reviewed in (Zingales et al., 2012). T. cruzi parasites 
are transmitted to animals and humans mostly through their insect vector, the 
triatomine or reduviid bug, but also congenital, through blood transfusions, organ 
transplants or through contaminated food.  
Depending on the vector habitat two kinds of transmission cycles are distinguished, 
the sylvatic and the domestic. In the sylvatic transmission cycle T. cruzi rarely 
encounters human hosts and mainly infects animals, while the domestic 
transmission cycle occurs when the insect vector lives in close proximity to human 
habitation and therefore the rate of infection in humans is much higher. The 
transmission through the triatomine bug is very inefficient, but the bugs often live 
in poor housing with adobe walls, thatched roofs and animal stalls close to the 
house, so the ineffective transmission is compensated by the frequency of the 
encounter.  
All T. cruzi DTUs are human infective. TcI is by far the most abundant and 
genetically diverse and uses both sylvatic and domestic transmission cycles. While 
TcIII and TcIV infections are rare due to mainly sylvatic transmission cycles, human 
infections with TcII, TcV and TcVI are more common because of their preferentially 
domestic transmission cycles. Co-infection with multiple DTUs is common, which 
provides the opportunity of hybridisation events to occur, as was the case for TcII 
and TcIII, which gave rise to the hybrids TcV and TcVI. The commonly used 
laboratory strains Sylvio X10/1 and CL Brener belong to the DTUs TcI and TcVI 
respectively. In vivo and in vitro the behaviour of different DTU’s varies drastically 
and even within the DTUs differences occur, which makes investigations more 
complicated. 
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1.4.1 T. cruzi life cycle 
T. cruzi’s life cycle (Figure 1-9) differs significantly from that of T. brucei, as reviewed 
in (Vickerman, 1985), e.g. no mitochondrial cycle or switch in metabolism is seen in 
T. cruzi and the main replicative stage takes place inside a host cell. 
 
 
Figure 1-9: Life cycle stages of T. cruzi. 
I. Metacyclic trypomastigotes, II. Intracellular stage of T. cruzi with amastigotes and trypomastigotes, III. 
Trypomastigotes residing the bloodstream, IV. Epimastigotes. More details in the main text. 
 
When the infected triatomine bug takes a blood meal, it defecates. Infective 
metacyclic trypomastigote T. cruzi parasites (Figure 1-9 I.) in the faeces enter the 
human or animal host through the bite wound, mucous membranes or hair follicles. 
The trypomastigotes show the same general morphology as T. brucei. While in the 
bloodstream they do not divide, but invade macrophages. They enter the host cells 
via recruited lysosomes forming parasitophorous vacuoles, which they disrupt to 
gain access to the cytoplasm (Figure 1-9 II.). There they differentiate into the 
amastigote form. The amastigote parasites are intracellular in the cytoplasm and 
not motile with very short, buried flagella. Their kinetoplast is close to the nucleus. 
In this form the parasites replicate by binary fission and after several rounds of 
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division they fill up the host cell and differentiate back to trypomastigotes. These 
trypomastigotes are released into the bloodstream (Figure 1-9 III.) and infect other 
cells in target tissues, like heart, smooth muscle of the digestive system liver, spleen 
and lymph nodes, and repeat the differentiation cycle until the infection is cured. A 
triatomine bug taking a blood meal takes up trypomastigotes circulating in the 
bloodstream. 
Within the midgut of the triatomine bug the parasites differentiate into 
epimastigotes (Figure 1-9 IV.). This form of the parasite is characterised by a 
centrally located kinetoplast anterior of the nucleus with the flagellum emerging 
from the middle of the cell forming a short undulating membrane. These parasites 
are less motile than trypomastigotes. They undergo binary fission for replication 
while they pass the digestive system and attach to the epithelium of the rectal 
gland of the insect vector. There they differentiate into mature metacyclic 
trypomastigotes, detaching from the epithelium, prepared for transmission to a 
mammalian host. 
 
1.4.2 Chagas’ Disease 
Chagas’ disease, named after the Brazilian physician Carlos Chagas, is caused by 
T. cruzi parasites. An estimated 8 million people in Central and South Americas are 
infected, most of whom are not aware of their infection. Globalisation and travel 
expose even more people to this disease. The clinical course of Chagas’ disease has 
an acute and a chronic stage. Most of the clinical information is based on children 
infected through vector-borne transmission, but severity and course of the disease 
can vary with the T. cruzi strain involved, age and life stage of the patient and way 
of infection (Centers for Disease Control and Prevention, 2014c).  
The acute phase, immediately after the infection, showing high parasitaemia, can 
last several weeks or months. This phase can be entirely a- or oligo-symptomatic 
and the symptoms vary greatly. Symptoms include initial skin chancre at the site of 
infection or unilateral purplish orbital oedema (Romaña’s sign), which can be 
accompanied by fever, headache, cough, rash, abdominal pain, myocarditis or many 
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other symptoms (Centers for Disease Control and Prevention, 2014c, World Health 
Organisation, 2014c). The initial symptoms usually fade even if untreated after a 
few weeks or months, but the parasite infection remains. In young children, elderly 
or immunocompromised people the symptoms can be severe and in some cases 
fatal. 
The chronic phase, after the initial symptoms fade away, can last decades or life-
long, unless diagnosed and treated. During this phase, the parasites are hidden in 
target tissues, mostly heart or the smooth muscle of the digestive system. In most 
patients the chronic phase is asymptomatic. However, about 30 % of the patients 
develop problems, often decades after the infection, like cardiac complications, 
with cardiomyopathy, heart failure or cardiac arrest, or intestinal complications, 
with enlarged oesophagus or colon. 
Reactivation of Chagas’ infection can happen decades after the original infection, 
often due to immunosuppression, e.g. caused by HIV infection or use of 
immunosuppressants after transplantations.  
 
1.4.3 Diagnosis and Current treatment of Chagas’ disease 
During the acute phase, parasitaemia is high and the parasites can be identified by 
microscopic examination of blood wet smears or a blood concentration technique, 
e.g. microhaematocrit (World Health Organisation, 2014c). During the chronic 
phase diagnosis is more difficult, especially if the disease is asymptomatic. Usually 
two independent methods are used to confirm infection. Serological tests are used, 
identifying T. cruzi antibodies, e.g. enzyme-linked immunosorbent assay (ELISA), 
indirect hemagglutination assay, indirect immunofluorescence assay, western blot 
or other tests. A common method with varying sensitivity is xenodiagnosis, where 
the infection of the insect vector after feeding on the patient’s blood is detected. 
There are two approaches for treatment, symptomatic and anti-parasitic (World 
Health Organisation, 2014c, Centers for Disease Control and Prevention, 2014c). 
The symptomatic treatment is especially important in the acute phase and in cases 
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of cardiac and intestinal complications. Anti-parasitic treatment to remove the 
parasites from the patient is effective in the early stages of infection, but effectivity 
is low during the chronic phase (Marin-Neto et al., 2008, Issa & Bocchi, 2010). The 
two available drugs for treatment of Chagas’ disease are benznidazole and 
nifurtimox (Figure 1-10).  
 
 
Figure 1-10: Anti-parasitic compounds used for treatment of Chagas’ disease.  
Details in main text. Figure made with MarvinSketch (ChemAxon). 
 
Both drugs show strong toxicity and limited effectivity during the chronic phase of 
the disease. Strong side effects lead to very poor patient compliance (Viotti et al., 
2009). The mechanism of action is not well characterised and suspected to be 
related to production of radicals.  
In general, effectiveness of treatment is difficult to assess and strongly dependent 
on the T. cruzi strain, life-cycle stage of the parasite and time after the primary 
infection. Also, evaluation of cure is problematic as parasitaemia is very low during 
the chronic phase and the parasites not only reside in the blood, but also in tissues, 
which make their detection and elimination challenging. 
 
1.5 Leishmania spp. 
Leishmania spp. is a very diverse family among the order Trypanosomatida, class 
Kinetoplastida (Figure 1-11) and the exact taxonomic positions of some are still 
under discussion. Currently 31 species are assigned to the genus, divided in groups 
(World Health Organisation, 2014d). The diversity of Leishmania species is further 
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complicated by the parasites’ capacity for genetic exchange within the insect vector 
(Akopyants et al., 2009).  
 
Figure 1-11: Taxonomic tree of Leishmania spp.  
Species highlighted in green are endemic in the old world; the ones in yellow are endemic in the new world. 
The taxonomic positions of species marked with an asterisk are still under discussion. Figure taken from the 
PhD thesis of Johannes Doehl (Doehl, 2013). 
 
Leishmania are endemic in tropical and subtropical regions of Africa, Middle East, 
Asia (= old world) and Southern and Middle America (= new world), but increased 
travel and global warming increases their range and vectors. There are 20 human 
infective Leishmania species and dependent on the species, different forms of 
Leishmaniasis are caused, namely cutaneous Leishmaniasis (CL), mucocutaneous 
Leishmaniasis (MCL) and visceral Leishmaniasis (VL). L. major, L. tropica and 
L. aethiopica in the old world and L. mexicana species complex (L. mexicana, 
L. amazonensis, and L. venezuelensis) and the L. braziliensis species complex 
(subgenus Viannia, L. [V.] braziliensis, L. [V.] guyanensis, L. [V.] panamensis, and 
L. [V.] peruviana) in the new world cause CL (Centers for Disease Control and 
Prevention, 2014a). Transfer of Leishmania parasites, mainly the subgenus Viannia 
and L. amazonensis, to the mucosal membranes causes MCL. The species 
L. donovani and L. infantum (= L. chagasi) cause VL.  
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1.5.1 Leishmania spp. life cycle 
Leishmania’s life cycle and morphological stages (Figure 1-12, (Gossage et al., 2003) 
differ from those described for T. brucei and T. cruzi.  
 
 
Figure 1-12: Life cycle stages of Leishmania spp. 
I. metacyclic promastigotes, II. Amastigote parasites in phagolysosome, III. Amastigotes in the bloodstream, 
IV. Promastigotes. More details in the main text. 
 
When infected sand flies of the genera Phlebotomus (old world) and Lutzemyia 
(new world) take a blood meal, they transfer the parasites. The Leishmania 
parasites in their metacyclic promastigote form (Figure 1-12 I.) reside in the anterior 
part of the gut and pharynx and the breakdown of the valve of the midgut entrance 
leads to a regurgitation of parasite containing material during the process of 
feeding. The metacyclic promastigotes are non-dividing and characterised by a free 
flagellum emerging from the anterior end of the cell. The nucleus is located in the 
centre of the cell and the kinetoplast anterior close to the basal body of the 
flagellum. 
Once in the mammalian host the metacyclic parasites are phagocytised by 
macrophages and dendritic cells. Within the phagosome the parasites differentiate 
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into the amastigote form (Figure 1-12 II.), which allows them to survive the acidic 
pH and hydrolase-rich environment after lysosome fusion. The amastigotes 
replicate by binary fission and are released by the host cells into the bloodstream 
(Figure 1-12 III.). The released amastigotes are phagocytised by new host cells. 
Neither promastigotes nor amastigotes are able to actively enter cells, but require 
phagocytosis. 
When a sand fly takes a blood meal, it takes up amastigotes, which differentiate 
into procyclic promastigotes (Figure 1-12 IV.), which proliferate and attach to the 
epithelium of the midgut. Procyclic promastigotes are not infective for mammalian 
hosts. Differentiation of the procyclic promastigotes to metacyclic promastigotes 
happens via two intermediate stages and is accompanied by a cessation of 
proliferation.  
 
1.5.2 Leishmaniases 
Leishmaniases, caused by parasites of the genus Leishmania, are transmitted by 
sand flies. Major risk factors include poor and crowded housing in or close to areas 
inhabited by the sand fly vector and malnutrition compromising the immune 
system. The WHO estimates 1.3 million new cases of Leishmaniases and 20 000 – 
30 000 deaths annually (World Health Organisation, 2014d).  
Cutaneous Leishmaniasis (CL) is the most common form of Leishmaniasis. It causes 
ulcers on the exposed areas of the body, which often heal spontaneously, but leave 
scars and, in severe cases, disability. About 95 % of CL cases occur in the Americas, 
the Mediterranean, Middle East and Central Asia (Figure 1-13). The WHO estimates 
0.7 – 1.3 million new cases worldwide each year.  
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Figure 1-13: Geographic endemicity of cutaneous leishmaniasis, 2012.  
Red colours indicate the number of new CL cases reported in 2012; countries highlighted in green did not 
report new cases. Figure modified from WHO (World Health Organisation, 2013). 
 
Mucocutaneous Leishmaniasis (MCL) leads to destruction of mucosal membranes of 
mouth, nose and throat, severe scarring and disability, if left untreated. About 90 % 
of MCL cases occur in South America, mainly Bolivia, Brazil and Peru. 
Visceral Leishmaniasis (VL), in its severe form called kala-azar, is the most 
dangerous form of Leishmaniasis and ultimately fatal if left untreated. It affects the 
inner organs, like liver and spleen, and is associated with high fever, weight loss and 
anaemia (Centers for Disease Control and Prevention, 2014a), but is often 
asymptomatic for long periods. There are an estimated 200 000 – 400 000 new 
cases each year (World Health Organisation, 2014d), 90 % in Bangladesh, Brazil, 
Ethiopia, India, South Sudan and Sudan (Figure 1-14). Following VL, patients often 
display post-kala-azar dermal leishmaniasis (PKDL) in the form of macular, popular 
or nodular rashes on face and other body parts.  
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Figure 1-14: Geographic endemicity of viceral leishmaniasis, 2012.  
Red colours indicate the number of new VL cases reported in 2012; countries highlighted in green did not 
report new cases. Figure from WHO (World Health Organisation, 2013). 
 
1.5.3 Diagnosis and Current treatment of leishmaniasis 
Leishmaniases are diagnosed using combinations of clinical symptomatic, 
parasitological and, for VL, serological tests, detecting antibodies (World Health 
Organisation, 2014d, Centers for Disease Control and Prevention, 2014a). VL 
diagnosis can be difficult, especially when the disease is asymptomatic. Treatment 
of leishmaniases is strongly dependent on species involved, stage of the disease and 
geographic location. CL often heals spontaneously, but as some Leishmania species 
can spread from the CL sores to mucosal membranes causing MCL, early treatment 
is necessary to avoid scarring and disability. VL requires prompt and complete 
treatment, as the disease can be lethal. Several drugs with anti-leishmanial activity 
are currently available (Figure 1-15), which often show strong toxicity and side 
effects and limited efficiency, reviewed by (Olliaro et al., 2005, Singh et al., 2012). 
The MOAs are varying from drug to drug with some being poorly characterised or 
not known. All drugs currently available have severe drawbacks, leading to the need 
of new compounds for anti-leishmanial therapy. 
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Combinational therapy, reviewed by (van Griensven et al., 2010), could potentially 
reduce treatment duration, resulting in better patient compliance, lower costs and 
fewer toxic effects. Additionally, combinational therapy could increase the 
efficiency for complicated cases, like HIV co-infections. Several combinations have 
been studied, one of the most promising being a single application of liposomal 
amphotericin B followed by miltefosine (Sundar & Chakravarty, 2008), which 
showed good effectiveness and tolerance. 
 
Figure 1-15: Anti-parasitic compounds used for treatment of Leishmaniases.  
Details in main text. Figure made with MarvinSketch (ChemAxon). 
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1.5.4 HIV co-infection 
A major issue is HIV co-infection, which renders the symptoms of leishmaniases 
more severe and increases the rates of relapse and mortality (Alvar et al., 2008). It 
also renders the diagnosis and treatment more difficult, as symptoms are more 
atypical and antibody-based diagnostics give false negatives. Anti-leishmanial 
therapeutics show reduced efficiency with HIV co-infection, but treatment with 
antiretroviral mediation reduces symptoms in and relapse and mortality of co-
infected patients.   
 
1.6 Vaccine development against the TriTryps 
Vaccination is the most effective way of combating diseases as it provides long 
lasting protection against the pathogen without the need of constant monitoring or 
treatment. Currently, there are no vaccines effective against the TriTryps licensed 
for immunisation of humans. 
 Within the last 30 years extensive studies investigated the possible targets and 
strategies for development of anti-T. brucei vaccines without much success 
(reviewed in (Magez et al., 2010, La Greca & Magez, 2011). Many studies using 
attenuated parasites (Esser et al., 1982), VSGs (Cornelissen et al., 1985), 
cytoskeletal proteins like tubulin and actin (Lubega, Byarugaba, et al., 2002, Lubega, 
Ochola, et al., 2002, Li et al., 2007, Li et al., 2009), microtubule-associated proteins 
(MAPs, (Balaban et al., 1995), or flagellar pocket extracts (Mkunza et al., 1995, 
Olenick et al., 1988, Radwanska et al., 2000) for vaccination failed to produce long-
term B cell mediated immunity. T. brucei parasites evade the host’s immune system 
by hiding most of the cell surface under the VSG coat, which is not only switched to 
generate a new antigenic variant, but is also recycled constantly, removing bound 
antibodies from the surface (Engstler et al., 2007). Additionally, T. brucei parasites 
were shown to suppress the immune system upon infection (Murray et al., 1974a, 
b, Askonas et al., 1979, Clayton et al., 1979) via destruction of the B cell 
compartments (Radwanska et al., 2008) also removing acquired immune protection 
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against other pathogens. This renders long-term immunisation against this parasite 
extremely difficult.  
Vaccine development against T. cruzi parasites has been more successful. Many 
studies in mice and dogs provide promising proof-of-concept data for preventative 
and disease-controlling/therapeutic vaccines. The studies include vaccines based on 
attenuated (Basombrio & Besuschio, 1982) or killed (Basombrio et al., 1982) 
parasites, recombinant proteins like trans-sialidases or cruzipain (Frank et al., 2003, 
Araujo et al., 2005, de Alencar et al., 2007, Hoft et al., 2007, Giddings et al., 2010, 
Cazorla et al., 2010, Eickhoff et al., 2010), DNA (Limon-Flores et al., 2010, Garg & 
Tarleton, 2002, Chou et al., 2010, Eickhoff et al., 2011, Araujo et al., 2005) and viral 
vectors (Machado et al., 2006, Duan et al., 2009, Miyahira et al., 2005). Only 
immunisations causing strong cytotoxic T-cell responses seem effective, limiting the 
possible formulations for the vaccines. Despite the encouraging results, vaccine 
development has been hampered by worries of vaccination-stimulated 
autoimmunity (Kierszenbaum, 1999, Tarleton & Zhang, 1999, Engman & Leon, 
2002), discussions about the need of a vaccine in the presence of (momentarily) 
effective vector control strategies (Camargo, 2009, Junqueira et al., 2010) and 
problematic clinical trials due to the lowered infection rate and long course of the 
chronic phase of T. cruzi infection.  
Hundreds of antigens as potential vaccine candidates are described for 
Leishmania spp. (reviewed in (Nagill & Kaur, 2011, Singh et al., 2012), including 
killed and attenuated Leishmania parasites, recombinant proteins like kinetoplastid 
membrane protein 11 (KMP-11, (Jardim et al., 1995), hydrophilic acetylated surface 
protein B (HASPB) and small hydrophilic endoplasmic reticulum associated protein 
(SHERP) (Sadlova et al., 2010, Maroof et al., 2012). So far, vaccine candidates 
performed poorly in clinical trials (Noazin et al., 2008) and the limitation of animal 
models available for the different leishmaniases further complicates the 
development (Okwor & Uzonna, 2009). Two canine vaccines are licensed in Brazil, 
Leishmune and Leishtec (Evans & Kedzierski, 2012). Leishmune showing successful 
results in field trials, Leishtec producing more variable results. 
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An alternative to the immunisation against the parasites themselves might be the 
transmission blocking vaccines (TBVs). They aim to generate immunity against a 
different life cycle stage of the parasite or the parasite-insect vector interaction and 
therefore block infection of the insect vector or development of the parasite within 
the vector. It was shown that the presence of anti-procyclic parasite antibodies in 
the blood meal of the tsetse fly suppresses the development of the parasite in the 
vector (Maudlin et al., 1984, Nantulya et al., 1980). Possible targets for those 
immunisations are surface proteins of procyclic T. brucei parasites like GPEET, EP 
procyclins (Roditi & Lehane, 2008) and alanine-rich protein isoforms (BARP, 
(Urwyler et al., 2007). Immunisation with tsetse fly midgut extracts (Kinyua et al., 
2005) was shown to reduce the transmission rate of the parasites and decreased 
the viability of the insect vector itself, indicating tsetse fly midgut antigens to be 
promising candidates for TBV development. The canine vaccine against visceral 
leishmaniasis Leishmune (FML), a fucose-mannose ligand, was shown to generate 
antibodies inhibiting the attachment of Leishmania parasites to the sand fly midgut 
(Saraiva et al., 2006), thus interfering with the parasites development in the vector. 
Also, immunisation with sand fly salivary antigens was shown to reduce Leishmania 
transmission (Kamhawi et al., 2000, Thiakaki et al., 2005).  
Another vaccination strategy regards the possibility for symptomatic vaccination, 
aiming to reduce the problems caused not by the parasites themselves but by the 
parasite-host interactions or the reaction of the host’s immune system towards the 
parasite. This is of particular interest for the anti-T. brucei therapy in cattle where it 
was shown that the presence of antibodies against the cysteine protease congopain 
from T. congolense reduced the symptoms of T. congolense infection (Authie et al., 
1992, Lalmanach et al., 2002). For T. cruzi infections a therapeutic vaccine is of high 
interest as the chronic phase of infection lasts many years without symptoms. The 
same antigens used for preventative immunisation could be shown to decrease the 
parasite burden and inflammation of the heart when administered as therapeutic 
vaccine (Dumonteil et al., 2004, Zapata-Estrella et al., 2006, Limon-Flores et al., 
2010, Sanchez-Burgos et al., 2007). 
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Though vaccination is the most efficient way to combat diseases, the vaccine 
development proved difficult for the TriTryps. 
 
1.7 Drug discovery 
Drug discovery is the process of identification and partial validation of a drug 
candidate or lead compound for treatment of a specific disease. This includes the 
identification of an effective molecule and its modification in order to increase 
affinity, selectivity, potency, metabolic stability and bioavailability after 
administration. 
 
1.7.1 Classical Pharmacology – Forward Pharmacology 
In classical pharmacology (or forward pharmacology) chemical libraries containing 
small synthetic molecules, natural products and/or biological extracts are screened 
against whole cells or organisms in order to identify substances showing the desired 
effect, e.g. killing of a pathogen and survival of the human cells. Most drug 
candidates are small organic molecules, either of synthetic or biological origin, but 
sometimes bigger and more complex molecules are identified, e.g. antibiotics like 
vancomycin. The mechanism of action (MOA) of many of these active compounds is 
not initially known and the biological target and the MOA are sometimes identified 
in later stages of the drug discovery process.  
 
1.7.2 Target-based drug design – Reverse Pharmacology 
Here, a biological target is identified and molecules are screened or designed to 
specifically act on it. Biological targets are macromolecules, e.g. proteins, or 
pathways involved in the pathology of interest and often essential for cell 
proliferation and/or survival of an organism. The validation of a molecule or 
pathway as a potential drug target involves determination of its physiological role 
within the cell/organism and its involvement in the pathology. In the case of a 
 45 
pathogenic organism, the potential drug target in the pathogen is usually compared 
to its human counterpart to identify and exploit differences between pathogen and 
host, and thus reduce possible side effects of the drug. 
 
1.8 Identification of potential drug targets in the TriTryps 
In the last decades many potential drug targets for the TriTryps were identified 
from a variety of different pathways throughout the parasite cells. Many metabolic 
pathways and/or enzymes within these pathways are essential for the survival and 
infectivity of the parasites and show significant differences between the TriTryps 
and humans. These provide potential targets for anti-parasite chemotherapy.  
 
1.8.1 Nucleotide metabolism 
The nucleic acids DNA and RNA are central macromolecules in all kingdoms of life. 
They are large polymers built from nucleotides, which in turn are composed of a 
nitrogenous base, a 5-membered sugar ring (deoxyribose for DNA and ribose for 
RNA) and a phosphate group. The precursors used for DNA and RNA biosynthesis 
are the nucleoside triphosphates dATP, dCTP, dGTP and dTTP (dNTPs) for DNA and 
ATP, CTP, GTP and TTP (NTPs) for RNA. Besides being essential for nucleic acid 
synthesis the NTPs carry out a variety of important intracellular functions, like 
energy transfer (ATP), cell signalling (cAMP, cGMP) and as components of cofactors 
for enzymatic processes (e.g. NAD and Coenzyme A). Because of their crucial role 
the nucleotide pool inside the cell has to be tightly controlled. 
Cells synthesise nucleotides in two different ways, the de novo pathway and the 
salvage pathway. As the name suggests, the de novo pathway produces the 
nucleotides and all its components using basic components inside the cell. The 
salvage pathway takes advantage of nucleobases and nucleosides taken up from the 
cell’s environment. Most cells are able to use both pathways for purine and 
pyrimidine nucleotide synthesis. However, kinetoplastids have lost the ability to 
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synthesise purines de novo and rely solely on the salvage pathway (de Koning et al., 
2005).  
 
1.8.1.1 Purine nucleotide metabolism in T. brucei 
The uptake of purine nucleobases and nucleosides is facilitated by the high affinity 
transporters P1 and P2, which are able to outcompete the host’s purine uptake 
systems. Although they belong to the class of equilibrative nucleoside transporters 
(ENT) they use energy in the form of proton motive force to actively concentrate 
nucleosides inside the cell (de Koning & Jarvis, 1997, Molina-Arcas et al., 2009, 
Young et al., 2008). The P2 transporter has been shown to import trypanocidal 
nucleoside analogues, like cordycepin (Geiser et al., 2005). Additionally, 
trypanosomes have purine base and pyrimidine base/nucleoside transporters, H1-3.  
The salvaged nucleobases and nucleosides are interconverted by a complex and 
redundant network of enzymes, Figure 1-16. Because of their redundancy most of 
the enzymes in the salvage pathway are non-essential for proliferation (Hammond 
& Gutteridge, 1984). For example, AMP can be produced by adenosine (Ado) 
phosphorylation by adenosine kinase (AK), or by Ado hydrolysis through adenosine 
nucleosidase (purine nucleoside hydrolase, PNH) and subsequent 
phosphoribosyltransfer by adenine phosphoribosyltransferase (APRT) or from IMP 
via adenylosuccinate using the enzymes adenylosuccinate synthase (ADSS) and 
adenylosuccinate lyase (ASL). Generally all nucleosides can be hydrolysed to their 
nucleobases, which in turn are converted into nucleoside monophosphates. The 
monophosphates are further phosphorylated, converted into one another or used 
as precursors for signalling molecules.  
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Figure 1-16: Purine nucleotide metabolism in kinetoplastids.  
Shown are the purine nucleotides and the enzymes (grey circles) interconverting them. APRT = adenine 
phosphoribosyltransferase (PRT), EC 2.4.2.7; MTAP = methylthioadenosine phosphorylase; AK = adenosine 
kinase, EC 2.7.1.20; AMPDA = AMP deaminase, EC 3.5.4.6; ADSS = adenylosuccinate synthase, EC 6.3.4.4; ASL 
= adenylosuccinate lyase, EC 4.3.2.2; AAH = adenine deaminase (or adenine amino hydrolase), EC 3.5.4.2; PNH 
= purine nucleoside hydrolase, EC 3.2.2.1; HGPRT = hypoxanthine guanosine PRT, EC 2.4.2.8; XPRT = xanthine 
PRT, EC 2.4.2.22; IMPDH = IMP dehydrogenase, EC 1.2.1.14; GMPS = GMP synthase, EC 6.3.4.1; GMPR = GMP 
reductase, EC 1.6.6.8; GDA = guanine deaminase, EC 3.5.4.3. Dashed arrow indicates enzymes in Leishmania 
sp. and T. vivax.  
 
1.8.1.2 Pyrimidine nucleotide metabolism in the TriTryps 
While purine nucleotide metabolism in kinetoplastids is well studied, pyrimidine 
nucleotide metabolism is much less so. The TriTryps are able to use both the de 
novo and the salvage pathway to synthesise pyrimidine nucleotides with the 
exception of cytosine for which trypanosomes lack the enzymes of the salvage 
pathway (Hofer et al., 2001). A schematic summary of pyrimidine nucleotide 
metabolism is shown in Figure 1-17.  
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Figure 1-17: Pyrimidine metabolism in kinetoplastids.  
Shown are the pyrimidine nucleotides and the enzymes (grey circles) interconverting them. The de novo 
synthesis pathway is shown in green, the salvage pathway in black and blue. CTPS = CTP synthase, EC 6.3.4.2; 
RNR = ribonucleotode reductase, EC 1.17.4.1/2; TK = thymidine kinase, EC 2.7.1.21; TMPK = thymidylate 
kinase, EC 2.7.4.9; TS = thymidylate synthase, EC 2.1.1.45; UPRT = uracil phosphoribosyltransferase, EC 
2.4.2.9; UPase = uridine phosphorylase, EC 2.4.2.3; dUTPase = dUTP nucleotide hydrolase, EC 3.6.1.23. 
 
The de novo pathway utilises L-glutamine, ATP and carbonate to synthesise uridine 
monophosphate (UMP) in six enzymatically-catalysed steps. UMP is readily 
phosphorylated and converted into other pyrimidine nucleotides. Using the salvage 
pathway, kinetoplastids take up uracil and its nucleosides from the cell’s 
surroundings using the transporters U1 and U3 and thymidine (dThd) is taken up to 
a certain extent by the purine transporter P1 (Ali et al., 2013). Imported uridine 
(Urd) is converted into uracil, which is used to generate UMP, a reaction catalysed 
by uracil phosphoribosyltransferase (UPRT). UMP can be further phosphorylated to 
UDP and UTP. UDP is reduced by ribonucleotide reductase (RNR) to yield dUDP, 
which is in turn either phosphorylated to dUTP or dephosphorylated to dUMP. 
dUMP can be methylated to dTMP by thymidylate synthase (TS). RNR is regulated 
by dTTP, which shifts its specificity from pyrimidine to purine nucleotide reduction 
(Thelander & Reichard, 1979, Xu et al., 2006, Hofer et al., 2012). Salvaged dThd and 
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dUrd are phosphorylated by thymidine kinase (TK) leading to dTMP and dUMP 
respectively. Further phosphorylation by thymidylate kinase (TMPK) results in dTDP 
and dUDP and subsequently dTTP and dUTP, direct precursors for DNA and RNA 
synthesis.  
In eukaryotes, the intracellular dTTP pool is tightly regulated and coupled to the cell 
cycle and DNA synthesis (Hu & Chang, 2007, Mathews, 2006). While other dNDPs, 
including dUDP and purine nucleoside diphosphates, can also be synthesised by 
RNR, dTDP is generated only via phosphorylation of dTMP by thymidylate kinase 
(TMPK). Besides being essential for dTDP synthesis, TMPK has been shown to be 
involved in DNA damage repair, where blockage of TMPK results in dUTP 
incorporation into the DNA upon repair of double strand breaks (Hu et al., 2012). 
The only nucleosides not made in the salvage pathway are cytosine nucleotides, 
whose only source is synthesis from UTP by CTP synthetase (CTPS). 
 
1.8.1.3 Potential drug targets within the nucleotide metabolism  
The dependence on tightly regulated nucleotide pools for correct DNA synthesis, 
cell signalling and energy balance, provides many potential drug targets, e.g. 
phosphoribosyltransferases (PRTs), which synthesise nucleotide monophosphate 
from the nucleobase and phosphoribosyl pyrophosphate (Carter et al., 2008), 
deoxyuridine triphosphate nucleotidohydrolase (dUTPase), catalysing the hydrolysis 
of dUTP to dUMP and pyrophosphate (Hidalgo-Zarco et al., 2001, Castillo-Acosta et 
al., 2008), or cyclic AMP (cAMP) phosphodiesterases (PDEs), which degrades the 
secondary messenger molecule cAMP to AMP (Oberholzer et al., 2007, de Koning et 
al., 2012, Bland et al., 2011). 
 
1.8.1.4 Nucleoside analogues as chemotherapeutic agents 
Nucleoside analogues, mimicking the natural nucleosides, often have cytotoxic 
properties. Most analogues are phosphorylated by nucleoside kinases and used as 
building blocks in RNA or DNA synthesis, which leads to premature strand 
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termination, resulting in cell death. This property was developed into a variety of 
laboratory applications, e.g. 3’-end labelling of RNA (Lingner & Keller, 1993). 
Additionally, many of them in their phosphorylated form function as inhibitors of 
DNA- or RNA polymerases, like retroviral reverse transcriptases.  
Among the best-studied nucleoside analogues are the adenosine analogues (Figure 
1-18), which are activated by their phosphorylation by AK and adenylate kinase 
(AMPK). Their ability to cross the blood brain barrier makes them attractive 
candidates in drug development and their pharmacokinetic properties are well 
characterised in humans.  
 
 
Figure 1-18: Some medically relevant purine analogues.  
Details in main text. Ara-A = vidarabine, F-Ara-A = fludarabine. Figure made using MarvinSketch (ChemAxon). 
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While Ara-A was used against Herpes simplex infections (Shiota et al., 1978), F-Ara-
A, clofarabine and deoxycoformycin have been used as chemotherapeutics in 
cancer therapy (Gray et al., 1982, Leahey et al., 1997, Kline & Larson, 2005). 
Tubercidin has been shown to be highly toxic to most cells, including the TriTryps, 
being phosphorylated and built into nucleic acids, as well as affecting their 
glycolysis (Drew et al., 2003). Anti-trypanosomal and anti-leishmanial activity was 
shown and its effectivity as well as a reduction of host toxicity could be achieved by 
co-administration with nitrobenzylthioinosine (NBMPR), a mammalian specific 
purine nucleoside transport inhibitor (el Kouni et al., 1983, Ogbunude & Ikediobi, 
1982, Aoki et al., 2009). Some purine nucleoside analogues were shown to inhibit 
retroviral reverse transcriptase in their phosphorylated form (Richman, 1990, 
Wainberg et al., 2005) and others stop dThd phosphorylation by TK (Susan-Resiga et 
al., 2007, Lynx & McKee, 2006, Lynx et al., 2006). This can be used in cases where 
the target cells express the type I TK or generally a TK with broader substrate 
specificity than the cytosolic human type II TK. Examples of pathogens 
overexpressing a lower specificity TK are human herpes simplex virus (HSV), 
varicella-zoster virus (VZV) and cytomegalovirus (CMV). The treatments for these 
viruses include nucleoside analogues, such as acyclovir for HSV and VZV infections 
and ganciclovir in CMV therapy. Adefovir in its phosphorylated form acting as a 
polymerase inhibitor is used in treatment of hepatitis B (Birkus et al., 2003) and 
HSV. 
Cordycepin is trypanocidal in vitro (Williamson, 1972, Williamson & Macadam, 
1976). Besides its integration into RNA, terminating its elongation, cordycepin has 
been shown to inhibit mammalian poly-A polymerase and hinder nucleoside-
activated protein kinase activity in Trypanosoma spp. (Walter & Ebert, 1977). Its 
trypanocidal properties were shown to depend on its activation by phosphorylation 
through AK indicated by RNAi experiments in which AK knock down in T. brucei did 
result in reduction of cordycepin and tubercidin sensitivity (Luscher et al., 2007). 
Sub-lethal doses of AK inhibitors resulted in cordycepin resistance indicating a 
switch to AMP production via the PNH-APRT pathway. Tubercidin remained 
trypanocidal due to its cytotoxic modification being in the nucleobase rather than 
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the ribose ring. Unfortunately, in vivo studies in mice revealed a rapid deactivation 
of cordycepin via deamination by the host’s adenosine deaminase (ADA) in the 
plasma (Aiyedun et al., 1973, Agarwal et al., 1975). Co-administration of cordycepin 
and the ADA inhibitor deoxycoformycin, blocking the metabolism of cordycepin, 
could cure mice suffering late stage African trypanosomiasis (Rottenberg et al., 
2005, Vodnala et al., 2009). As deoxycoformycin has proven to be teratogen, a 
combinational therapy is not reasonable (Airhart et al., 1996). To circumvent the 
problem of co-administration, it might be possible to modify cordycepin in a way 
which makes it resistant to deamination by human ADA, but does not affect its 
trypanocidal properties. In order to keep its cytotoxic properties the new 
compound would have to remain a substrate of the T. brucei nucleoside transport 
systems (P1 and P2) and the enzymes activating it inside the trypanosomes, e.g. AK 
and AMPK. 
Not only purine nucleotide analogues have been successfully used as prodrugs, but 
also pyrimidine analogues (Figure 1-19). In this context, there has been a big 
interest in TKs and TMPKs in drug development because of differences in substrate 
specificity and expression profile of the human enzymes compared to the 
pathogens. While all TKs prefer dThd as substrate and are usually able to 
phosphorylate dUrd, type I TKs have generally lower substrate specificity and 
phosphorylate dC readily. This ability to accept a broader range of substrates 
enables the type I TKs to phosphorylate cytotoxic nucleoside analogues. The 
pyrimidine analogues (E)-1-β-D-(arabinofuranosyl)thymine (AraT) and (E)-5-(2-
bromovinyl)-2’-deoxyuridine (BVDU) are well characterised for their antiherpetic 
properties, while 2’-fluoro-5-iodo-(1-β-D-arabinofuranosyl)uracil (FIAU) has been 
shown to be effective anti-hepatitis B agents (Tennant et al., 1998). The substrate 
analogue 3’-azido-3’deoxythymidine (AZT) is used in HIV therapy as it is 
phosphorylated by the human TK1 and inhibits the HIV reverse transcriptase. 
Additionally, it was shown to inhibit growth of L. amazonensis promastigotes 
(Araujo et al., 2011), indicating AZT to be a potential candidate for anti-leishmanial 
therapy. Uninfected resting human cells are much less affected by these nucleoside 
analogues, as the human cytosolic TK is only expressed during cell division, when 
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the cells are actually synthesising DNA. However, some toxicity has been observed 
for AZT and FIAU, probably mediated by the mitochondrial type I TK (Wang et al., 
2011). 
 
Figure 1-19: Some medically relevant pyrimidine analogues.  
AZT = 3’-azido-3’deoxythymidine, AraT = 1-β-D-(arabinofuranosyl)thymine, BVDU = (E)-5-(2-bromovinyl)-2’-
deoxyuridine, FIAU = 2’-fluoro-5-iodo-(1-β-D-arabinofuranosyl)uracil. Figure made using MarvinSketch 
(ChemAxon). 
 
1.8.2 Amino acid metabolism  
Amino acids are essential molecules within all organisms. Approximately 500 
different amino acids are known, which are all comprised of carboxylic acid and 
amine groups with different side chains specific for each amino acid. Of these, 20 L-
amino acids are components of proteins. Additionally, amino acids function as 
signalling molecules and precursors for a number of important metabolites, as well 
as fatty acids. Amino acid synthesis and catabolism show large differences between 
organisms. 
Cells have the ability to synthesise certain amino acids de novo from inorganic 
compounds, amino acid remodelling and conversion of non-amino acid carbon 
skeletons into amino acids. Amino acids that cannot be synthesised, but have to be 
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taken up from the environment are considered essential for the given organism. 
The uptake from the environment can be either as free amino acids or in the form 
of proteins and peptides, which are broken down to amino acids by various 
proteases and peptidases.  
Amino acids are catabolised into a variety of different metabolites. They are 
categorised as glucogenic or ketogenic. Glucogenic amino acids are transformed 
into pyruvate or citric acid cycle intermediates, e.g. oxaloacetate or α-ketoglutarate, 
which can be used in gluconeogenesis. Most amino acids are at least partially 
glucogenic, the only exception being leucine, which is solely ketogenic. Ketogenic 
amino acids are used to produce acetyl-CoA and acetoacetyl-CoA. Isoleucine, lysine, 
plenylalanine, tryptophan and tyrosine are both glucogenic and ketogenic and give 
rise to glucose and fatty acid precursors. Some amino acids, e.g proline, can serve as 
an energy source by oxidation of the carbon skeleton.  
 
1.8.2.1 Amino acid metabolism in the TriTryps 
Amino acid metabolism in the TriTryps is complex and varies depending on the life 
cycle stage and environment of the parasites. Generally the parasites maintain an 
amino acid pool of alanine, glutamate and proline as precursors of metabolites and 
for osmoregulation (Vieira et al., 1996, Rohloff et al., 2003, Darlyuk et al., 2009), 
where amino acid efflux is used to reduce cell swelling upon hypotonic stress 
(Lefurgey et al., 2005, Vieira et al., 1996, Rohloff et al., 2003). Additionally, the 
hydrolysis of peptides and proteins plays a crucial role in the parasites ability to 
invade the host’s tissues and cells and in the evasion of the immune system. 
Bloodstream form T. brucei parasites rely on D-glucose in the host’s blood stream as 
energy source, which they metabolise to succinate and acetate. As soon as they are 
transferred to their insect vector and differentiate into the procyclic form parasites, 
their metabolism changes to use L-proline as main carbon and energy source, which 
is metabolised to succinate and further to alanine. The same applies for the insect 
stages of T. cruzi and Leishmania spp. (Bringaud et al., 2012). However, procyclic 
T. brucei cultured in glucose-rich media prefer D-glucose as energy and carbon 
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source and convert it to succinate and acetate (Coustou et al., 2008). The ability of 
amino acid biosynthesis of T. brucei parasites is less well studied and it is not clear 
which amino acids are essential for the parasites’ survival and differentiation. 
However, threonine was shown to be essential for growth of procyclic T. brucei 
parasites. It is converted to glycine and acetate (Linstead et al., 1977), and was 
shown to be a precursor in lipid biosynthesis (Gilbert et al., 1983). In the databases 
homologues of only two out of the five enzymes necessary for leucine biosynthesis 
are present in T. brucei, none of which are characterised in the parasite. Therefore, 
leucine is expected to be essential in T. brucei. In T. cruzi and Leishmania spp. 
leucine is used for sterol and fatty acid synthesis (Ginger et al., 2000). Leishmania 
spp. parasites were shown to produce up to 77 % of the sterol from leucine, while it 
was only 8 % in T. cruzi. However, experiments in T. brucei showed no integration of 
radioactively labelled leucine into sterol biosynthesis in this parasite (Guiomar 
Perez-Moreno et al., personal communication). T. cruzi parasites were shown to 
metabolise asparagine, glutamine, aspartate, glutamate, leucine, isoleucine and 
proline (Zeledon, 1960, Sylvester & Krassner, 1976, Mancilla et al., 1967). While 
glycolysis is active, alanine is produced from pyruvate (Zelada et al., 1996). The 
growth of some T. cruzi life cycle stages, mainly epimastigotes, was shown to 
depend on the availability of arginine (Pereira et al., 1999, Pereira, Alonso, Ivaldi, et 
al., 2002, Canepa et al., 2004) in spite of the necessary genes found in the T. cruzi 
genome, indicating the need for further investigations. The presence of glucose 
together with aspartate, glutamate and proline promote differentiation from 
epimastigote to metacylic trypomastigote T. cruzi (metacyclogenesis) (Contreras et 
al., 1985). Leishmania spp. have three main amino acid transporters, taking up 
proline, alanine, methionine and valine from the environment (Bonay & Cohen, 
1983, Mazareb et al., 1999). As all kinetoplastids, Leishmania spp. can convert L-
proline into glutamate (Coustou et al., 2008, van Weelden et al., 2003, van Weelden 
et al., 2005, Krassner & Flory, 1972, Sylvester & Krassner, 1976), but unlike T. brucei 
and T. cruzi they also can catalyse the reverse reaction and synthesise proline from 
glutamate or ornithine (Bringaud et al., 2012).  
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Overall, amino acid metabolism in the TriTryps is complex and tightly regulated 
depending on environmental conditions, species and life cycle stage of the parasite. 
Therefore, identification of potential drug targets in amino acid metabolism can be 
a difficult task. 
 
1.8.2.2 Potential drug targets within the amino acid metabolism 
Many potential drug targets have been identified, e.g. proline racemase, which 
converts L-proline into a racemic mixture (Chamond et al., 2003), alanine 
aminotransferase, producing alanine from pyruvate (Spitznagel et al., 2009), 
arginine kinase, which catalyses the reversible transphosphorylation between N-
phospho-L-arginine and ADP (Pereira et al., 1999, Pereira et al., 2000, Pereira, 
Alonso, Ivaldi, et al., 2002, Pereira, Alonso, Torres, et al., 2002), the S9 family serine 
peptidases prolyl oligopeptidase (POP) and oligopeptidase B (OPB), involved in host 
tissue invasion of T. cruzi (Grellier et al., 2001, Santana et al., 1997, Burleigh et al., 
1997) and crossing the blood-brain-barrier of T. brucei (Bastos et al., 2010, 
Lonsdale-Eccles & Grab, 2002).  
 
1.8.2.3 Peptidases 
Peptidases catalyse the hydrolysis of peptide bonds (EC 3.4.-.-, MEROPS, (Rawlings 
et al., 2014) and are divided into “endopeptidases” which cleave peptide bonds 
within a polypeptide chain, and “exopeptidases” which cleave amino acid residues 
off the N- or C-terminus. There are two ways to classify peptidases: 1) by their 
substrates and products, and 2) homology based. Peptidases are divided into 
families depending on the substrates and products, but as substrate specificities are 
often difficult to define, the catalytic mechanism is often used to support this 
classification. Peptidase clans are homology-based classifications and represent one 
or more families of enzymes with a common evolutionary origin reflected in their 
structure, and/or conserved catalytic residues. Peptidase clans are assigned a two 
letter code, the first depending on their catalytic mechanism, e.g. clans of 
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metallopeptidases are assigned the first letter M. In case of an evolutionary 
divergence within the clan, it is divided into sub-clans. 
 
1.8.2.4 Metallopeptidases 
Many peptidases require co-catalytic metal ions for their activity and are classified 
into a number of metallopeptidase families, named M1-M98. For example M17 
(Clan MF), M24 (Clan MG), M20 and M28 (Clan MH), all use penta-coordinated 
divalent metal ions. The M17 and M24 families contain aminopeptidases, M20 
contains carboxypeptidases and M28 contains members of both.  
 
1.8.2.5 Aminopeptidases 
Aminopeptidases catalyse the cleavage of a single amino acid residue off the N-
terminus of peptides and proteins (EC 3.4.11.-). They are divided into families 
dependent on their substrates, cofactors and mechanisms. Some of these are 
metallopeptidases of the families M17, M24 or M28, containing one or two co-
catalytic metal ions, usually zinc, manganese or cobalt. The leucyl aminopeptidases 
(LAPs) were the first group to be characterised (Prescott & Wilkes, 1966, Dick et al., 
1970), but early studies did not distinguish between the different enzyme families, 
which makes it difficult to put studies of a specific enzyme family into context.  
 
1.8.2.6 Aminopeptidase inhibitors and their use as drug candidates 
There are many effective aminopeptidase inhibitors, including aminoketones and 
their derivatives (Birch et al., 1972, Kettner et al., 1974), microbial peptide 
analogues (Umezawa et al., 1976, Aoyagi et al., 1978, Umezawa, 1982) (Umezawa 
et al., 1985, Rich et al., 1984, Wilkes & Prescott, 1985), α-aminoboronic acids (Baker 
et al., 1983, Shenvi, 1986), amino acid hydroxamates (Chan et al., 1982, Baker et al., 
1983, Wilkes & Prescott, 1985), α-aminoaldehydes (Andersson et al., 1982), amino 
acid thiols (Chan et al., 1982) and (aminoalkyl)phosphonic acids (Giannousis & 
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Bartlett, 1987). Many of those inhibit leucyl aminopeptidases (LAPs) and some 
examples are shown in Figure 1-20.  
 
 
Figure 1-20: Some well-characterised leucyl aminopeptidase inhibitors.  
Details in main text. Figure made with Marvin Sketch (ChemAxon). 
 
Among the microbial peptide analogue inhibitors actinonin (Gordon et al., 1962, 
Umezawa et al., 1985), amastatin (Aoyagi et al., 1978, Rich et al., 1984, Wilkes & 
Prescott, 1985), arphamenine A (Umezawa, 1982) and bestatin (Umezawa et al., 
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1976, Rich et al., 1984, Wilkes & Prescott, 1985) are the best-studied ones. A variety 
of derivatives, especially of actinonin and bestatin, have been synthesised and 
studied for their antibiotic and anti-parasitic properties (Anderson, Devlin, et al., 
1975, Anderson, Ollis, et al., 1975, Rich et al., 1984, Howarth & Lloyd, 2000). 
Actinonin is a competitive inhibitor of aminopeptidase-N and LAP (Umezawa et al., 
1985) and peptide deformylase (Chen et al., 2000) and has antibiotic properties 
against Gram-positive and Gram-negative bacteria and some phage strains in vitro 
(Gordon et al., 1962). Amastatin is a slow-binding competitive inhibitor of 
aminopeptidase-A and -N and LAP, but not of aminopeptidase-B, while bestatin is a 
potent slow-binding inhibitor of aminopeptidase-B and LAP, but not 
aminopeptidase-A (Aoyagi et al., 1978, Umezawa et al., 1976, Tobe et al., 1980) 
(Rich et al., 1984, Wilkes & Prescott, 1985, Nagata et al., 1991). Bestatin and its 
derivatives display anti-malarial activity, inhibiting the growth of P. falciparum 
(Nankya-Kitaka et al., 1998). They also have been reported as immunomodifiers 
(Bruley-Rosset et al., 1979), analgestic (Chaillet et al., 1983) and inhibiting tumor 
growth (Umezawa, 1980). 1,2-aminoalcohols, based on the aminoalcohol core 
structure of bestatin, were shown to have anti-malarial properties (Howarth & 
Lloyd, 2000). Some of these derivatives act as LAP inhibitors, while others increase 
LAP activity. Apstatin, a not very efficient inhibitor of M24 prolyl aminopeptidases 
(Prechel et al., 1995, Maggiora et al., 1999, Cottrell et al., 2000), was shown to be a 
potent slow-binding competitive inhibitor of Leishmania LAPs (Morty & Morehead, 
2002). This compound has proven cardio-protective potential via a kinin-dependent 
pathway (Wolfrum et al., 2001). Arphamenine A is a specific inhibitor of 
aminopeptidase B and is not effective against LAP or aminopeptidase A (Ohuchi et 
al., 1984, Umezawa et al., 1983). However, it was shown to have activity against 
T.brucei parasites in vitro (Knowles, 1993). 
α-aminoaldehydes like L-leucinal, and aminophosphonic acids like L-leucine 
phosphonic acid, are potent, slow-binding inhibitors of porcine kidney LAP, cytosolic 
di- and tri-peptidase (Andersson et al., 1982, Frick & Wolfenden, 1985), and 
aminopeptidase-N and LAP (Giannousis & Bartlett, 1987), respectively. Like 
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bestatin, they mimic the gem-diolate transition state of the reaction and therefore 
provide strong inhibition. 
 
1.8.3 Other potential drug targets in the TriTryps  
There are many potential drug targets identified in the TriTryps outside of the 
nucleotide or amino acid metabolisms, e.g. squalene synthase (SQS) and squalene 
epoxidase (SQE), which are involved in ergosterol biosynthesis (Perez-Moreno et al., 
2012), N-myristoyltransferase (NMT) involved in subcellular targeting of proteins 
(Price et al., 2003), trypanothione reductase, which is crucial for maintenance of the 
redox homeostasis (Dumas et al., 1997, Tovar et al., 1998, Krieger et al., 2000), 
mitogen-activated protein (MAP) kinase important for parasite differentiation 
(Wang et al., 2005) and DNA topoisomerase which is involved in processes 
influencing the topology and organisation of the DNA (Das et al., 2006). 
 
1.9 Trypobase 
Trypobase, an acronym for “Nucleobase derivatives as drugs against trypanosomal 
diseases”, was a collaborative research project funded for three years under the 
European Community’s 7th Framework Programme, with collaborators in 
parasitology (the groups of Dolores Gonzalez-Pacanowska at “Consejo Superior de 
Investigaciones Cientificas”, Granada, Spain, Carlos Robello at “Institute Pasteur de 
Montevideo-Uruguay, Montevideo, Uruguay and Reto Brun at “Swiss Tropical and 
Public Health Institute” Basel, Switzerland), medicinal chemistry (the groups of Ian 
Gilbert at the University of Dundee, Dundee, UK, Nils Gunnar Johansson at Medivir 
AB, Huddinge, Sweden and Ashis Baran Mandal at Syngene, Bangalore, India) and 
structural biology (the group of Keith Wilson, University of York, York, UK). 
Trypobase addressed the neglected tropical diseases caused by the TriTryps 
(T. brucei, T. cruzi and L. major) and aimed to identify lead compounds for drug 
development against these pathogens, initially focussing on nucleobase derivatives 
and nucleotide metabolism. Two approaches were chosen to achieve this: 1) 
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classical pharmacology with phenotypic assays, screening compound libraries based 
on nucleobase derivatives against the parasites in culture; and 2) target-based drug 
design. 
 
1.10  Target selection in Trypobase 
Trypobase’s target-based drug design approach initially focussed on the 
identification of inhibitors of the TriTryp dUTPases, essential enzymes for the 
parasites’ survival. The dUTPases of the TriTryps belong to a distinct enzyme family 
from the human dUTPase and therefore provide the opportunity to selectively 
target the parasite enzymes, leaving the human counterpart unaffected. 
Unfortunately, the high specificity of these dUTPases for their substrates made drug 
candidate design and identification a difficult task. I joined the Trypobase project 18 
months after its start, when other targets from nucleotide metabolism were 
included in the project to increase the chances of identification of drug candidates 
against the TriTryps. The nucleotide metabolism of the TriTryps has unique features 
compared to human, e.g. the parasites lack the de novo synthesis pathway for 
purines, making them depend entirely on the salvage pathway. Also, cytotoxic 
nucleoside analogues have been well characterised and established as treatments 
against several viral pathogens, but usually require activation via phosphorylation 
by enzymes from nucleotide metabolism. The differences in substrate specificity of 
human and pathogen enzymes are exploited leading to pro-drug activation only in 
infected cells. Because of the successful application of nucleoside-based pro-drugs 
against viral infections and differences of the pathways between human and 
TriTryps, the pro-drug activating enzymes adenosine kinase (AK), thymidine kinase 
(TK) and thymidylate kinase (TMPK) were chosen as potential targets.  
In addition to the target-based approach, the Trypobase project applied phenotypic 
screens to identify compounds with trypanocidal activity. After extensive screening, 
a lead compound against T. cruzi parasites was identified and after investigation of 
the biological target using metabolomics, a possible mechanism of action (MOA) 
was suggested to be inhibition of a leucyl aminopeptidase, an enzyme shown 
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previously to be a potential drug target in P. falciparum (Harbut et al., 2011). 
Following this hypothesis, the M17 family leucyl aminopeptidases of the TriTryps 
were included in the list of targets. 
 
1.11  Aims 
The initial work in this thesis was conducted as part of the Trypobase project, 
aiming to determine the X-ray structures of adenosine kinase (AK), thymidine kinase 
(TK), thymidylate kinase (TMPK) and leucyl aminopeptidase (LAP-A) from the 
TriTryps to aid target-based drug design. Additionally, this project was aimed to 
evaluate LAP-A as a potential drug target in the TriTryps, addressing the initial 
hypothesis of LAP-As as possible target for an anti-T. cruzi lead compound identified 
within the Trypobase project. 
 Chapter 2 Adenosine Kinase from T. brucei brucei 
2.1 Introduction 
Adenosine kinase (AK) catalyses the phosphorylation of adenosine (Ado) and 
deoxyadenosine (dAdo) to AMP or dAMP, respectively. This enzyme has been 
identified exclusively in eukaryotes with the exception of Mycobacterium spp. AKs 
of several species, including that of T. brucei (TbAK), are well characterised and 
structures of the open (apo) form and the closed form in complex with a number of 
substrates and substrate analogues are available (Cook et al., 2000, Kuettel et al., 
2011, Reddy et al., 2007, Muchmore et al., 2006, Mathews et al., 1998, Schumacher 
et al., 2000, Zhang et al., 2007, 2006), e.g. Toxoplasma gondii AK, Figure 2-1. The 
protein is comprised of two α/β-domains, a large domain and small lid domain, 
highlighted in Figure 2-1 A and B. The active site is located between the two 
domains, which close upon substrate binding.  
The AKs belong to the phosphofructokinase B family of carbohydrate kinases with 
two characteristic sequence motifs: the di-glycine switch close to the N-terminus 
and the signature sequence DXNGAGD close to the C-terminus (Park & Gupta, 
2008), highlighted in Figure 2-1 C in dark blue and green, respectively. The two 
catalytically active residues R136 and S318 are conserved in all AKs and are 
highlighted in red. In solution, AKs are monomeric, with the exception of 
M. tuberculosis AK, which was shown to be dimeric (Reddy et al., 2007).  
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Figure 2-1: Overall view of adenosine kinase.  
Shown is the adenosine kinase from T. gondii (TgAK). (A) TgAK-Ado-AppCp in ribbon representation coloured 
as rainbow from N-terminus (blue) to C-terminus (red), the ligands as spheres coloured by atom type. (B) 
Protein cartoon representation of TgAK-Ado-AppCp coloured as rainbow with β-strands as arrows and α-
helices as tubes. The β-sheets are underlaid in light blue. Cartoon generared with Pro-origami (Stivala et al., 
2011). (C) TgAK-Ado-AppCp in ribbon representation with catalytically important residues (red), di-glycine 
switch (dark blue) and signature sequence (lawn green) as spheres. (A) and (C) were made with CCP4mg 
(McNicholas et al., 2011). 
 
2.1.1 Adenosine Kinase from T. brucei brucei 
The genome of T. brucei brucei encodes two ORFs for AK, Tb927.6.2360 (TbAK-1) 
and Tb927.6.2300 (TbAK-2), each encoding a protein of 345 amino acid residues 
(37.9 kDa). The coding sequences differ in only eight nucleotides, resulting in just 
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four amino acid substitutions near the C-termini of the respective enzymes. The two 
genes are located on chromosome 6 in close proximity, probably the result of a 
tandem-duplication of a 7.8 kbp region including the TbAK gene and four ORFs of 
unknown function. Both genes are transcribed in procyclic as well as bloodstream 
parasites and the produced proteins localise to the cytoplasm (Luscher et al., 2007). 
This work focuses on TbAK-1, the subject of most studies published to date. For 
simplicity, TbAK-1 will be referred to as TbAK in this thesis except when compared 
directly to TbAK-2. Comparison of AKs from different species reveals a rather low 
sequence identity with 62 % to T. cruzi AK, 55 % to L. major AK and 41 % to HsAK, 
Figure 2-2. Sequence similarities span the whole length of the protein with highest 
conservation in regions important for the function, e.g. the di-glycine switch, the P-
loop and the adjacent helix, substrate coordinating and catalytically essential 
residues. Loop regions have low sequence similarity as expected. 
AK is a non-essential enzyme in T. brucei as was shown by RNAi-mediated depletion 
of AK (Luscher et al., 2007). This is not surprising as AMP can be produced not only 
by Ado phosphorylation, but also using the PNH-APRT pathway or from IMP using 
the ADSS-ASL pathway (as explained in more detail in section 1.8.1.1). However, 
hyper-activation of AK seems to have trypanocidal effects in vitro (Kuettel et al., 
2009). 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine (KRM) and some of its 
derivatives were shown to be trypanocidal (Kuettel et al., 2007) and after 
identification of TbAK as the protein binding to these compounds, it was shown that 
they increase TbAK’s activity and abolish substrate inhibition. The crystal structure 
of AK from T. brucei rhodesiense in complex with the activator (2xtb, Kuettel et al., 
2011) shows one molecule bound per AK chain, its binding site overlapping with the 
Ado binding site.  
 
4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl] morpholine 
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Figure 2-2: Structure-based alignment of TbAK sequences 1 and 2 with other AKs.  
Conserved residues highlighted in red, similar residues in yellow. The secondary structure elements (from 
TbAK structure) are displayed above the sequences: spiral = α-helix, arrow = β-strand.  The di-glycine switch is 
marked with blue triangles below the sequences, catalytically important residues with red stars and the P-
loop residues with green circles. The alignment was generated using Expresso (from T-Coffee (Armougom et 
al., 2006) and Espript 3.0 (Gouet et al., 2003). 
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The preferred substrate of TbAK is Ado, but it also phosphorylates dAdo, inosine 
and nucleoside analogues like cordycepin, Ara-A and F-Ara-A. It tolerates all NTPs as 
phosphate donors, but clearly prefers ATP and GTP as indicated by their lower KM 
values (Vodnala et al., 2008). TbAK’s activity is stimulated (increase in Vmax) by 
inorganic phosphate without affecting the affinity for Ado. Like mammalian, yeast 
and plant AKs, TbAK shows substrate inhibition, while AKs of most other protozoan 
parasites, like L. donovani, do not show inhibition by high Ado concentrations (Datta 
et al., 1987).  
 
2.1.2 AK Mechanism 
The mechanism of γ-phosphoryl transfer from the ATP to the Ado was described as 
an ordered bi-bi mechanism for the human enzyme (HsAK, Mathews et al., 1998), 
Figure 2-3. As the Ado binding site is much more deeply buried than the ATP-
binding site, it can be assumed that Ado is the first substrate to bind.  
 
Figure 2-3: Scheme of the ordered bi-bi mechanism of AK. 
 
The substrate binding site is conserved amoung different species, and the protein – 
substrate interactions are summarised in Figure 2-4. The proposed mechanism of 
AK based on the structural information of the active site of TgTK is shown in Figure 
2-5. The catalytic aspartate (D318 in TgAK) acts as the catalytic residue and 
deprotonates the 5’-OH of the ribose ring of the Ado, which then performs a 
nucleophilic attack on the γ-phosphate of the phosphate donor, usually ATP. After 
formation of a transition state with a penta-coordinated γ-phosphate, the products 
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AMP and ADP leave the active site. An Mg2+ ion is essential for catalysis helping 
correct orientation of the substrate and acting as a counter ion. 
AK shows strong, non-competitive substrate inhibition and it was proposed that the 
enzyme has an additional Ado-binding site differing from the substrate and 
triphosphate site, which was supported by chemical modification studies (Palella et 
al., 1980, Hawkins & Bagnara, 1987). None of the structures published to date show 
a regulatory binding site for Ado, but that of HsAK solved with Ados bound in both 
the Ado and the ATP-binding pockets, suggests a competitive inhibition mode of 
ATP binding by Ado (Mathews et al., 1998). 
 
Figure 2-4: Schematic view of the substrate binding site of TgAK with protein-substrate interactions. 
Shown are the ligands and residues coordinating substrates via hydrogen bonds (green labels, hydrogen 
bonds as dashed lines), and hydrophobic interactions (black labels, red half circles). Ligand and hydrogen 
bonding residues are shown as ball and stick models coloured by atom type. Figure drawn with LigPlot+ 
(Laskowski & Swindells, 2011). 
 
2.81
2.65
2.89
2.77
2.82
2.40
2.47
3.10
3.06
2.87
3.09
O5’
C5’
C4’
O4’
C3’
O3’
C2’
O2’ C1’
N9
C8
N7
C5
C6
N6
N1
C2
N3
C4
Ado
PG
O1G
O2G
O3G
PB
O1B
O2B
C3B
PA
O1A
O2A
O3A O5’
C5’
C4’ O4’
C3’
O3’
C2’
O2’
C1’
N9
C8
N7
C5
C6 N6
N1C2
N3
C4
AppCp
Tyr169
N
CA
C
O
Gly280
N
CA
C
O
CB
CG
CD
NE
CZ
NH1
NH2
Arg136
N
CA
C
O
Gly315
N
CA
C
O
CB
OG1
CG2
Thr140
N
CA C
O
CBOG1
CG2
Thr278
N
CA
C
O
Gly69
N CA
C
O
CB
CG
OD1
ND2
Asn20
N
CA
C
O
CB
OG
Ser70
N
CA
C
O
CB
CG
OD1
ND2
Asn342
Ile22
Asp24
N
CA
C
O
CB
CG
OD1
ND2
Asn73
Asn314
Ala316
His281
Asp318
Ala345
MG
Mg
Gly68
Val302
Gln346
Leu46
Cys127
Leu142
Asn223
Val284
Val305
Thr313
Gly317
Phe320
1lii
 69 
 
Figure 2-5: Mechanism of γ-phosphoryl transfer in AK. 
R1 = adenosine moiety of the phosphate donor ATP, residue numbering after TgAK. Hydrogen bonding 
indicated by dashed lines, hydrophobic interactions indicated in dark red. Figure made with MarvinSketch 
(ChemAxon). 
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2.1.3 Transition state analogues for phosphoryl transfer 
Phosphoryl transfers in kinases happen via a planar, trigonal phosphoryl 
intermediate (middle panel in Figure 2-5, Cleland & Hengge, 2006, Rosta et al., 
2008). Compounds mimicking the reaction intermediate or transition states help to 
study the conformational changes an enzyme undergoes during the reaction. 
Transition state analogues with AlF4
-, AlF3
-
, BeF3
- and MgF3
- mimicking the 
transferring phosphoryl group (Wittinghofer, 1997, Baxter et al., 2006) have been 
used successfully for a variety of enzymes, e.g. the human phosphoglycerate kinase 
(HsPGK), which has been co-crystallised with ADP, phosphogyceric acid (3PG) and 
AlF4
-, AlF3
- (+ H2O) and MgF3
-, Figure 2-6 (Cliff et al., 2010). These analogues 
assemble spontaneously in the active site of the enzymes and lock them into place, 
therefore functioning as potent inhibitors. The MgF3
-
 in the complex shows the 
typical trigonal bipyramidal geometry close to isosteric to a transferring phosphoryl 
group (Figure 2-6 A). AlF4
-
 was shown to readily outcompete MgF3
- (Baxter et al., 
2008) although it has non-isosteric octahedral geometry, like in Figure 2-6 B. 
Transition states with AlF3
-, like in Figure 2-6 C, show the same geometry as AlF4
- 
with a water molecule replacing one of the fluorines. 
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Figure 2-6: Transition state analogues in HsPGK.  
The ligands shown as cylinders, coloured by atom type, electron density map contoured at 1.5σ. (A) ADP-
MgF3-3PG +Mg, PDB ID: 2wzb. (B) ADP-AlF4-3PG +Mg, PDB ID: 2wzc. (C) ADP-AlF3-3PG +Mg, PDB ID: 2wzd. 
Figure made with CCP4mg (McNicholas et al., 2011). 
 
2.1.4 Aims 
The aim was to determine the X-ray crystal structures of T. brucei brucei AK in its 
apo form and in complex with its substrate Ado plus the non-hydrolysable ATP 
analogue AppNHp. Insights gained from these structures and the structural 
information available for human ADA should lead to a better understanding of 
cordycepin modifications possible to improve its stability against deamination while 
retaining its trypanocidal properties. 
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2.2 Experimental 
2.2.1 Cloning of TbAK constructs 
The gene encoding the AK from T. brucei brucei (Tb927.6.2360) was amplified by 
PCR from genomic DNA using the reaction conditions and temperature cycles 
detailed in Table 2-1 and Table 2-2. Primer sequences are listed in appendix A.2.3. 
The size of the amplified gene was checked by agarose gel electrophoresis (Figure 
2-7) and then cloned into the YSBLIC and YSBLIC3C vectors using ligation-
independent cloning (Aslanidis & de Jong, 1990, Fogg et al., 2006).  
 
Table 2-1: PCR reaction mix used for TbAK. 
Reagent Volume/reaction [µL] 
10 x Pfu buffer (incl. MgSO4, Promega) 5 
dNTP mix (10 mM each) 1 
Forward primer (10 µM) 2.5 
Reverse primer (10 µM) 2.5 
ddH2O 38.5 
Pfu polymerase (2.5 U/µL, Promega) 0.5 
Template (genomic DNA) 1 (= ~100 ng) 
Total volume 50 
 
Table 2-2: Temperature profile of the PCRs used for TbAK. 
Step Temperature [°C] Time [s] No. of cycles 
Initial denaturation 95 2 1 
Denaturation 95 30 
30 
Annealing 60 30 
Extension 72 90 
Final extension 72 300 1 
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Figure 2-7: Agarose gel of TbAK amplification.  
Loaded onto a 1.5 % agarose gel: 1Kb ladder (lane 1), TbAK gene for YSBLIC (lane 2) and TbAK gene for 
YSBLIC3C (lane 3).  
 
In brief, long overhangs on linearised vector and insert DNA fragments are created 
using the T4 DNA polymerase (reaction conditions specified in Table 2-3). 
Subsequently the T4 treated vector was purified using a Miniprep Kit (Qiagen) and 
stored in aliquots at -20°C, the insert was not purified. Insert and vector are then 
annealed by incubation of 2 µL insert (2 fmol) and 1 µL purified vector (0.3 fmol), 
both with long overhangs, for 10 min at room temperature before addition of 1 µL 
EDTA (6.25 mM) and another incubation for 10 min at room temperature. 
Chemically competent E. coli were then transformed with the mixture (4 µL total) 
where the construct is ligated. 
 
Table 2-3: Reaction conditions of the T4 reaction. 
Reagent  Vector  Insert  
10x T4 pol. Buffer (Promega) 40 µL (1x) 2 µL (1x) 
DTT (100 mM) 20 µL (0.5 mM) 1 µL (0.5 mM) 
dTTP (25 mM) 2 µL (2.5 mM) - 
dATP (25 mM) - 2 µL (2.5 mM) 
DNA (linearised) 24 µL = 4 pmol 1.8 µL = 0.2 pmol 
ddH2O 268 µL 12.8 µL 
T4 polymerase (10 U/µL, Promega) 8 µL = 80 units 0.4 µL = 4 units 
Total volume 400 µL 20 µL 
 Incubation for 30 min at room temperature 
 Incubation for 20 min at 75°C 
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The generated construct, named TbAK-LIC, encodes a Histag fusion to the N-
terminus of the protein, whereas the construct TbAK-3C contained a N-terminal 
Histag connected via a HRV 3C protease recognition site for subsequent removal of 
the tag. The cloning success was confirmed by colony PCR. For this colonies were 
picked and suspended in 50 μL ddH2O. One μL was used to inoculate 1 mL LB 
cultures for plasmid propagation, the remaining 49 μL were heated at 95°C for 
5 min and centrifuged for 2 min before the PCR. The PCR reaction was carried out 
using the conditions in Table 2-4 and Table 2-5. The positive clones were 
propagated and further verified by sequencing. 
 
Table 2-4: Reaction mix for colony PCRs. 
Reagent Volume/reaction [µL] 
10 x Pfu buffer (incl. MgSO4, Promega) 5 
dNTP mix (10 mM each) 1 
T7 promotor primer (10 µM) 2.5 
Reverse primer (10 µM) 2.5 
ddH2O 29.5 
Pfu polymerase (2.5 U/µL, Promega) 0.5 
Template (boiled colony in ddH2O) 10  
Total volume 50 
 
Table 2-5: Temperature profile of the colony PCRs. 
Step Temperature [°C] Time [s] No. of cycles 
Initial denaturation 95 2 1 
Denaturation 95 30 
30 
Annealing 50 30 
Extension 72 90 
Final extension 72 300 1 
 
2.2.2 Expression of TbAK 
For initial expression testing chemically competent E. coli BL21 gold (DE3), C41 and 
pLEMO cells were transformed with TbAK-LIC and TbAK-3C and plated on Luria-
Bertani Miller (LB) plates containing 35 µg mL-1 kanamycin. The next day colonies 
were washed off the plates with 5 mL LB medium and these resuspended colonies 
were used for inoculation of new 5 mL cultures. The cultures were grown at 37°C to 
an optical density of 0.8 at 600 nm. One culture of each strain was transferred to 
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20°C and expression in all cultures was induced by addition of 1 mM isopropyl thio-
β-D-galactoside (IPTG). The expression culture at 37°C was left for 4 h, the 
expression at 20°C was left overnight. After SDS-PAGE analysis of lysed 1 mL 
samples of expression culture, the expression of both constructs was found to be 
best in C41 cells.  
For large scale expression the constructs were transformed into C41 cells as in the 
expression test and subsequently 8 x 500 mL LB was inoculated with cells washed 
off the plates of the fresh transformants. The cells were grown at 37°C with shaking 
at 180 rpm (Innova44, New Brunswick Scientific) until they reached an optical 
density of 0.2 at 600 nm and then transferred to 20°C with shaking at 251 rpm. 
Protein expression was induced by addition of 1 mM IPTG at an optical density of 
0.6 at 600 nm for 6 h. Cells were harvested by centrifugation at 5000 x g for 30 min 
and washed with 100 mL PBS prior to freezing and storage at -20°C. 
 
2.2.3 Purification and characterisation of TbAK  
The purification protocol for both TbAK constructs used the same buffers and 
general procedure. Reducing agents were added to all buffers. Initial purification 
buffers contained 10 mM β-mercapto-ethanol and 100 µM PMSF, but later the 
reducing agent for the TbAK-3C buffers was changed to 1 mM DTT and PMSF was 
left out (details discussed in 2.3.1). 
Cell pellets were thawed on ice, resuspended in 80 mL lysis buffer A (20 mM Tris 
pH 7.5, 200 mM NaCl, 30 mM imidazole, 10 mM β-mercapto-ethanol and 100 µM 
PMSF) or B (20 mM Tris pH 7.5, 200 mM NaCl, 30 mM imidazole and 1 mM DTT) and 
lysed by sonication. Cell debris was removed by centrifugation at 5000 x g and 4°C 
for 40 min. The cleared lysate (supernatant) was loaded onto a pre-equilibrated 
5 mL HisTrap FF crude column (GE Healthcare), which was then washed with three 
column volumes of lysis buffer (A or B respectively). The protein was eluted using 
an imidazole gradient from 30 mM to 500 mM imidazole (Figure 2-8 A). For 
purification of the TbAK-3C the protein-containing fractions, identified by SDS-PAGE 
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(Figure 2-8 B) were pooled and concentrated to ~ 2 mg mL-1 before addition of HRV 
3C protease in a ratio of 1:100 (protease:TbAK). Proteolysis was monitored by 12 % 
SDS-PAGE and had reached completion overnight at 4°C. To remove the Histag and 
uncleaved TbAK the protein buffer was exchanged into the lysis buffer using 
Centrifuge filters (Amicon® Ultra Centrifugal Filter from Millipore or Vivaspin6 from 
SartoriumStedim biotech, 30 kDa cutoff) and another nickel affinity purification was 
performed using the same buffers as before, resulting in untagged protein in the 
flowthrough (Figure 2-8 C). The resulting protein was concentrated and loaded onto 
a Superdex 75 column (GE Healthcare), in buffer containing 10 mM Tris pH 7.5, 
200 mM NaCl and 10 mM β-mercapto-ethanol (BME) or 1 mM DTT as reducing 
agent (Figure 2-8 D). For purification of TbAK-LIC the protein-containing fractions of 
the nickel affinity chromatography were pooled, concentrated and directly loaded 
onto a Superdex 75 column (without preceding proteolysis). Protein purity was 
monitored by SDS-PAGE (Figure 2-8 E). 
Because of the higher degree of purity and better behaviour in the initial 
crystallisation screen, the main focus was set on the sample with the cleavable 
Histag.  
After purification, TbAK was concentrated to an approximate volume of 1 mL and 
dialyzed (12-14 kDa cutoff) against the size exclusion chromatography buffer 
overnight at 4°C. Subsequently, the protein was flash cooled in liquid nitrogen and 
stored at -80°C at a concentration of 46, 50 or 67 mg mL-1 dependent on the 
purification batch.  
To confirm the identity of the purified protein, electrospray ionisation mass 
spectrometry (ESI-MS) was used. Before crystallisation experiments were carried 
out, the polydispersity of TbAK was determined by dynamic light scattering (DLS).  
For this the protein was diluted to a concentration of 3 mg mL-1 at 20°C with a total 
sample volume of 20 µL. DLS measurements were carried out using a DynaPro™ 
(Protein Solutions™). 
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Figure 2-8: Purification of TbAK. 
(A) Nickel affinity chromatography trace from a 5 mL HisTrap crude column. UV trace shown in blue, 
imidazole concentration shown in orange, black bar indicates the fractions analysed by SDS-PAGE. (B) SDS gel 
after nickel affinity chromatography with L = cell lysate and FT = flowthrough. (C) SDS-gel after 3C digest and 
subsequent nickel affinity chromatography. E = TbAK-containing fractions of first HisTrap, 3C o/n = after o/n 
incubation with 3C protease, 2. HT = nickel affinity chromatography after digest, FT = flowthrogh. (D) Size 
exclusion trace from a 10/300 Superdex 75 column. The black bar indicates the elution volume of TbAK, 
which was confirmed by SDS-PAGE. (E) SDS gel after size exclusion chromatography showing TbAK as a single 
band without degradation or contamination. In all gels: lane 1 = low molecular weight marker with bands for 
97, 66, 45, 31, 21 and 14 kDa sized proteins. 
 
2.2.4 Crystallisation of TbAK 
The initial crystallisation screens, Index and PACT, were set up at TbAK 
concentrations of 46 mg mL-1 with and without ligands, using sitting drop vapour 
diffusion at 20°C. Drops of 150 nL protein solution + 150 nL well solution were 
pipetted using a Mosquito robot (TTP Labtech Ltd. UK). Ligands used were 1 mM 
Ado and 1 mM β,γ-imidoadenosine 5′-triphosphate (AppNHp), and both TbAK 
constructs, but the work focussed on the protein with its Histag removed as the 
histagged TbAK-LIC did not show any crystallisation. After the initial screening, the 
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concentration of untagged TbAK purified in the presence of BME was lowered to 
30 mg mL-1. Crystal conditions were optimised using hanging drop vapour diffusion 
with 1 μL TbAK plus 1 μL well solution. The best crystals in complex with Ado and 
AppNHp grew in 0.1 M Bis Tris propane pH 8.5, 0.2 M sodium citrate and 24 % (w/v) 
PEG 3350 within 3 weeks to a maximum size of ~ 600 x 100 x 50 µm3. The crystal 
used for structure solution was cryo-protected in mother liquor containing 5 % 
ethylene glycol and vitrified prior to data collection. 
For the apo-TbAK further screening with several commercially available screens 
(PACT, Index, JCSG, Hampton 1 and 2 and CSS) did not lead to crystals. Following the 
publication of the structure of the TbAK complex with the activator KRM in the 
open conformation (Kuettel et al., 2011) the screening focussed around the 
conditions reported therein, using a protein sample purified with buffers containing 
DTT as reducing agent. This led to a large number of crystals of which 200 were 
tested for diffraction. However, very few showed any diffraction, and finally only 
one provided a usable diffraction pattern with the rest showing very restricted 
resolution or substantial splitting and disorder. The single usable crystal grew at 4°C 
in 0.1 M Tris pH 8.8 and 60 % (v/v) MPD, and reached a maximum size of 
~ 80 x 20 x 20 µm3 after one week, and was not cryo-protected before vitrification. 
Interestingly, the choice of reducing agent in purification appeared to have a strong 
influence on the crystallisation behaviour. While TbAK purified in the presence of 
BME crystallised only in the closed conformation (with ligands added), TbAK 
purified with DTT crystallised only in the open conformation (without ligands). 
Additionally, repetition of purification under the same or modified conditions did 
not lead to diffracting crystals, and even after extensive screening it was not 
possible to obtain crystals with improved diffraction. Extensive screening in order to 
crystallise TbAK in complex with cordycepin and the transition state analogue 
ADP:MgF4:Ado were unsuccessful. Crystallisation screening of TbAK in complex with 
ADP:AlF4:Ado, followed by optimisation with several rounds of seeding produced 
crystals diffracting to ~ 6 Å. Further optimisation did not improve the resolution. 
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2.2.5 Data collection, structure solution and refinement of TbAK 
Computations were made using programs from the CCP4 software package (Winn 
et al., 2011) unless otherwise stated. The data were processed with XDS (Kabsch, 
2010a, b), POINTLESS (Evans, 2011) and SCALA (Evans, 2006).  
The X-ray diffraction data for both crystals were collected at the Diamond Light 
Source (DLS). The TbAK-Ado-AppNHp crystal was in space group C2 with four 
molecules of TbAK in the asymmetric unit. The apo crystal was split, which limited 
data quality, and belonged to space group P41212 with one molecule of TbAK per 
asymmetric unit. The crystallographic data and statistics are summarised in Table 
2-6. 
The structures were solved by molecular-replacement using PHASER (McCoy, 2007). 
At the time, HsAK (PDB ID: 1bx4) with a protein sequence identity of 40 % showed 
the highest similarity to TbAK and was used as the search model for the TbAK-Ado-
AppNHp. For apo TbAK the structure of the TbAK-KRM (PDB ID: 2xtb) was used as 
the search model. 
Structure refinement was carried out using maximum-likelihood restrained 
methods in REFMAC5 (Murshudov et al., 2011) with automatically generated local 
NCS. The manual fitting of the electron-density maps, model building and fitting of 
the ligands were carried out in COOT (Emsley et al., 2010). The models were 
validated using COOT and MolProbity (Chen et al., 2010). 
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Table 2-6: Crystallographic data and statistics of the TbAK crystals. 
Data for the highest resolution shell shown in brackets, the Ramachandran Plot was calculated using COOT 
(Emsley et al. 2010), the poor rotamer analysis was carried out in Molprobity (Chen et al. 2010). 
 apo TbAK TbAK-Ado-AppNHp 
Data collection   
Diffraction Source DLS beamline I03 DLS beamline I24 
Wavelength (Å) 0.9763 0.9686 
Temperature (K) 100 100 
Detector Pilatus 6M-F Pilatus 6M Prosport+ 
Rotation range per image (°) 0.2 0.2 
Total Rotation range (°) 180 220 
Crystal data   
Space group P41212 C2 
a, b, c (Å) 60.08, 60.08, 192.86 184.53, 90.22, 98.04 
α, β, γ (°) 90.00, 90.00, 90.00 90.00, 103.78, 90.00 
Resolution (Å) 57.36 - 2.60  (2.74-2.60) 95.21 - 2.60 (2.74-2.60) 
Total Reflections 132048 (20863) 160133 (23793) 
Unique Reflections  11649 (1664) 47962 (6973) 
Completeness (%) 99.90 (100) 99.5 (99.4) 
Redundancy 11.3 (12.5) 3.3 (3.4) 
Rmerge  0.120 (0.395) 0.176 (0.991) 
[I/σ (I)] 15.8 (6.3) 6.6 (2.3) 
Matthew’s coefficient 2.28 2.59 
Refinement statistics   
Reflections, working set 10989 45507 
Reflections, test set 660 2455 
Resolution Range (Å) 57.36 - 2.60 95.21 - 2.60 
R-factor 0.170 0.186 
Rfree 0.231 0.221 
No. of non-H atoms   
Protein 2463 10276 
Ligand - 192 
Water 157 148 
Mean B factors (Å
2
)   
Protein 38.0 45.2 
Ligands - 44.4 
Water 40.5 38.3 
RMS deviation from ideal   
Bond length (Å) 0.013 0.012 
Bond angles (°) 1.466 1.531 
Ramachandran Plot (%)   
Residues in favored region 93.6 96.05 
Residues in allowed region 5.8 3.58 
Outliers  0.6 0.37 
Molprobity score  1.35 1.45 
Poor Rotamers (%) 1.61 2.01 
PDB ID 4n08 4n09 
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2.3 Results 
2.3.1 Purification and Characterisation of TbAK 
TbAK was expressed in E. coli C41 cells and purified using nickel affinity and size 
exclusion chromatography in sufficient quality and quantity for crystallisation 
experiments.  
Initially, TbAK was purified using buffers containing β-mercapto ethanol (BME) and 
PMSF for protease inhibition. However, characterisation by DLS revealed a 
polydispersity of approximately 75 % (Figure 2-9 A) and analysis by ESI-MS showed 
peaks of 80 and 156 Da higher than expected for the native protein, which could be 
the result of phosphorylation (80 Da) and a BME adduct (76 Da) or a PMSF adduct 
(156 Da) (Figure 2-9 B). This first batch was used for initial screening, which led to 
crystals of TbAK grown in the presence of Ado and AppNHp.  
After the characterisation and crystallisation of the first TbAK preparation, the 
buffers used for purification were changed to avoid possible BME and PMSF adducts 
and reduce the polydispersity. DLS showed the protein to be monodisperse (10 % 
polydispersity) for this second batch (Figure 2-9 C) and ESI-MS indicated a single 
species with a MW of 38187 Da (expected value 38184 Da for the protein with the 
extra three residues remaining at the N-terminus after cleavage of the Histag, 
Figure 2-9 D). This new TbAK preparation was used for further crystallisation 
screening.  
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Figure 2-9: DLS and ESI-MS analysis of TbAK purification batches.  
(A) DLS Histogram and (B) ESI-MS trace of TbAK purified with buffers containing BME as reducing agent. 
(C) DLS Histogram and (D) ESI-MS trace of TbAK purified in presence of DTT as reducing agent. 
 
2.3.2 Crystallisation of TbAK 
Crystals of TbAK grown in the presence of Ado and AppNHp (Figure 2-10 A) using 
the protein purified with BME as reducing agent diffracted to 2.6 Å (Figure 2-11 A), 
and were in space group C2 with four TbAK monomers in the asymmetric unit. All 
four chains had clear density for the Ados and the α- and β-phosphate of the 
AppNHp, but there was no density for the γ-phosphate and the ligand is therefore 
referred to as ADP in the figures. This could be the consequence of hydrolysis or of 
high flexibility of the γ-phosphate due to the lack of a coordinating Mg2+ ion. The 
crystallisation condition contained sodium citrate, which probably chelated any 
metal ions. There was no magnesium in the crystallisation buffer.  
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Figure 2-10: TbAK crystals.  
(A) TbAK-Ado-ADP crystal used for structure determination. Black bar = ~ 200 μm. (B) Optimised TbAK-
ADP:AlF4:Ado crystals after 2 rounds of seeding, diffracting to ~ 6 Å. Black bar = ~ 50 μm. (C) Apo TbAK 
from the condition used to solve the structure. Black bar = ~ 40 μm. 
 
Attempts to reproduce the TbAK-Ado-AppNHp crystals failed with protein purified 
in the presence of DTT, as did attempts to co-crystallise TbAK with cordycepin or 
with magnesium fluoride plus nucleotides. Crystallisation experiments of TbAK in 
complex with ADP:AlF4:Ado produced crystals (Figure 2-10 B), some of which 
diffracted to approximately 6 Å, but all showed multiple lattices. Further rounds of 
seeding and optimisation did not improve the resolution or diffraction quality. At 
this point, the structures of TbAK in complex with the bi-substrate analogue 
diadenosine pentaphosphate (AP5A) and the activator 4-[5-(4phenoxyphenyl)-2H-
pyrazol-3-yl]morpholine (KRM) were published (Kuettel et al., 2011). In order to 
obtain crystals of TbAK in complex with the activator these authors crystallised the 
protein in its apo form and soaked in the activator. With the information about 
their crystallisation conditions it was possible to design an optimisation screen 
specifically for obtaining crystals of apo TbAK using the protein from the DTT 
purification. Many single crystals grew (Figure 2-10 C) but showed no or very poor 
diffraction and inherent defects resulting in many overlapping lattices. However, 
one of the crystals diffracted up to 2.0 Å and allowed structure determination, 
although the diffraction was anisotropic and data quality remained rather poor with 
many overlapping lattices (Figure 2-11 B). The crystal was in space group P41212 
with one TbAK molecule per asymmetric unit and the data were integrated to 2.6 Å. 
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Figure 2-11: Diffraction patterns of TbAK crystals.  
This figure shows a close-up of images used for structure determination of the (A) TbAK-Ado-ADP and (B) apo 
TbAK structures with rings annotation the resolution. Although the diffraction of the apo TbAK crystal 
seemed to extend to 2.0 Å, the diffraction was anisotropic and therefore only integrated to 2.6 Å overall. 
Figure was made using the adxv software (Arvai, 2012). 
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2.3.3 Structures of TbAK 
2.3.3.1 Overall fold 
The structures of the T. brucei brucei enzyme reported here are highly similar to 
those from a closely related subspecies, T. brucei rhodesiense (Kuettel et al., 2011), 
which has an identical amino acid sequence, the gene only differing by two silent 
mutations. Also they show only minor differences to the other published structures 
of AKs, like those from Anopheles gambiae (AgAK, (Cassera et al., 2011), human 
(HsAK, (Mathews et al., 1998, Muchmore et al., 2006), Toxoplasma gondii (TgoAK, 
(Cook et al., 2000, Schumacher et al., 2000, Zhang et al., 2006, 2007) and 
Mycobacterium tuberculosis (MtuAK, (Reddy et al., 2007).  
TbAK shows the typical architecture consisting of two domains, a large ATP-binding 
α/β-domain and a small lid domain (Figure 2-12 A). The larger domain shows a α/β 
structure consisting of a central 9-stranded predominantly parallel β-sheet (β6, β5, 
β1, β9, β10, β11, β12, β13, β14) with β13 being the only antiparallel strand. This β-
sheet is sandwiched between two layers of α–helices with 11 α–helices in total (α3- 
α13). The smaller lid domain consists of a 5-stranded β-sheet (β4, β2, β7, β8, β3) at 
the interface to the large domain and two α–helices (α1, α2) on top of it. Two 
alternative conformations are possible depending on the position of the lid domain, 
an open and a closed form (Figure 2-12 B).  In the absence of substrate, AK is in the 
open conformation (apo), in presence of substrates the lid domain closes down, 
forming the closed conformation. The active site is located at the interface of the 
two domains. 
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Figure 2-12: Overall structure of TbAK.  
(A) Structure in the closed conformation in ribbon representation coloured by secondary structure with α–
helices in ice blue and β-strand in lemon. (B) Stereo view of a superposition structures in the open (tan for 
α/β-domain, dark crimson for lid domain) and closed (light blue and ice blue) conformations based on the 
core structure of the α/β-domain in worm representation, clearly showing the closure of the small lid 
domain. Ado and ADP bound in the active site are shown as spheres coloured by atom type. This and all 
subsequent structure figures were made using CCP4mg (McNicholas et al., 2011)  with all superpositions 
carried out using SSM (Krissinel & Henrick, 2004). 
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2.3.3.2 Substrate binding  
In the structure co-crystallised with Ado and AppNHp, there are four independent 
protein molecules in the asymmetric unit, with well-defined density for both the 
Ado and the AppNHp missing the γ-phosphate. The four chains are very similar – 
the RMSD between all C atoms is 0.37, 0.39 and 0.29 Å for Chains B, C and D 
superposed on Chain A using SSM (Krissinel & Henrick, 2004). Chain A is therefore 
used in the rest of the discussion and other panels of the figures. TbAK adopts a 
closed conformation similar to all other structures of AK complexes with substrates 
or substrate analogues in both of the binding pockets of the active site. 
Superposition of the structures of TbAK in its closed and open forms confirmed that 
the smaller lid domain closes down over the active site and the large domain 
contracts slightly (Figure 2-12 B). This results from a rigid body rotation of 28° with 
hinge motions of the amino acids connecting the two domains. Among the critical 
residues for this motion are the two glycines of the di-glycine switch. In addition, 
TbAK undergoes smaller structural rearrangements while binding to and orienting 
its substrates (Figure 2-13). The Ado forms hydrogen bonds to residues N13, D17, 
G63, N67, D299 and stacking interactions of its adenine ring with F169. The 
coordination of the 2’- and 3’-hydroxyl groups of its ribose ring to D17 assists in the 
closure of the lid domain. The ADP forms hydrogen bonds to N222, T264, T270, 
D266, G298 and Q288. The interactions with the ADP cause a slight closing of the 
loop between residues 266 and 268 and a rearrangement of the loop comprising 
residues 282-292. These smaller movements orient the substrates in the binding 
pockets and bury the two Ado moieties. Additionally, the 13 residues at the very N-
terminus of the protein, disordered in the apo structure, form a loop behind the 
α13 helix. 
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Figure 2-13: Active site of TbAK.  
The substrates Ado and ADP are shown in ball and stick representation coloured by atom type; the substrate-
coordinating residues are shown as cylinders and the region around these residues are represented as 
ribbons. Dashed lines represent hydrogen bonds. (A) Active site with adenosine and ADP bound. (B) Overlay 
of the active sites of apo TbAK (tan) and TbAK-adenosine-ADP (ice blue).  
 
TbAK was co-crystallised with AppNHp, but only shows clear electron density for the 
α- and β-phosphate and none for the γ-phosphate. To address this, the structure 
was refined with REFMAC5 with ADP and AppNHp with γ-phosphate occupancies of 
50 % and 100 %. Comparison of the electron density and difference maps of these 
refined structures with the unbiased map, generated before ligand modelling 
(Figure 2-14), strongly indicated the γ-phosphate to be absent. At this resolution it 
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is not possible to distinguish O and N atoms in the AppNHp from the maps, 
therefore, the ligand is referred to as ADP.  
 
 
Figure 2-14: Electron density and difference maps of TbAK ligands.  
The weighted electron density maps (2mFo-DFc) and difference maps (mFo-DFc) were calculated using 
REFMAC5 (Murshudov et al., 2011). Ado and AppNHp are shown as ball-and-stick models coloured by atom 
type, mFo-DFc maps contoured at 3σ in green (positive) and red (negative), the 2mFo-DFc maps are contoured 
at 1σ and drawn in blue. (A) Unbiased maps generated before ligand modelling. (B) Maps after refinement 
with ADP (not AppNHp). (C) Maps after refinement with AppNHp, occupancies of the γ-phosphate atoms set 
to 50 %. (D) Maps after refinement with AppNHp, occupancies of the γ-phosphate atoms set to 100 %.  
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Important for the catalysis of nucleoside kinases is the anion hole motif 
(Schumacher et al., 2000), a conserved sequence of residues (amino acids 290-300 
in TbAK) essential for binding and correct orientation of the phosphates (Figure 
2-15). Superposition of the TbAK-Ado-ADP structure (4n09) on those of TbAK-AP5A 
(3otx, (Kuettel et al., 2011) and HsAK in complex with two Ados (1bx4, (Mathews et 
al., 1998) (Figure 2-15 A) shows it to be in an intermediate state between the latter 
two conformations, reflecting the importance of this motif. In our complex the γ-
phosphate of the AppNHp (mimicking the phosphate donor ATP) is missing, so that 
its interactions cannot help to arrange the P-loop completely to form the anion 
hole, which is therefore not bent outwards as far as it would be with all three 
phosphates present. The structure of TbAK-AP5A (3otx) shows a fully developed but 
slightly distorted anion hole due to the presence of too many phosphates in the 
active site. The complex of HsAK with two Ados (1bx4) lacks the anion hole motif 
and instead has an extended α11 helix, as there are no phosphates in the active 
site. In particular, residues 294-298 (centred around G296) take up a helical 
conformation in the absence of phosphate ligands, but change to a loop producing 
the anion hole when phosphates are present. Superposition of the apo TbAK 
structure (4n08) with TbAK-Ado-ADP (4n09) and TbAK-KRM (2xbt, Figure 2-15 B) 
shows the anion hole being formed by the binding of the activator KRM (Kuettel et 
al., 2011). In TbAK-KRM and TbAK-Ado-ADP the loop has nearly identical 
conformations, while in apo TbAK the loop adopts a different conformation. How 
binding of KRM induces this change in the loop region of residues 294-298 is not 
clear, as its binding site is ~ 9 Å away from the loop. 
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Figure 2-15: Anion hole motif.  
(A) Superposition of the anion hole motifs of HsAK (lemon, 1bx4, (Mathews et al., 1998), TbAK-AP5A (coral, 
3otx, (Kuettel et al., 2011) and TbAK-Ado-ADP (ice blue, TbAK co-crystallised with AppNHp, but missing the γ-
phosphate in the structure, 4n09). (B) Superposition of the anion hole motifs of apo TbAK (tan, 4n08), TbAK-
Ado-ADP (ice blue, 4n09) and TbAK-KRM (grey, 2xtb, (Kuettel et al., 2011). The main chain is represented as 
ribbons; ligands are represented as cylinders coloured by atom type with the carbon and phosphorous atom 
coloured by chain.  
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2.4 Discussion 
2.4.1 Comparison to other published structures 
The apo structure is in the open conformation is essentially identical to that 
reported for TbAK soaked with the activator KRM (PDB: 2xtb, (Kuettel et al., 2011) 
and that of apo-TgoAK (Schumacher et al., 2000). Comparison with 2xtb showed 
that the overall structures are effectively the same (Figure 2-16 A), the only 
differences being in the flexible loop region of the anion hole motif, spanning 
residues 281-297 (Figure 2-15 B). Additionally, the activator complex seems slightly 
more open, but this probably does not directly reflect the binding of the activator 
but is rather an artefact of crystallisation. The side chain of L138, close to the 
activator, has a different position in the two structures but makes no direct or 
indirect interactions with the activator itself.  
The structure of TbAK-Ado-ADP in the closed conformation is very similar to that for 
the complex with the bi-substrate analogue TbAK-AP5A (3otx, (Kuettel et al., 2011), 
with an RMSD on C positions of 0.57 Å (Figure 2-16 B). The adenines in both 
structures occupy essentially identical positions, as does the ribose on the ADP and 
AP5A (Figure 2-16 C). The only regions showing differences are loop regions and in 
the anion hole motif (Figure 2-15 A).  
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Figure 2-16: Comparison of TbAK structures.  
Proteins in ribbon representation and ligands are shown as cylinders coloured by atom type. (A)Superposition 
of TbAK-KRM (grey, 2xtb, (Kuettel et al., 2011) with apo TbAK (blue and light blue, 4n08). (B) Superposition of 
TbAK-AP5A (black, 3otx, (Kuettel et al., 2011) and TbAK-Ado-ADP (orange and lemon, 4n09). (C) Close-up of 
the ligands in a superposition of TbAK-AP5A (3otx) and TbAK-Ado-ADP (4n09). Ribbon in the background 
shows the TbAK-Ado-ADP structure. Ligands are shown as cylinders coloured by atom type, with carbon and 
phosphor atoms of AP5A in ice blue.  
 
In the TbAK-AP5A complex, there are five phosphates between the two Ado 
moieties, two more than would be present in the transition state, so the 
phosphates would need to be in different conformations in the Michaelis complex 
and the transition state. The structures of AMPK from Aquifex aeolicus have been 
determined in complex with both AP5A (2rgx, (Henzler-Wildman et al., 2007) and 
with the phosphoryl transfer transition state mimic ADP:AlF4:AMP in the active site 
(3sr0). The enzyme was in a very similar closed conformation in both, suggesting 
that the enzyme conformation and the adenine binding sites in the AP5A analogues 
were indeed representative of the true ligand binding state. Unfortunately, 
extensive crystallisation screens with nucleotides and magnesium and aluminium 
fluorides with the aim of obtaining a better mimic of the transition state failed to 
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produce diffracting crystals of sufficient quality. One problem may lie in the fact 
that the aluminium fluoride in TbAK would be coordinated by a P-O oxygen on one 
side and a ribose oxygen on the other, distinct from the AMPK system where the 
aluminium is coordinated by phosphate oxygens on both sides.  
 
2.4.2 Modelling of TbAK-2 and comparison to TbAK-1 
The amino acid sequences of TbAK-1 and TbAK-2 differ in only four positions. This 
high degree of identity allows the assumption that the structures of the two 
proteins are identical. Modelling of the four amino acid substitutions onto the 
structure of TbAK-1 solved within this work (Figure 2-17), revealed no clashes or 
obvious potential effects on substrate binding or catalysis. The substitutions are 
located approximately 7 Å (S269P), 9.6 Å (L272I), 11 Å (M302V) and 12.5 Å (R332Q) 
away from the ATP-binding site and even further from the Ado-binding site. It is 
possible that S269P has an effect on the movement of the adjacent loop during 
ATP-binding, but the other amino acid substitutions are unlikely to have an effect 
on structure or function. Therefore, it can be assumed the two proteins have 
identical functions within the parasites, where one copy is free to mutate as long as 
the other retains its function. 
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Figure 2-17: Amino acid substitutions in TbAK-2. 
Structure of TbAK-Ado-ADP shown in ribbon representation coloured by secondary structure with α-helices in 
ice blue and β-sheets in lemon. Ado and ADP are shown as cylinders coloured by atom type. Residues that are 
substituted (S269P, L272I, M302V and R332Q) are shown as ball-and-stick coloured by atom type with the Cα
 
atoms of TbAK-1 in lemon and the Cα
 
atoms of TbAK-2 in dark purple.  
 
2.4.3 Cordycepin and its derivatives as anti-trypanosomal agents 
Cordycepin was shown to have trypanocidal properties in vitro (Williamson, 1972, 
Williamson & Macadam, 1976) and the toxicity of this pro-drug is strongly 
dependent on its activation by phosphorylation by AK (Luscher et al., 2007). 
Somewhat disappointingly, attempts to crystallise TbAK in complex with cordycepin 
failed to produce diffracting crystals. Nevertheless, the structure of TbAK-Ado-ADP 
allows assumptions to be made about possible cordycepin modifications which 
might influence its binding to AK. Looking at the active site of TbAK and Ado 
binding, key interactions can be identified, like the hydrogen bonding of the 
hydroxyl groups of the ribose ring and the adenine ring stacking to F169, which are 
crucial for binding of the substrate and therefore need to be maintained in modified 
substrates. In vivo cordycepin is inactivated by deamination by human ADA 
(Aiyedun et al., 1973, Agarwal et al., 1975), resulting in 3’-deoxyinosine (Figure 
2-18). The structure of ADA and its substrate-binding mode are known (Wilson et 
al., 1991), so that the possible cordycepin modifications can be discussed in respect 
to resistance against its deamination. 
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Figure 2-18: Cordycepin and derivatives. 
 
In the course of this work, Vodnala et al. published a detailed study of cordycepin 
and its derivatives in respect of their trypanocidal activity in vivo and resistance to 
deamination (Vodnala et al., 2013). They found the free amine at the C6 position of 
the adenine ring to be essential for trypanocidal activity. Moreover, modifications 
on the ribose moiety, such as changes in the stereochemistry of the 2’-OH group, 
inactivated the compound. Gillerman and Fischer found that substitutions at the C2 
position of the adenine ring transform ADA substrates into non-substrates or 
inhibitors of ADA depending on the size of the substitution (Gillerman & Fischer, 
2011). Based on this study combined with the structural information (Wilson et al., 
1991) Vodnala et al. tested different C2 substitutions using electron-withdrawing 
substituents to lower the hydrogen bonding capability and reactivity of the adenine 
nitrogens in the ADA active site (Vodnala et al., 2013). This resistance to 
deamination due to C2 halogenation was shown previously for compounds like F-
AraA (Brockman et al., 1977). Indeed, fluorination of cordycepin at the C2 position 
abolished deamination by ADA, while retaining its trypanocidal activity in vitro. 2-
fluorocordycepin was shown to be a substrate of the aminopurine transporter and 
TbAK. In vivo experiments in mice showed administration of 2-fluorocordycepin was 
able to cure acute trypanosomiasis (Vodnala et al., 2013). Further investigations to 
validate 2-fluorocordycepin’s potential in anti-trypanosomal therapy in humans are 
needed. 
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2.5 Summary and future work 
Obtaining TbAK crystals with sufficient quality proved to be difficult. However, the 
structures in open (apo) and closed (in complex with Ado and AppNHp) 
conformation were solved, both to 2.6 Å. They are essentially identical to 2xtb and 
3otx, respectively (Kuettel et al., 2011), and show high homology to other published 
AK structures in the PDB. Unfortunately, attempts to solve the structures of TbAK in 
complex with cordycepin and the transition state mimics Ado:AlF4:ADP and 
Ado:MgF3:ADP were not successful.  
The TbAK-Ado-ADP structure allows identification of the key interactions necessary 
for substrate binding and permits assumptions about the binding of cordycepin. An 
independent study by Vodnala et al. (Vodnala et al., 2013) suggests the structures 
of TbAK can be used for the rational design of further modifications optimising the 
pharmacokinetic properties of 2-fluorocordycepin. 
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Chapter 3 Thymidine Kinases of the TriTryps 
3.1 Introduction 
TKs catalyse the phosphorylation of dThd to dTMP (EC. 2.7.1.21, Arner & Eriksson, 
1995, Jordan & Reichard, 1998) and are divided into two distinct families (Gentry, 
1992, Birringer et al., 2005), type I (e.g. herpes simplex virus 1 TK and human 
mitochondrial TK2) and type II (e.g. the human cytosolic TK1 and the trypanosomal 
TKs). The sequences and folds of these two types have no homology, a comparison 
shown in Figure 3-1, and they most likely have distinct evolutionary origins.  
Type I TKs are monomeric or dimeric and show high structural similarity to other 
deoxyribonucleoside kinases, e.g. TMPK, human deoxycytidine kinase (dCK) and 
insect deoxyribonucleoside kinase (dNK, Figure 3-1 A & D). They can be subdivided 
into herpes-viral, pox-viral and cellular subfamilies, with the three subfamilies 
showing very low sequence identity (Wild et al., 1997). One of the most prominent 
examples is the Herpes simplex virus enzyme (Figure 3-1 B), which is bigger than the 
other family members, but still shows a very similar fold. Each protomer contains a 
central five-stranded β-sheet, surrounded by α-helices. The substrate-binding site is 
formed by two helix pairs and a helical lid structure. Type I TKs generally have 
broader substrate specificity than type II, though they preferentially phosphorylate 
dThd (Vogt et al., 2000, Johansson et al., 2001). Although constitutively expressed 
throughout the cell cycle these enzymes show complex regulation of their activity, 
not only by product inhibition with the end product dTTP binding in the thymidine-
binding site, but also in the form of negative cooperativity. Although showing this 
negative cooperativity the human TK2 appeared to be monomeric in solution and a 
second substrate-binding site could not be identified (Munch-Petersen, 1984, 
Munch-Petersen et al., 1991, Knecht et al., 2002). 
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Figure 3-1: Protomer structures of three deoxyribonucleoside kinases.  
(A) Drosophila melanogaster TK type 1-like enzyme, DmdNK PDB: 1j90, in complex with deoxycytidine 
(B) HRV1 TK type 1 in complex with dThd, PDB: 1e2j, (C) human TK1 type II in complex with dTTP, PDB: 1w4r; 
protein in ribbon representation; ligands are shown as spheres coloured by atom type. (D) Topology cartoon 
of DmdNK PDB: 1j90 coloured in rainbow from N-terminus (blue) to C-terminus (red). (E) Topology cartoon of 
human TK1, PDB: 1w4r coloured same as (D). Structure representations in this and all subsequent figures 
made with CCP4mg (McNicholas et al., 2011), protein topology cartoons generated using Pro-Origami (Stivala 
et al., 2011). 
 
Type II TKs are very well studied and structures from several species have been 
solved including those from human (HsTK1, Figure 3-2, Welin et al., 2004, Birringer 
et al., 2005), Ureaplasma urealyticum (UuTK, Kosinska et al., 2005), Bacillus 
anthracis and B. cereus (BaTK and BcTK, Kosinska et al., 2007), Thermotoga 
maritima (TmTK, Segura-Pena, Lichter, et al., 2007, Segura-Pena, Lutz, et al., 2007) 
and Clostridium acetobutylicum (CaTK, Kuzin et al. not published). They occur as 
homodimers (Figure 3-2 B) and tetramers (Figure 3-2 C), where each protomer 
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consists of two lobes. The bigger of the two lobes contains a central six-stranded 
parallel β-sheet surrounded by α-helices and the P-loop. The second one comprises 
four conserved cysteine residues coordinating a Zn2+ ion, and a lasso structure, 
covering the substrate-binding site.  
 
 
Figure 3-2: Overall structure of type II TKs. 
Shown is the structure of a HsTK1 protomer (A), homodimer (B), and homotetramer (C). The protein 
represented as ribbons coloured by chain and the ligands (dTTP and zinc) as spheres coloured by atom type. 
The figure was made using CCP4mg. 
 
While the overall structure is highly conserved, the substrate specificity varies 
greatly between species. Type II TK’s main function is proposed to be supplying cells 
with dTMP as a precursor of dTTP, which is used in DNA synthesis. This is supported 
by studies with the HsTK1 showing the transcription level and activity being highest 
in cells immediately before and during DNA synthesis (late G1 until mid S phase of 
the cell cycle) and its degradation when DNA synthesis is not taking place (Dou & 
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Pardee, 1996, Ke & Chang, 2004, Munch-Petersen et al., 1993, Munch-Petersen, 
2009). The cell cycle dependent difference in TK concentration leads to an 
additional regulatory effect of TK activity. It was shown for TKs from higher 
vertebrates that the oligomeric state changes dependent on the concentration and 
by presence or in the absence of ATP; TK being dimeric at low concentration and 
absence of ATP and tetrameric at high concentrations and in the presence of ATP. 
The activity of the tetrameric TK was determined to be 30-fold higher than that of 
the dimeric TK (Munch-Petersen et al., 1993, Munch-Petersen, 2009). TKs of 
bacteria and plants were shown to be predominantly dimeric even in the presence 
of ATP (Mutahir et al., 2013). All TKs studied to date show product inhibition and 
cooperativity. 
 
 
3.1.1 Thymidine kinases from the TriTryps 
The TriTryp TKs belong to the type II TKs like the human cytosolic enzyme (HsTK1). 
The overall structure and the assembly to dimers and tetramers is conserved among 
different species, and the amino acid sequences show an identity between ~ 35 % 
(T. brucei to bacterial) and ~ 50 % (T. brucei to human), Figure 2-2. Not surprisingly 
the degree of identity is highest in regions important for function, like the P-loop, 
the active site residues and the residues coordinating the structural zinc.  
The TK from L. major (LmTK) is a 40.6 kDa protein, with a C-terminal extension of 
unknown function most of which is predicted to be disordered using DISOPRED2 
(Ward et al., 2004). It is expressed in large amounts in Leishmania amastigotes 
(Bente et al., 2003) and localises to the cytoplasm (Thiel et al., 2008). It was shown 
to be involved in flagellum formation, as well as cell shape and infectivity of the 
parasites, making it a potential drug target. 
T. brucei TK (TbTK) is a tandem protein of 51 kDa total size, containing two domains 
with homology to the TK family, an N-terminal inactive one (TbTK-N) and a C-
terminal catalytically active one (TbTK-C), forming a pseudo-dimer in solution 
(Ranjbarian et al., 2012). These two TK-homology domains show an amino acid 
sequence identity of 67 % and their high sequence identity on the DNA level 
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indicates a relatively recent interchange of genetic material. Ranjbarian et al. 
investigated the kinetic parameters in detail, showing TbTK had relaxed phosphate 
donor specificity and exhibited similar enzymatic activities with ATP, GTP, CTP and 
UTP. TbTK’s substrate specificity was shown to be broader than the HsTK1, as it 
phosphorylated not only dThd and dUrd, but also dC and dG. TbTK-N’s inactivity can 
be traced back to the substitution of residues important for catalysis, namely D45, 
R47 and E87. When expressed individually the catalytically active TbTK-C was 
predominantly monomeric and showed a lower binding affinity for the substrate 
than the full-length enzyme. The authors concluded that the inactive TbTK-N 
domain helps substrate binding of the active TbTK-C and is required for 
tetramerisation. TbTK has a flexible extension on the C-terminus, which is shorter 
than that from LmTK and whose function is not known.  
The sequence of the T. cruzi TK (TcTK) has two possible start codons, one resulting 
in a long N-terminal extension (omitted for the sequence alignment), leaving a 
protein of 34 kDa (TcTK A) and the other leaving a protein of 30 kDa (TcTK B). Like 
LmTK and TbTK, TcTK has a flexible extension at the C-terminus. No detailed kinetic 
or functional studies on TcTK have been published to date.  
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Figure 3-3: Sequence alignment of type II TKs.  
Conserved residues with red (identical) and yellow (similar) background, residue numbering and secondary 
structure of LmTK shown above the sequences (arrows = β-strands, spirals = α-helices), green bar = p-loop, 
red stars = residues coordinating dThd by main chain hydrogen bonds, orange stars = residues coordinating 
dThd via stacking and hydrophobic interactions, yellow triangles = Zn
2+
-coordinating cysteines. Alignment 
carried out using T-coffee and Espript 3.0 (Notredame et al., 2000, Gouet et al., 2003). 
 
 
 
 
 104
3.1.2 TK Mechanism  
The mechanism of thymidine phosphorylation in TKs of both types has been studied 
extensively (Wild et al., 1997, Welin et al., 2004). Many nucleoside kinases have a 
very similar mechanism (Eriksson et al., 2002). The protein substrate-interactions 
based on structural analysis of TmTK in complex with dThd and AppNHp are 
summarised in Figure 3-4. The proposed mechanism of TK based on this is shown in 
Figure 3-5. In brief, the carboxylate of a glutamate residue in the active site is 
proposed to act as base, deprotonating the 5’-OH group of the dThd. This activated 
5’-O then makes a nucleophilic attack on the γ-phosphate of the ATP, leading to a 
transition state with a penta-coordinated γ-phosphate and subsequently the 
products ADP and dTMP. A magnesium ion is crucial for catalysis as coordinating 
counter ion for the phosphates. While TKs of both types exclusively utilise non-
phosphorylated nucleosides as primary substrates, the HSV-1 TK is an exception 
being able to phosphorylate its product dTMP even further forming dTDP (Wild et 
al., 1997). This ability has not been described for other TKs so far.  
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Figure 3-4: Schematic view of the substrate binding interactions in the TmTK active site. 
Shown are the ligands and residues coordinating substrates via hydrogen bonds (green labels, hydrogen 
bonds as dashed lines), and hydrophobic interactions (black labels, red half circles). Ligand and hydrogen 
bonding residues are shown as ball and stick models coloured by atom type. Figure drawn with LigPlot+ (REF). 
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Figure 3-5: Mechanism of γ-phosphate transfers in TK. 
R1 is the adenosine moiety of the phosphate donor ATP. Residue numbering after TmTK. Figure made with 
MarvinSketch (ChemAxon). 
 107 
 
3.1.3 TKs in drug development 
The viral type I TKs have been of great interest as they activate cytotoxic nucleoside 
analogues with substrate specificities differing from the type II TKs, resulting in the 
possibility to specifically target pathogens with these prodrugs. Additionally, type II 
TKs are of great interest in cancer monitoring and therapy. The cell cycle specific 
expression of human cytosolic TK and its influence on nucleoside uptake can be 
exploited to monitor active tumor proliferation in PET scans (Barthel et al., 2003, 
Chao, 2006, Salskov et al., 2007, de Langen et al., 2009, Shields et al., 2008) and has 
been shown to be a useful tool for distinguishing slow-growing from aggressive fast-
growing cancers (Aufderklamm et al., 2012). The high substrate specificity of the 
HsTK1 (type II) did not permit the development of nucleoside-based cytotoxic 
prodrugs for cancer therapy at this point. 
 
3.1.4 Aims 
The main focus of the work discussed in this chapter was to overexpress, purify and 
determine the crystal structures of the TKs of the TriTryps and compare them to 
HsTK1. This should highlight unique features of the TriTryp TKs, which could then be 
exploited for target-based drug design.  
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3.2 Experimental 
3.2.1 Cloning and expression testing in E. coli 
The full-length genes as well as various truncations of TKs from T. brucei Lister427, 
T. cruzi Sylvio X10/1 and L. major Friedlin were originally cloned into YSBLIC and 
YSBLIC3C vectors using ligation-independent cloning (Aslanidis & de Jong, 1990, 
Fogg et al., 2006) and tested for expression by Dr. Glyn Hemsworth. I continued 
with design, cloning and expression testing of additional constructs (21 in total, 
including MBP fusion tags) using different E. coli strains (BL21 (DE3), BL21 (DE3) 
gold, Rosetta2 (DE3), pLysS (DE3), pLEMO (DE3), C41 and ArcticExpress), 
temperatures (10, 16, 20, 25, 37°C) and media (LB, autoinduction, 2XYT, M9).  
For these additional constructs the genes and truncated versions were amplified 
from genomic DNA by PCR using the same reaction conditions as described in Table 
2-1 and Table 2-2, with the primer sequences given in appendix A.2.3. The 
templates for the MBP constructs were the constructs LmTK-F-3C, TbTK-F-3C and 
TcTK-F-3C. The MBP-fusion constructs were cloned using conventional cloning 
methods with the restriction enzymes EcoR1 and Sal1 (Promega) and subsequent 
ligation with the T4 ligase (New England Biolabs, NEB). In brief, approximately 2 μg 
of the amplified TK genes and pMAL-C2 vector, purified using the PCR purification 
Kit (Qiagen) or Miniprep Kit (Qiagen) respectively, were digested with EcoR1 and 
Sal1 for 3 h at 37°C. The reaction mix compositions are summarised in Table 3-1. 
Subsequently the digested pMAL-C2 vector was dephosphorylated by incubation 
with alkaline phosphatase for 1 h at 37°C. After purification with the PCR 
purification kit, inserts and vector were ligated by incubation of the reaction 
mixture specified in Table 3-2 at room temperature for 24h. The ligated constructs 
were transformed into E. coli (NEB5α, NEB) cells and the cloning success was 
confirmed by colony PCR and sequencing.  
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Table 3-1: Compositions of the resitriction digests for the pMAL-C2 constructs. 
 LmTK-F LmTKdC TcTK-A TcTK-B TbTK-F pMAL-C2 
10x buffer D (Promega) 5 μL 
DNA (~ 2 μg) 24 μL 21 μL 24 μL 32 μL 25 μL 35 μL 
BSA (10 μg/μL, Promega) 0.5 μL 
ddH2O 15.5 μL 18.5 μL 15.5 μL 
μL 
8.5 μL 14.5 μL 5.5 μL 
EcoR1 (12 U/μL, Promega) 2.5 μL 
Sal1 (10 U/μL, Promega) 2.5 μL 
Total volume 50 μL 
 
Table 3-2:  Composition of T4 ligase dependent ligations for pMAL-C2 vectors. 
Reagent Volume [μL] 
10x T4 ligase buffer (NEB) 2 
ddH2O 9.8 
Vector (digested) 5 (= ~100 ng) 
Insert (digested) 3 (= ~100 ng) 
T4 ligase (400 U/μL, NEB) 0.2 
Total volume 20 
 
All expression tests were carried out in 5 mL culture volumes using different E. coli 
strains, temperatures and expression media (as mentioned above). For each strain 
and expression condition 1 mL culture samples were lysed chemically using 
BugBuster® (Millipore) and soluble and insoluble fractions were analysed via SDS-
PAGE. 
While TbTK and TcTK did not give soluble protein, some of the LmTK constructs 
showed soluble expression, but these proved to be unstable during purification and 
only very small amounts at low concentrations could be obtained, of insufficient 
purity and quantity for crystallisation experiments. After Ranjbarian et al. 
(Ranjbarian et al., 2012) successfully expressed full-length TbTK in BL21 (DE3) codon 
plus cells, I tested their expression protocol, which resulted in soluble but heavily 
degraded protein showing half of the expected molecular weight. No soluble full-
length TbTK was obtained.  
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3.2.2 Cloning of TK constructs for expression with the baculovirus 
system  
A more high throughput approach was applied for which 30 constructs were cloned 
for expression in insect cells using the baculovirus system with a ligation-
independent cloning method developed at the Oxford protein production facility 
(OPPF, (Berrow et al., 2007) with the commercially available In-Fusion™ enzyme 
(Clontech-Takara Bio Europe). In parallel, the same approach was taken with 
constructs for TMPK expression, discussed in the appendix A.1. I spent two weeks at 
the OPPF in Harwell for cloning and expression testing.  
Full-length and re-designed truncated versions of TK from the TriTryps were 
amplified by PCR from genomic DNA (T. brucei Lister427, T. cruzi Sylvio X10/1 and 
L. major Friedlin) in 96-well format using the reaction conditions and temperature 
profile summarised in Table 3-3 and Table 3-4.  
 
Table 3-3: PCR condition of TK constructs for baculovirus expression. 
Reagent Volume/reaction  [μL] 
2x Phusion™ Flash Mastermix 25 
Forward primer (10 μM) 3 
Reverse primer (10 μM) 3 
ddH2O 18 
Template (genomic DNA) 1 
Total volume 50 
 
Table 3-4: Temperature profile for PCRs of the baculovirus expression constructs. 
Step Temperature [°C]  Time [s] No. of cycles 
Initial denaturation 98 10 1 
Denaturation 98 5 
30 
Annealing 70 5 
Extension 72 60 
Final extension 72 60 1 
 
The PCR products were purified using Agencourt AMPure XP magnetic beads 
according to manufacturers instructions and analysed on a 1.6 % agarose gel.  
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Each TK version was cloned into three different vectors:  
- pOPINI (N-terminal non-cleavable Histag fusion),  
- pOPINF  (N-terminal HRV3C cleavable Histag) and  
- pOPINE (C-terminal non-cleavable Histag).  
The cloning was carried out using the dried In-Fusion™ enzyme mix to which 7 μL 
ddH2O, 2 μL purified PCR product and 1 μL prepared vector were added before 
incubation at 42°C for 30 min. Each reaction was stopped by addition of 40 μL Tris-
EDTA buffer. Three μL of each of the reactions were transformed into competent 
OmniMAX2-TIR cells (Invitrogen) and plated in 24 well plates containing LB, 
carbenicillin, IPTG and XGal for blue-white screening (positive clones in white). 
Positive clones were confirmed by colony PCR. 
For tracking of the constructs within the text, an OPPF number is given. Constructs 
tested for expression and their identification numbers are given in Table 3-5. 
 
3.2.3 Construction of baculoviruses and insect cells lines for 
expression 
For generation of the baculoviruses the protocol developed at OPPF was followed 
(Berrow et al., 2007). Sf9 cells were grown in Sf900 II-SFM media and plated in 24-
well plates to a density of ~ 5 x 105 cells mL-1 at 500 μL per well. Attachment to the 
well surface took place within 1 h incubation at room temperature prior to co-
transfection. For transfection 4 μL (= 100-500 ng) of each pOPIN vector, 2.5 μL 
(= 500 ng) linearised Autographa califonica bacmid (Durocher et al., 2002), 0.75 μL 
FuGene® HD (Promega) and 50 μL Sf900 II-SFM were mixed and pre-incubated for 
30 min at room temperature before addition to the adherent Sf9 cells. The primary 
viral stocks were harvested manually from the media 168 h post-transfection. These 
virus stocks were used for infection of fresh Sf9 cells. For this, Sf9 cells were grown 
to a density of ~ 1 x 106 cells mL-1, plated in 24-well plates with 500 μL per well and 
allowed to attach to the well surface 1 h prior to infection. Adherent cells were 
infected with 5 μL primary virus stock, and harvested manually from the 
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supernatant 168 h post-infection and stored frozen at -80°C. The final virus stocks 
were harvested and stored at OPPF.  
 
Table 3-5: TK constructs cloned for expression with the baculovirus system.  
Cloning performed in 96 well plate format (using half of the plate); “well” gives the location in the plate, 
OPPF number for tracking in the OPPF database. 
Well Gene name Amino acid 
range 
Mw of expected protein 
(+ tag) [Dalton] 
Vector 
pOPIN 
OPPF No. 
A01 LmTK 2-284 31471.0 (+969) E 11318 
B01 LmTK 2-185 21045.2 (+969) E 11319 
C01 LmTK 2-185 21045.2 (+2158) F 11320 
D01 TcTK 2-313 34604.4 (+2158) F 11435 
E01 TcTK 2-228 25402.2 (+2158) F 11438 
F01 TcTK 45-313 29573.6 (+2158) F 11441 
G01 TcTK 45-228 20371.4 (+2158) F 11444 
H01 TcTK 2-313 34604.4 (+1274) I 11433 
A02 TcTK 2-228 25402.2 (+1274) I 11436 
B02 TcTK 45-313 29573.6 (+1274) I 11439 
C02 TcTK 45-228 20371.4 (+1274) I 11442 
D02 TcTK 2-313 34604.4 (+969) E 11434 
E02 TcTK 2-228 25402.2 (+969) E 11437 
F02 TcTK 45-313 29573.6 (+969) E 11440 
G02 TcTK 45-228 20371.4 (+969) E 11443 
H02 TbTK 2-455 50713.2 (+2158) F 11335 
A03 TbTK 2-382 42753.4 (+2158) F 11338 
B03 TbTK 2-180 20435.0 (+2158) F 11341 
C03 TbTK 198-455 28496.2 (+2158) F 11344 
D03 TbTK 198-382 20536.3 (+2158) F 11347 
E03 TbTK 2-455 50713.2 (+1274) I 11333 
F03 TbTK 2-382 42753.4 (+1274) I 11336 
G03 TbTK 2-180 20435.0 (+1274) I 11339 
H03 TbTK 198-455 28496.2 (+1274) I 11342 
A04 TbTK 198-382 20536.3 (+1274) I 11345 
B04 TbTK 2-455 50713.2 (+969) E 11334 
C04 TbTK 2-382 42753.4 (+969) E 11337 
D04 TbTK 2-180 20435.0 (+969) E 11340 
E04 TbTK 198-455 28496.2 (+969) E 11343 
F04 TbTK 198-382 20536.3 (+969) E 11346 
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3.2.4 Expression tests of TKs with the Baculovirus system 
Expression tests from the TK baculoviruses were carried out by Heather Rada at 
OPPF following standard procedures. Sf9 cells were infected with 50 μL of each 
virus stock described in 3.2.3. Cells were harvested 72 h after infection, lysed by 
incubation for 30 min in lysis buffer (NPI-10 Tween) complemented with lysozyme 
and either benzonase or DNase type 1. Subsequently cell debris was removed by 
centrifugation and expressed Histagged protein was isolated using magnetic Ni-NTA 
beads. After washing twice with buffer NPI-20, bound Histagged protein was eluted 
with NPI-250 (containing 250 mM Imidazole).  The eluates were analysed by SDS-
PAGE, Figure 3-6. 
 
 
Figure 3-6: SDS-PAGE of TK expression tests with the baculovirus system.  
First and last lanes are protein standards. Each other lane contains a NiNTA purified expression test sample 
from the baculovirus expression test. Lane labelling corresponds to the well numbers in Table 3-5. 
 
3.2.5 Expression of LmTK and TbTK in Sf9 cells 
After identification of baculovirus stocks leading to soluble expression of LmTK and 
TbTK in Sf9 cells, these were amplified and used for larger scale expression. Up-
scaled expression of these was carried out at OPPF by Joanne Nettleship. Cells of 1 L 
cultures were harvested and frozen at -80°C before shipment to York. 
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3.2.6 Purification and Characterisation of LmTK 
The cell pellets from 1 L Sf9 cell cultures expressing the protein (11319 or 11320) 
were resuspended in 35 mL buffer A (20 mM Tris pH 8.0, 300 mM NaCl, 30 mM 
imidazole, 1 mM DTT and 100 μM PMSF) and lysed by sonication. This was followed 
by addition of 25-29 U benzonase, incubating for 10 min at room temperature. The 
cell debris was removed by centrifugation for 30 min at 5000 rcf and 4°C. The 
supernatant was loaded onto a 1 mL HisTrap crude FF column for 1 h in a loop on 
ice. After washing with 10 mL buffer A the column was connected to an AKTA 
purifier washed with another 10 mL of buffer A and eluted with an imidazole 
gradient from 30 to 500 mM in buffer A. The protein containing fractions were 
pooled and concentrated up to 4 mL total volume. In order to stabilise the protein, 
it was diluted with 1 mL SEC buffer (10 mM Tris pH 8.0, 200 mM NaCl, 1 mM DTT) 
containing 1 μM ZnSO4.  
LmTK 11319 (containing a non-cleavable C-terminal Histag) was concentrated 
further to 250 μL total volume and directly loaded onto a Superdex 200 column 
(Figure 3-7 A). Size exclusion chromatography was performed using SEC buffer 
(composition described above). Protein purity was assessed by SDS-PAGE and the 
protein-containing fractions were pooled (Figure 3-7 B). As the protein started to 
precipitate, it was split into two fractions and stabilised by addition of either 
1 mM dThd + 1 mM AppNHp + 3 mM MgCl2 or 1 mM dTTP + 3 mM MgCl2. The 
stabilised protein was concentrated to 2.4 mg mL-1 (dThd + AppNHp + MgCl2) and 
7.3 mg mL-1 (dTTP + MgCl2), aliquoted, flash frozen in liquid nitrogen and then 
stored at -80°C. 
LmTK 11320 (containing a cleavable N-terminal Histag) was diluted with SEC buffer 
in the ratio 1:2. To cleave off the Histag, HRV 3C protease was added in a ratio of 
1:100 (protease:LmTK) and incubated at 4°C overnight. The proteolysis was 
monitored by SDS-PAGE and reached ~ 90 % after 16 h. To remove the Histag and 
non-cleaved LmTK the protein buffer was exchanged into lysis buffer using 
Centrifuge filters (Amicon® Ultra Centrifugal Filter from Millipore, 30 kDa cutoff) 
and nickel affinity purification was performed with the same buffers as before. The 
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cleaved (untagged) LmTK in the flowthrough was concentrated to 250 μL total 
volume and injected onto an equilibrated Superdex 200 column (Figure 3-7A). The 
same SEC buffer was used as for LmTK 11319. The separation of cleaved and 
uncleaved LmTK and the final purity was analysed by SDS-PAGE (Figure 3-7C). A high 
molecular weight band on the SDS-PAGE indicated the presence of a HRV 3C 
contamination, which was not removed, as it did not bind to the HisTrap column 
and co-eluted with the LmTK in size exclusion chromatography. Alternatively, this 
band might have been caused by LmTK dimers. Due to the limited amount of 
protein available, this was not further investigated. Protein-containing fractions 
were pooled and concentrated to 15.1 mg mL-1 in the presence of 1 mM dThd, 
1 mM AppNHp and 3 mM MgCl2. Concentrated protein was aliquoted, flash frozen 
in liquid nitrogen and stored at -80°C. 
The polydispersity of LmTK was determined by dynamic light scattering (DLS) at 
20°C, with the protein diluted in SEC buffer to a total concentration of 3 mg mL-1 
with a total sample volume of 20 µL. DLS measurements were carried out using a 
DynaPro™ (Protein Solutions™). 
Although the protocols were kept identical LmTK from subsequent purifications 
could not be stabilised and precipitated completely during lysis (11320) or after 
nickel affinity chromatography (11319). 
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Figure 3-7: Purification of LmTK.  
(A) Superposition of the chromatogram (absorption at 280 nm) of construct 11319 (blue) with that from 
11320 (red). (B) SDS-PAGE analysis of protein containing fractions of LmTK11319 after SEC. (C) SDS-PAGE 
analysis of LmTK11320 purification showing pooled protein fractions from the first HisTrap column (lane 1), 
the protein after HRV3C proteolysis overnight (lane 2) and flowthrough of the second HisTrap column (lane 
3), followed by the protein containing fractions of the SEC. * LmTK 11320 with Histag, **LmTK 11320 without 
the Histag. 
 
 
3.2.7 Purification and Characterisation of TbTK 
For purification of TbTK constructs 11343, 11345 and 11347 the pellets of 1 L Sf9 
culture were thawed and lysed as described for LmTK. Nickel affinity purification 
followed the same protocol and used the same buffer as was used for LmTK. After 
nickel affinity chromatography of 11343 (non-cleavable C-terminal Histag) the 
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protein yield was very poor and many contaminants were still present, so this 
construct was not further purified.  
TbTK 11345 (non-cleavable N-terminal Histag) was stabilised after nickel affinity 
chromatography by addition of 1 μM ZnSO4, 5 mM MgCl2, 0.5 mM dThd and 0.5 mM 
AppNHp. It was concentrated to 500 μL total volume and injected onto an 
equilibrated Superdex 200 column in SEC buffer (10 mM Tris pH 8.0, 300 mM NaCl, 
1 mM DTT) (Figure 3-8 A). The protein containing fractions were pooled and after 
addition of 10 mM MgCl2, 1 mM dThd and 1 mM AppNHp, concentrated to 
35 mg mL-1 and aliquoted. Aliquots were flash frozen in liquid nitrogen and stored 
at -80°C.  
TbTK 11347 (cleavable N-terminal Histag) appeared stable after nickel affinity 
chromatography, but similar to 11343, the yield was very low and contaminations 
were present. The Histag was cleaved by HRV 3C proteolysis over 36 h at 4°C in 
dialysis against buffer A. During proteolysis the protein showed strong precipitation, 
which was removed by centrifugation before nickel affinity purification. 
Flowthrough and elution fractions contained TbTK and HRV 3C protease and were 
concentrated separately before loading onto Superdex 200 column (Figure 3-8 B). 
SDS-PAGE analysis revealed the presence of 3C protease contamination in all 
fractions of both size exclusion chromatography runs and only a very small amount 
of TbTK (< 200 μg), insufficient for further studies. 
A second batch of TbTK 11347, which was mislabelled at the OPPF as LmTMPK 
11357, was stabilised after nickel affinity chromatography by addition of 1 mM 
TMP, 1 mM AppNHp and 3 mM MgCl2. The protein was concentrated to ~500 μL 
and was loaded onto a Superdex 200 column (Figure 3-8 C). Protein purity was 
monitored by SDS-PAGE. The protein-containing fractions were pooled and 
concentrated to 35 mg mL-1 in the presence of 1 mM TMP, 1 mM AppNHp and 
3 mM MgCl2. Aliquots were flash frozen in liquid nitrogen and stored at -80°C. 
Electrospray ionisation mass spectrometry (ESI-MS) and tandem mass spectrometry 
(MS/MS, using a Bruker autoflex III MALDI-TOF/TOF) after trypsin digest, confirmed 
the protein to be TbTK, most likely construct 11347. The polydispersity was 
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determined by DLS at 20°C using protein diluted in SEC buffer to a concentration of 
3 mg mL-1 with a total sample volume of 20 µL.  
 
 
Figure 3-8: SEC chromatograms of TbTK purifications.  
The black bars indicate the peaks caused by TbTK (identified by SDS-PAGE analysis), peaks at elution volumes 
above 20 mL are most likely caused by nucleotide that was added for protein stabilisation. (A) Size exclusion 
chromatogram of TbTK 11345 (stabilised with dThd). (B) SEC chromatogram of TbTK 11347 (not stabilised). (C) 
Size exclusion chromatogram of TbTK 11347 (stabilised with TMP because of mislabelling by the OPPF). 
 
 
3.2.8 Crystallisation of LmTK and TbTK 
Initial screens (Index, PACT and JCSG) were set up in sitting-drop vapour diffusion 
format with 150 nL protein solution including additives plus an equal volume of 
precipitant, using a Mosquito robot (TTP Labtech, UK).  Crystals were optimised 
using hanging-drop vapour diffusion with 1 μL protein solution plus an equal 
volume of precipitant. To produce crystals in complex with the bi-substrate 
analogue AP5dT 1 mM ligand was added to LmTK 11319 containing dThd and 
AppNHp and incubated on ice, allowing AP5dT to replace the substrates in the 
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active site. In order to crystallise TbTK in a different crystal form, cross seeding 
experiments were carried out using an Oryx 4 robot (Douglas Instruments, UK), 
using the Index screen in sitting-drop vapour diffusion with 250 nL protein solution 
plus 170 nL precipitant and 80 nL seed stock. The seed stock was made up using 
seed beads from LmTK 11320 crystals in buffer as for the LmTK-dThd crystal. The 
TbTK crystals obtained without seeding were cryo-protected before vitrification in 
precipitant solution containing 10 % glycerol. All other crystals were not cryo-
protected. The conditions leading to crystals that allowed structure solution as well 
as the ligands bound in the active sites are summarised in Table 3-6. 
 
Table 3-6: Crystallisation conditions of LmTK and TbTK. 
Crystal name Additives in 
protein solution 
Crystallisation 
condition 
Ligand bound in the 
active site 
LmTK-dThd 1 mM dThd, 
1 mM AppNHp, 
3 mM MgCl2 
1.4 M Na/K PO4 pH 5.4 dThd, PO4
2- 
LmTK-dTTP 1 mM dTTP 
3 mM MgCl2 
50 mM HEPES pH 8.0, 
36% (v/v) 
Pentaerythritol 
propoxylate 
dTTP, Mg2+ 
LmTK- AP5dT 1 mM AP5dT, 
1 mM dThd, 
1 mM AppNHp, 
3 mM MgCl2 
0.1 M tri-Na citrate 
pH 5.5, 
20 % (w/v) PEG 3K 
AP5dT 
TbTK- 
dThd/dTMP 
1 mM TMP, 
1 mM AppNHp, 
3 mM MgCl2 
0.1 M HEPES pH 7.0, 
0.9 M Succinic acid 
dThd/dTMP 
TbTK- dTMP-
PO4
2--a 
1 mM TMP, 
1 mM AppNHp, 
3 mM MgCl2 
0.1 M HEPES pH 7.0, 
0.9 M Succinic acid, 
1% (w/v) PEG 2K MME 
dTMP, PO4
2- 
TbTK- dThd-
Glycerol 
1 mM TMP, 
1 mM AppNHp, 
3 mM MgCl2 
0.1 M HEPES pH 7.0, 
0.8 M Succinic acid 
dThd, glycerol 
TbTK- dTMP-
PO4
2--b 
1 mM TMP, 
1 mM AppNHp, 
3 mM MgCl2 
Seed stock of 
LmTK-dThd sister 
crystals 
0.15 M DL-Malic acid 
pH 7.0, 
20% (w/v) PEG 3350 
dTMP, PO4
2- 
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3.2.9 Data collection and Structure solution of LmTK and TbTK 
Diffraction data of LmTK and TbTK crystals were collected on beamline I04 of the 
Diamond Light Source (DLS). Binding of zinc ions was confirmed by X-ray 
fluorescence experiments for two of the LmTK and TbTK crystals. All computations 
were carried out using the CCP4 software package (Winn et al., 2011). The 
diffraction images were processed with MOSFLM (Battye et al., 2011) and AIMLESS 
(Evans & Murshudov, 2013). The image quality of the LmTK-dTTP was poor at some 
rotation angles resulting a reduction of the completeness to 94.7 %. 
Crystallographic data and statistics are summarised in Table 3-7 - 9.  
The LmTK and TbTK structures were determined by molecular replacement using 
PHASER (McCoy, 2007). At the time the HsTK1 (PDB ID: 1w4r) had the highest 
homology with a sequence identity of 49% and was selected as search model for 
TbTK. Subsequently, the structure of TbTK-dThd/dTMP with its 58 % sequence 
identity to LmTK was chosen as search model for LmTK. Refinement was performed 
using the maximum-likelihood restrained method in REFMAC5 (Murshudov et al., 
2011) with one TLS group per chain and automatically generated local NCS. For the 
first few rounds external restraints generated from TbTK-dThd/dTMP using 
ProSMART (Nicholls et al., 2012) in REFMAC5 were used. The last rounds of 
refinement were carried out with the jelly body refinement option (with sigma 
0.02). Manual fitting of the electron-density maps, model building and fitting of the 
ligands were carried out in COOT (Emsley et al., 2010). The models were validated 
in COOT and MolProbity (Chen et al., 2010). 
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Table 3-7: Crystallographic data and statistics for the LmTK crystals. 
In this and all subsequent data tables: Data for the highest resolution shell shown in brackets, the 
Ramachandran Plot was calculated using COOT (Emsley et al. 2010), the poor rotamer analysis was carried 
out in Molprobity (Chen et al. 2010). 
 LmTK-dThd- PO4
2-
 LmTK-dTTP LmTK-AP5dT 
Data collection    
Diffraction Source DLS beamline I04 DLS beamline I04 DLS beamline I24 
Wavelength (Å) 0.9795 0.9795 0.9686 
Temperature (K) 100 100 100 
Detector Pilatus 6M-F Pilatus 6M-F Pilatus3 6M 
Rotation range per image (°) 0.2 0.2 0.1 
Total Rotation range (°) 72 80 90 
Crystal data    
Space group P6522 P1 P6522 
a, b, c (Å) 121.1, 121.1, 116.2 61.60, 61.63, 110.1 64.15, 64.15, 324.6 
α, β, γ (°) 90, 90, 120 81.07, 85.8, 74.94 90, 90, 120 
Resolution (Å) 52.46-2.74 
(2.88-2.74) 
59.45-3.00 
(3.16-3.00) 
45.84-2.40 
(2.49-2.40) 
Total Reflections 271650 (35991) 58503 (8708) 137341 (12676) 
Unique Reflections  13223 (1772) 29290 (4271) 16728 (1684) 
Completeness (%) 96.3 (100) 94.7 (94.7) 99.9 (99.6) 
Redundancy 20.5 (20.3) 2.0 (2.0) 8.2 (7.5) 
Rmerge  0.110 (1.174) 0.135 (0.600) 0.118 (0.690) 
Mean [I/σ (I)] 17.3 (2.9) 6.2 (2.1) 11.0 (2.7) 
Matthew’s coefficient 2.93 2.26 2.19 
Refinement statistics    
Reflections, working set 12506 27884 15762 
Reflections, test set 648 1404 829 
Resolution Range (Å) 52.46-2.74 59.45-3.00 45.84-2.40 
R-factor 0.2822 0.2603 0.1955 
R 
Table 3-8 
free 
0.3104 0.2784 0.2569 
No. of non-H atoms    
Protein 2370 9673 2598 
Ligand 49 232 112 
Water 13 53 57 
Mean B factors (Å
2
)    
Protein 88.8 49.5 29.8 
Ligands 71.7 38.1 51.6 
Water 57.1 22.8 40.4 
RMS deviation from ideal    
Bond length (Å) 0.0065 0.0094 0.0124 
Bond angles (°) 1.2916 1.4449 1.6943 
Ramachandran Plot (%)    
Residues in favored region 94.94 96.00 95.43 
Residues in allowed region 5.06 4.00 4.57 
Outliers  0 0 0 
Molprobity score  1.67 1.69 1.07 
Poor Rotamers (%) 0 0.11 0.75 
PDB ID 4uxi 4uxj 4uxh 
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Table 3-8: Crystallographic data and statistics for TbTK crystals. 
 TbTK-dThd-glycerol TbTK-dThd/dTMP 
Data collection   
Diffraction Source DLS beamline I04 DLS beamline I02 
Wavelength (Å) 0.9795 0.9795 
Temperature (K) 100 100 
Detector Pilatus 6M Pilatus 6M-F 
Rotation range per image (°) 0.2 0.2 
Total Rotation range (°) 220 180 
Crystal data   
Space group P4322 P4322 
a, b, c (Å) 114.7, 114.7, 105.6 115, 115, 104.8 
α, β, γ (°) 90, 90, 90 90, 90, 90 
Resolution (Å) 44.25-2.30 (2.39-2.30) 64.24-2.20 (2.27-2.20) 
Total Reflections 456390 (47217) 422851 (33374) 
Unique Reflections 31864 (3298) 36299 (3079) 
Completeness (%) 99.9 (99.9) 100 (100) 
Redundancy 14.3 (14.3) 11.6 (10.8) 
Rmerge 0.085 (1.024) 0.105 (0.885) 
Mean [I/σ (I)] 17.0 (2.6) 11.8 (2.6) 
Matthew’s coefficient 4.01 3.81 
Refinement statistics   
Reflections, working set 30146 34470 
Reflections, test set 1708 1757 
Resolution Range (Å) 44.25-2.30 64.24-2.20 
R-factor 0.1680 0.1800 
Rfree 0.1888 0.1889 
No. of non-H atoms   
Protein 2598 2588 
Ligand 59 36 
Water 94 123 
Mean B factors (Å
2
)   
Protein 42.2 39.3 
Ligands 56.7 52.8 
Water 55.5 59.0 
RMS deviation from ideal   
Bond length (Å) 0.0202 0.0201 
Bond angles (°) 2.0820 1.9079 
Ramachandran Plot (%)   
Residues in favoured region 97.26 96.93 
Residues in allowed region 2.44 3.07 
Outliers 0.30 0 
Molprobity score 1.44 1.36 
Poor Rotamers (%) 0.36 0 
PDB ID   
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Table 3-9: Crystallographic data and statistics for TbTK crystals. 
 TbTK-dTMP-PO4
2-
-a TbTK-dTMP-PO4
2-
-b 
Data collection   
Diffraction Source DLS beamline I02 DLS beamline I04 
Wavelength (Å) 0.9795  
Temperature (K) 100 100 
Detector Pilatus 6M-F Pilatus 6M 
Rotation range per image (°) 0.2 0.2 
Total Rotation range (°) 180 220 
Crystal data   
Space group P4322 C222 
a, b, c (Å) 114.8, 114.8, 104.5 87.61, 97.0, 304.4 
α, β, γ (°) 90, 90, 90 90, 90, 89.99 
Resolution (Å) 43.92-2.20 (2.27-2.20) 65.02-2.80 (2.95-2.80) 
Total Reflections 441889 (37765) 173354 (20274) 
Unique Reflections 36045 (3273) 31168 (4599) 
Completeness (%) 100 (100) 95.9 (98.7) 
Redundancy 12.3 (11.5) 5.6 (4.4) 
Rmerge 0.071 (1.215) 0.098 (0.373) 
Mean [I/σ (I)] 18.9 (2.3) 8.5 (2.7) 
Matthew’s coefficient 3.97 2.34 
Refinement statistics   
Reflections, working set 34261 29477 
Reflections, test set 1749 1570 
Resolution Range (Å) 43.92-2.20 65.02-2.80 
R-factor 0.1810 0.2062 
Rfree 0.1887 0.2344 
No. of non-H atoms   
Protein 2582 7420 
Ligand 54 162 
Water 76 32 
Mean B factors (Å
2
)   
Protein 43.1 48.6 
Ligands 60.3 60.5 
Water 60.2 47.5 
RMS deviation from ideal   
Bond length (Å) 0.0203 0.0132 
Bond angles (°) 2.0027 1.7817 
Ramachandran Plot (%)   
Residues in favoured region 96.60 96.06 
Residues in allowed region 3.40 3.94 
Outliers 0 0 
Molprobity score 1.43 1.39 
Poor Rotamers (%) 0.36 0.26 
PDB ID   
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3.3 Results  
3.3.1 Expression and purification of LmTK and TbTK 
In E. coli, constructs coding for N-terminal Histagged TKs from all three species did 
not give soluble and stable protein in sufficient quantities. Fusion to an MBP tag 
helped LmTK and TbTK constructs to express soluble protein, but these were not 
stable after removal of the MBP tag and precipitated when separated from non-
cleaved protein. The C-terminal Histagged LmTK showed soluble expression, but the 
protein was not stable during purification showing rapid precipitation. Collaborators 
at the Instituto de Parasitologia y Biomedicina “Lopez-Neyra” in Granada, Spain, 
expressed full-length LmTK in E. coli BL21 (DE3) cells, obtaining sufficient amounts 
for kinetic measurements. The amounts obtained with their protocol were not high 
enough for crystallisation experiments and problems with protein stability hindered 
further use of protein produced with this method. 
When expressed in Sf9 cells using the baculovirus system at OPPF two LmTK 
constructs, spanning amino acid residues 2-185, and three TbTK constructs, 
spanning amino acid residues 198-455 and 198-383, showed soluble expression and 
potentially good yield. These constructs were chosen for expression in bigger 
volumes (1 L cell cultures) and four of these could be purified in sufficient quality 
and quantity for crystallisation experiments. While purification of each of the four 
constructs was successful once, subsequent purifications of the same constructs 
gave protein precipitating during purification. The reason for the instability of TKs in 
the second batch is unclear and precipitated protein could not be refolded.  
 
3.3.2 Crystallisation of LmTK and TbTK  
LmTK constructs 11319 and 11320 crystallised in several conditions, but showed 
limited diffraction quality and seeding experiments did not improve the crystal 
quality. The TbTK construct 11347 crystallised, 11343 and 11345 did not.  
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3.3.3 Structures of LmTK and TbTK 
3.3.3.1 Overall structure  
The TK constructs forming diffracting crystals were of heavily truncated versions, 
removing the C-terminal extensions of unknown function. For TbTK only the 
catalytically active of the two TK domains expressed in soluble form, so that the 
solved structure represents less than half of the full-length protein. However, the 
core structures of LmTK and TbTK were solved, showing a high sequence homology 
to type II TK from other species. They show nearly identical folds with an overall 
RMSD of 0.30 Å (superposition shown in Figure 3-9 B) and to HsTK1 (PDB ID: 1w4r, 
(Welin et al., 2004) with an overall RMSD of 0.31 Å. Each TK protomer shows the 
typical bilobal structure with the active site sitting between the domains (Figure 
3-9).  
 
Figure 3-9: Structures of TbTK and LmTK. 
 (A) TbTK-dThd-glycerol with dThd shown as spheres coloured by atom type. (B) Overlay of TbTK-dThd-
glycerol (green) and LmTK (blue, ligand not shown). Superposition in this figure and all subsequent ones was 
carried out using SSM (Krissinel & Henrick, 2004). 
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The large N-terminal α/β-domain consists of a central six-stranded parallel β-sheet 
(β1, β2, β3, β4, β5, β8), flanked by a long α-helix (α1) and a loop region of 15-20 
amino acids on one side and 2 shorter α-helices (α2 and α3) and a loop on the 
other. The conserved P-loop, responsible for phosphate binding and essential for 
the kinase activity, is located between β1 and α1. This domain shows similarity to 
ATP-binding domains of the RecA-F1-ATPase family, which is also found in helicases 
and DNA repair proteins (Sawaya et al., 1999, Welin et al., 2004). There is a flexible 
loop region between residues 245 and 260 in TbTK (42-59 in LmTK), which is 
disordered in most TK structures published to date. 
The smaller C-terminal domain (Figure 3-10) contains three β-strands (β9-11) and a 
short α-helix (α4) at the very C-terminus of the structure. It contains a structural 
Zn2+ ion tetrahedrally coordinated by four cysteine residues, C341 and C344 (TbTK) 
in the loop between β9 and β10 and the C374 and C377 (TbTK) at the start of the 
α4-helix. The long loop between β10 and β11 forms a lasso structure covering the 
thymidine-binding site, held in place by conserved R354 and Y370 residues, 
stabilising the main chain by hydrogen bonds. The conformations of the 
corresponding side chains in the LmTK structures (C140, C143, C173, C176, R153 
and Y169) are in identical positions. 
 
Figure 3-10: The C-terminal domain of TbTK.  
The Zn
2+
 coordinating cysteine residues (C341, C344, C374 and C377) and lasso-stabilising arginine (R354) and 
tyrosine (Y370) residues shown as cylinders coloured by atom type.  
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3.3.3.2 Substrate and Inhibitor binding  
LmTK crystallised in the presence of the substrate dThd + AppNHp, and the 
inhibitors dTTP and AP5dT. The crystal grown with dThd + AppNHp shows clear 
electron density for dThd (Figure 3-11 A). While there was no density for AppNHp, 
there seems to be a partially occupied phosphate where the β-phosphate of the 
AppNHp would be expected. The LmTK-dTTP crystal clearly shows electron density 
for dTTP in the thymidine-binding site (Figure 3-11 B), the phosphates being 
coordinated by a magnesium ion while the ATP-binding site is empty. The LmTK-
AP5dT crystal has two chains in the AU of which both show clear density for the 
thymidine moiety and the 5 phosphates, but only chain A exhibits good density for 
the adenosine moiety (Figure 3-11 C).  
TbTK was crystallised in complex with dThd (+glycerol), dThd/dTMP and 
dTMP + PO4
2-. The TbTK-dThd-glycerol crystal was soaked in cryo-protectant 
containing 10 % glycerol, dThd and AppNHp in order to replace the co-crystallised 
TMP. This crystal shows clear electron density for the dThd, but none for AppNHp 
and seems to have glycerol molecules bound from the cryo-protection (Figure 3-12 
A). The TbTK-dThd/dTMP crystal shows clear electron density for the dThd from the 
dTMP it was co-crystallised with (Figure 3-12 B), as well as additional density most 
probably resulting from a partially occupied PO4
2- (from the dTMP), which was not 
modelled because of the bad electron density fit upon refinement with dTMP. 
There is no density for AppNHp and the expected position of its phosphate groups 
seems occupied by water molecules. The TbTK-dTMP-PO4
2--a crystal shows very 
similar density to the TbTK-dThd/dTMP crystal, with a well-resolved dThd, but a 
higher occupied PO4
2- (from dTMP) in the active site (Figure 3-12 C). Additionally, it 
shows clear electron density for a PO4
2- where the β-PO4
2- of the AppNHp was 
expected to be bound. To obtain TbTK crystals in a different space group, which 
allows AppNHp to bind in the site expected from comparison to other TK structures, 
seeding experiments were carried out. This led to the crystals TbTK-dTMP-PO4
2--b 
with the phosphate in the β-position (Figure 3-12 D). 
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Figure 3-11: Electron densities for the ligands bound in the LmTK structures.  
Shown are the ligands in the active sites of the chain A from (A) LmTK-dThd-PO4
2–
 (B) LmTK-dTTP (C) LmTK-
AP5dT. The ligands are shown as cylinders coloured by atom type, mFo-DFc maps contoured at 3σ in green 
(positive) and red (negative), the 2mFo-DFc maps are contoured at 1σ and drawn in blue. Shown are the maps 
generated before (left) and after (right) ligand modelling. The weighted electron density maps (2mFo-DFc) and 
difference maps (mFo-DFc) were calculated using REFMAC5 (Murshudov et al., 2011).  
 
The active site residues forming the thymidine-binding site have identical 
conformations in all structures (Figure 3-13 A) and very similar to the conformation 
in other TKs with the exception of F321 in TbTK, which is pushed outwards. A 
detailed description of the active site was given for HsTK1 (Welin et al., 2004), BaTK 
and BcTK (Kosinska et al., 2007) among others, so that it can be described concisely 
for LmTK and TbTK. In brief, the dThd molecule, deeply buried between the two 
domains, is coordinated by hydrogen bonds to the main chain of residues, R361, 
L363 and G365 in TbTK and Q160, L162 and G164 in LmTK, located in the lasso 
domain, and Y316/Y115 (TbTK/LmTK) from the α/β-domain (Figure 3-13 A). 
Additionally, stacking interactions with Y370/Y169 (TbTK/LmTK) of the lasso domain 
and hydrophobic interactions of F289, L312 and F321 (TbTK)/F88, L111 and F120 
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(LmTK) on the α/β-domain are holding the thymidine ring in place. In the structures 
with dThd in the active site, the E286/E85 (TbTK/LmTK), essential for catalysis, 
forms a hydrogen bond to the 5’-oxygen of the ribose ring. It is therefore in a 
position to serve as a catalytic base, abstracting a proton from the oxygen, which is 
then enabled to perform a nuceophilic attack on the γ-phosphate of the phosphate 
donor.  
 
Figure 3-12: Electron densities for the ligands bound in the TbTK structures.  
Shown are the ligands in the active sites of the chain A from (A) TbTK-dThd-glycerol, (B) TbTK-dThd/dTMP, (C) 
TbTK-dTMP-PO4
2-
-a and (D) TbTK-dTMP-PO4
2-
-b. The ligands are shown as cylinders coloured by atom type, 
mFo-DFc maps contoured at 3σ in green (positive) and red (negative), the 2mFo-DFc maps are contoured at 1σ 
and drawn in blue. Shown are the maps generated without (left) and with (right) ligands present in 
refinement. The weighted electron density maps (2mFo-DFc) and difference maps (mFo-DFc) were calculated 
using REFMAC5 (Murshudov et al., 2011).  
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Figure 3-13: TK substrate binding site. 
 (A) Thymidine-binding site and P-loop in cylinder representation, coloured by atom type with carbons and 
phosphates coloured as follows: TbTK-dThd/dTMP in light green, TbTK-TMP-PO4
2-
-b in lawn green, LmTK-
dThd-PO4
2-
 in ice blue, LmTK-dTTP in light blue. Numbering according to TbTK and LmTK in brackets. Hydrogen 
bonds are shown as dashed lines. (B) Overlay of the substrates of TbTK-TMP-PO4
2-
-b (light green), LmTK-dTTP  
(ice blue), LmTK-AP5dT  (light blue) and TmTK-dThd-AppNHp, PDB ID: 2qq0 (tan). The position of the P-loop is 
identical for all structures, shown here is the one from LmTK-AP5dT. 
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None of the structures contains the phosphate donor mimic AppNHp. However, in 
some structures a phosphate is coordinated by the main chain of the P-loop in the 
expected position of the β-phosphate of the phosphate donor, as seen in the 
structure of TmTK-dThd-AppNHp (PDB ID: 2qq0, Figure 3-13 B).  In the structure of 
LmTK-AP5dT the dThd moiety is bound in the same site as in the other structures, 
but the phosphates show different positions. Four of the five phosphates of the 
AP5dT show identical positions to the phosphates in the HsTK1 structure in complex 
with AP4dT (PDB ID: 2orv, Segura-Pena, Lutz, et al., 2007), which has no electron 
density for the adenine moiety.  
The expected ATP-binding site, according to the structures of CaTK and TmTK with 
adenosine bound in the phosphate donor site, is blocked in the structures of LmTK 
and TbTK by residues of the α1-helix of the adjacent, symmetry-related dimer, 
forming a closed tetramer, discussed in 3.3.3.3. The structure of LmTK-AP5dT shows 
clear electron density not only for the dThd moiety and the five phosphates, but 
also for the adenosine. The adenosine is not bound in the expected ATP-binding site 
identified in structures of CaTK (PDB ID: 1xx6), TmTK (PDB ID: 2qq0) and BcTK (PDB 
ID: 2ja1), but instead is flipped about 180°, lying on the α/β-domain (Figure 3-13 B). 
The adenosine moiety is coordinated via a hydrogen bond of residue T19 and 
hydrophobic interactions of residues M22, K39 and Y46 (Figure 3-14). 
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Figure 3-14: Schematic representation of the coordination of AP5dT in the active site of LmTK. 
Shown are the ligand AP5dT (TP5A) and residues coordinating it via hydrogen bonds (green labels, hydrogen 
bonds as dashed lines), and hydrophobic interactions (black labels, red half circles). Ligand and hydrogen 
bonding residues are shown as ball and stick models coloured by atom type. Figure drawn with LigPlot+ 
(Laskowski & Swindells, 2011). 
 
This position may be an artefact caused by tetramer formation in solution prior to 
binding of the AP5dT. It could indicate a low binding affinity and specificity for the 
nucleobase of the phosphate donor with the phosphate donor at the 
concentrations used not being able to change the conformation of the tetramer. 
Also, we cannot rule out a different binding site of the phosphate donor in LmTK 
compared to other solved structures. While it is not possible to pinpoint the amino 
acid residues coordinating the adenosine in LmTK and TbTK, the structures of LmTK-
AP5dT and LmTK-dTTP give insight into their mode of inhibition. Its dThd moiety 
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binds in the dThd binding site and the phosphates are bound by the P-loop. In this, 
dTTP’s γ-phosphate takes the place of ATP’s β-phosphate, blocking the site. The 
phosphates of AP5dT have different positions, but still binding tightly to the P-loop. 
 
3.3.3.3 Quaternary structure and subunit-subunit interactions 
Most of the TK crystals contain one dimer in the asymmetric unit, with the 
tetramers generated by applying the symmetry operators (Figure 3-15). The crystals 
displaying lower symmetry have either one tetramer and a dimer (TbTK-dTMP-PO4
2-
-b) or two tetramers (LmTK-dTTP) in the asymmetric unit. SSM superposition 
reveals tetramer formation of LmTK and TbTK to be identical. 
 
 
Figure 3-15: Superposition of LmTK and TbTK tetramers.  
Protein chains are represented as worms, LmTK-dTTP in lemon, dark cyan, light green and pink, TbTK-
dThd/dTMP in orange, dark blue, lawn green and tan.  
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Analysis using PISA (Krissinel & Henrick, 2007) suggested LmTK to be tetrameric 
independent of the ligand bound or its presence during the PISA analysis. TbTK was 
predicted to be a dimer or the tetramer in solution, depending on the presence or 
absence of phosphates in the P-loop during PISA analysis. If the phosphate was used 
in analysis, TbTK was predicted to be tetrameric, if all ligands were ignored, TbTK 
was suggested to be dimeric. SSM superposition shows LmTK and TbTK to form the 
same subunit-subunit interactions. 
There are two protomer-protomer interfaces, one defined by the central β-sheets 
of two protomers, which come together in an anti-parallel orientation to form one 
continuous 12-stranded β-sheet. This results in the formation of a stable dimer. The 
other interface, resulting in tetramer formation, is defined by the anti-parallel 
interaction of the long α1-helices of the α/β-domains of two adjacent subunits. 
In solution, TKs were reported to form tetramers at high concentrations and 
depending on the species, tetramer formation is induced by the presence of the 
phosphate donor (Mutahir et al., 2013). In crystal structures two different types of 
TK tetramers are observed depending on the presence or absence of phosphate 
donor, the open and the closed tetramer (Figure 3-16). In the absence of ligand in 
the phosphate donor site, TKs form a closed tetramer with the long α1-helices of 
the α/β-domains interacting directly. In the presence of the phosphate donor the 
tetramers formed are more open and the α1-helices are ~ 3 Å apart, so there is 
space for the nucleobase to bind. The dimer interfaces remain identical in both 
tetramers. The formation of the open and the closed tetramer can be observed in 
TKs shown to be dimeric in solution, e.g. BcTK (Kosinska et al., 2007, Mutahir et al., 
2013), while TKs, that have been shown to form ATP-induced tetramers in solution, 
e.g. HsTK1 (Welin et al., 2004, Mutahir et al., 2013), have only been crystallised as 
closed tetramers. The conformations of the dimer interfaces do not change upon 
phosphate donor binding.  
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Figure 3-16: Comparison of open and closed TK tetramers.  
(A) Closed LmTK-AP5dT (blue tones) and open TmTK-dThd-AppNHp (2qq0, red tones) tetramers superposed 
on one dimer each (upper dimer). Shown are the β-sheets and α1 helices of the tetramers viewed from two 
angles 90° rotated. (B) Surface representation of the open TmTK-dThd-AppNHp tetramer. (C) Surface 
representation of the closed LmTK-AP5dT tetramer.  
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LmTK and TbTK form closed tetramers in the crystals and do not show electron 
density for the AppNHp they were co-crystallised with. LmTK co-crystallised with 
the bi-substrate analogue AP5dT, is also seen as a closed tetramer in the crystal. 
This could be caused by formation of the closed tetramer in solution prior to 
addition of AP5dT to the protein, blocking the phosphate donor site. The adenosine 
part of the AP5dT apparently was not able to induce the change into the open 
tetramer, either a result of a low binding affinity of the phosphate donor 
nucleobase or indicating a different binding site compared to the one in CaTK (PDB 
ID: 1xx6), TmTK (PDB ID: 2qq0) and BcTK (PDB ID: 2ja1). 
 
3.3.3.4 Conformations of the mainly disordered loop region 
The 15-20 amino acid residue loop region between amino acid residues 245 and 260 
in TbTK (42-59 in LmTK) is disordered in most structures reported in the PDB. 
However, in some chains of the structures of UuTK (2b8t, Kosinska et al., 2005), 
BcTK (2ja1, Kosinska et al., 2007), HsTK1 (1w4r, Birringer et al., 2005) and CaTK 
(1xx6, Kuzin et al. unpublished) this region is ordered with their conformations 
varying greatly (Figure 3-17).  
This loop was proposed to be involved in the binding of the phosphate donor 
(Kosinska et al., 2005, Kosinska et al., 2007), although none of the structures solved 
so far directly supports this. In most chains of the LmTK and TbTK structures this 
loop is disordered. However, chain A of the LmTK-AP5dT structure shows a partial 
folding of this loop over the adenosine moiety, which is bound in a different 
position than the expected phosphate donor site, defined for other TK structures 
(CaTK 1xx6, TmTK 2qq0, BcTK 2ja1). The β-hairpin formed by the loop region of 
BcTK-dTTP (2ja1) is clashing with the site binding the adenosine moiety in the LmTK-
AP5dT structure (Figure 3-17 B).  
Additionally, in the LmTK-dTTP structure, this region can be traced in two of the 
eight chains. However, this can be assumed to be a crystallographic artefact since 
the loop forms an additional β-strand to extend the central β-sheet, connecting it to 
one of the central β-sheets of a neighbouring, symmetry-related tetramer. Dimers 
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of these are shown in Figure 3-18. The formation of a continuing β-sheet between 
tetramers is not likely to be of physiological importance. 
 
 
Figure 3-17: Conformations of the mainly disordered loop. 
The peptide chains are shown in ribbon representation, the ligands as cylinders coloured by atom type with C 
and P atoms according to model. The overall structure shows the chain A of TbTK in white with the relevant 
loop being completely disordered. Displayed are the loops of LmTK-AP5dT (ice blue, chain A), LmTK-dTTP 
(lawn green, chain C), LmTK-dThd (lemon, chain A) together with (A) HsTK1 (pale crimson, PDB: 1w4r, chain 
A), and (B) BcTK-dTTP (tan, PDB: 2ja1, chain A) after SSM superposition of the whole structures. 
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Figure 3-18: LmTK-dTTP dimer connection to a symmetry-related dimer.  
The black arrow indicates the β-strand formed in order to connect the two β-sheets. The dimers (half of the 
tetramers) shown are in adjacent symmetry-related tetramers (not in the same asymmetric unit).   
 
3.3.3.5 The TbTK pseudo-dimer 
TbTK is a tandem enzyme, containing two TK-homology domains fused to one 
another and it has been shown previously that the catalytically active domain does 
not dimerise efficiently in solution, when expressed as thioredoxin fusion in E. coli 
(Ranjbarian et al., 2012). Full-length TbTK forms a pseudo-dimer in solution and 
assembles into a dimer (pseudo-tetramer) at high concentrations and in the 
presence of ATP. For this assembly, the C-terminus of the N-terminal TK-homology 
domain needs to be close enough to the N-terminus of the other, so that the linker 
region of 18 amino acids (aa 181-197) is able to bridge this gap. To address this, the 
sequence of the N-terminal TK-homology domain was modelled onto the structure 
of the catalytically active, C-terminal TK-homology domain and coloured by 
sequence identity (Figure 3-19). As there are two different protomer-protomer 
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interfaces in a TK tetramer, one responsible for dimer formation and one for 
tetramer formation, there are two possible pseudo-dimers formed by full-length 
TbTK. In both modelled pseudo-dimer structures (Figure 3-19 A and B), the termini 
of the two protomers seem indeed close enough to be connected by an 18 amino 
acid linker (shown as dashed grey line in the figure). After visualisation of the 
sequence identity in respect of the structure, high sequence identity of the central 
β-sheet as well as the α1-helix becomes apparent, while the outside facing parts of 
helices α2 and α3 and the region between the β-strands β5 and β6 show amino 
acid replacements. Looking at the dimer interface (Figure 3-19 C), only 
approximately 50 % of the residues involved are identical; the tetramer interface 
(Figure 3-19 D) on the other hand seems not to contain any amino acid 
replacements. Analysis with PISA indicated the pseudo-dimer shown in Figure 3-19 
A is stable in solution, not so the pseudo-dimer in Figure 3-19 B. Therefore, the full-
length TbTK is most likely forming a pseudo-dimer similar to the one shown in 
Figure 3-19 A.  
Comparison of the active site residues of structures of catalytically active TKs with 
our modelled inactive TK-homology domain highlights the amino acid substitution 
D286N. Asparagine is not able to act as a catalytic base, which renders the protein 
inactive. Additionally the transition state stabilising residue R246 is deleted and the 
substitution D244N might influence the activity. All remaining active site residues 
are identical in the thwo TK-homology domains. 
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Figure 3-19: Model of TbTK pseudo-dimer coloured by sequence identity. 
 Green = identical residues, yellow = similar residues, red = amino acid replacements with very different 
residues. (A) Ribbon representation of the TbTK pseudo-dimer; first residue of chain A modelled TK-homology 
domain) and last residue of chain B (catalytically active domain, crystal structure from TbTK-dThd-glycerol) 
are shown as spheres; the dashed line represents the linker between the two TK-homology domains of full-
length TbTK. (B) Alternative pseudo-dimer formed by the full-length TbTK. (C) Surface view of the TbTK dimer-
interface coloured by sequence identity. (D) Surface view of the TbTK tetramer-interface coloured by 
sequence identity.  
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3.4 Discussion 
Expression and stabilisation of TKs of the TriTryps turned out to be difficult, which 
was surprising given that many structures of type II TKs have already been solved. It 
was possible to obtain soluble and stable protein of TKs from L. major and T. brucei, 
but all attempts to express T. cruzi TK failed. Somewhat disappointingly, only 
heavily truncated versions of the enzymes expressed in soluble form and structural 
work was limited to the core proteins closely homologous to other known 
structures in the PDB. However, analysis and comparison of the LmTK and TbTK 
structures with the HsTK1 structure alongside kinetic data provided by collaborators 
(Table 3-), allow conclusions about the potential use of TKs as potential targets for 
anti-trypanosomal chemotherapeutics.  
The structures of LmTK and TbTK are highly similar to those of other species (HsTK1, 
(Welin et al., 2004, Birringer et al., 2005); UuTK, (Kosinska et al., 2005); BaTK and 
BcTK, (Kosinska et al., 2007); TmTK, (Segura-Pena, Lichter, et al., 2007, Segura-Pena, 
Lutz, et al., 2007); CaTK, Kuzin et al. unpublished). The protomers overlay nicely and 
dimers and tetramers retain the same interfaces and overall architecture. The LmTK 
and TbTK structures form closed tetramers with the blocked phosphate donor site 
and therefore overlay better with other closed tetramers than with open tetramers.  
While the active site residues whose side chains coordinate the dThd are highly 
conserved, comparison of the actual thymidine-binding pockets of TbTK with the 
HsTK1 shows differences. TbTK has more space around the bound dThd, especially 
around the C5 position of the dThd ring. The thymidine-binding site has a widened 
cavity beside the dThd ring into the α/β-domain, where the main chain is bent 
outwards and the stacking F321 is ~ 1.1 Å further away from the dThd than in HsTK1 
or LmTK (Figure 3-20 A). The region around the 3’-oxygen of the ribose ring seems 
to be more open in most LmTK and TbTK structures (Figure 3-20 B) compared to 
HsTK1. This might be an artefact of the crystallisation as the loop, harbouring two 
amino acid residues, which coordinate this region of the dThd, is disordered in all 
LmTK and TbTK structures except for the LmTK-AP5dT, where this loop is partially 
ordered in chain A. In this structure the side chain conformations of these residues 
are identical to those reported for HsTK1. The alignment in Figure 3-3 indicated 
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these residues (D43 and R45 in LmTK) to be conserved in all TKs except the inactive 
TK-homology domain of TbTK.  
 
 
Figure 3-20: Comparison of the active sites of LmTK, TbTK and HsTK1. 
 (A) Stereo view of the substrate environment focusing on F321 in TbTK and F120 in LmTK. Phenylalanines and 
dThd in cylinder representations, the helix of TbTK (light green) is extended and pushed outwards compared 
to LmTK (ice blue) and HsTK1 (1W4R, black). (B) Stereo view of the surface of LmTK active site focusing on the 
region around the 3’-oxygen of the ribose ring, D43 and R45 of LmTK in ice blue (D58 and R60 in HsTK1, black) 
cover the ribose region of the active site, while these residues are disordered in other LmTK and TbTK 
structures.  
 
The structural differences in the active site of TbTK indicate lower substrate 
specificity compared to the human enzyme. Lower substrate specificity was 
demonstrated previously (Ranjbarian et al., 2012), showing TbTK to readily 
phosphorylate deoxyinosine (dIno) and deoxyguanosine (dG), while the activity of 
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HsTK1 against these substrates was shown to be poorer. This leads to the possibility 
of developing nucleoside analogues and other ligands that selectively bind to TbTK 
either as alternative substrates or inhibitors. During the course of this work, 
collaborators at the Instituto de Parasitologia y Biomedicina “Lopez-Neyra” in 
Granada, Spain, showed TK being essential for the survival and proliferation of 
T. brucei parasite, which confirms this enzyme as a potential drug target in these 
parasites. 
The structure of LmTK on the other hand does not show major differences in the 
active site, so that design of LmTK-specific ligands might be difficult. However, 
during the course of this work, collaborators at the Instituto de Parasitologia y 
Biomedicina “Lopez-Neyra” in Granada, Spain, studied the substrate specificity and 
inhibition kinetics of LmTK (Table 3-11). They found LmTK to have as high substrate 
specificity as HsTK1, only phosphorylating dThd, dUrd and to some extent uridine 
(Urd). Additionally, they were able to show the phosphorylation of 5’-modified 
dUrd, as well as AZT, which was shown to be toxic to L. amazonenses (Araujo et al., 
2011) and therefore is a potential candidate for anti-leishmanial therapy.  
 
Table 3-11: Kinetic parameters of full-length LmTK.  
Parameters are averages of two or more independent experiments. N.D. = not determined. 
a 
activity 
measurements at 10 mM substrate concentration. Data provided by collaborators at the Instituto de 
Parasitologia y Biomedicina “Lopez-Neyra” in Granada, Spain.  
Substrate KM 
(μM) 
Vmax 
(μmol∙min-1∙mg-1) 
kcat 
(s-1) 
kcat/KM 
(s-1.M-1) 
dThd 1.10 ± 0.33 4.66 ± 0.63 2.62 2.38 x 10
6
 
dUrd 11.1 ± 2.7 5.45 ± 0.77 3.06 2.76 x 10
5
 
dC N.D. 0.07
a
 - N.D. 
dA N.D. 0.01
a
 - N.D. 
dG N.D. 0.04
a
 - N.D. 
Urd 1462 ± 158 0.79 ± 0.12 0.44 3.03 x 10
2
 
Cyd N.D. 0.00
a
 - N.D. 
Ado N.D. 0.00
a
 - N.D. 
Guo N.D. 0.00
a
 - N.D. 
dIno N.D. 0.04
a
 - N.D. 
AZT 3.04 ± 0.76 3.52 ± 0.56 1.97 6.51 x 10
5
 
5F-2’dU 5.72 ± 0.56 8.29 ± 1.12 4.66 8.14 x 10
5
 
5Br-2’dU 2.05 ± 0.33 6.17 ± 0.19 3.47 1.69 x 10
6
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3.5 Summary and future work 
The C-terminally truncated versions of LmTK, spanning amino acid residues 2-185, 
and TbTK, spanning amino acid residues 198-382, were soluble and produced in 
sufficient amounts for structural studies when expressed using the baculovirus 
expression system. Therefore, the structural work was restricted to the core 
proteins with high homology to other TK structures in the PDB. Comparison of LmTK 
and TbTK with HsTK1 allows conclusions to be drawn about the use of TKs as 
potential targets against Leishmania spp. and T. brucei. All LmTK and TbTK 
structures show the formation of closed tetramers as seen in many other TK 
structures in the PDB. The dThd binding site is well resolved in all of the structures 
and allows analysis of the substrate site. LmTK’s dThd site is very similar to the 
HsTK1, but TbTK shows a slightly widened cavity. This, together with its essentiality 
in the parasite (unpublished data) and the lower substrate specificity demonstrated 
previously (Ranjbarian et al., 2012), supports TbTK’s potential as a drug target. In 
future studies, the TbTK structures will aid identification and design of lead 
compounds to treat HAT. 
LmTK phosphorylates AZT, a compound shown to inhibit the growth of Leishmania 
amastigote growth (Araujo et al., 2011). In this context, the structures of LmTK will 
allow future studies to focus on the structural analysis of ligand binding and 
phosphorylation in respect to possible modifications of AZT to maximise its 
potential as an anti-leishmanial chemotherapeutic.  
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Chapter 4 Characterisation of the M17 family leucyl 
aminopeptidases from the TriTryps  
4.1 Introduction 
4.1.1 M17 family of leucyl aminopeptidases 
This family is subdivided into eukaryotic leucyl aminopeptidases (LAP, EC 3.4.11.1), 
bacterial leucyl aminopeptidases (EC 3.4.11.10), prolyl aminopeptidases (PAP, 
EC3.4.11.5) and PepB aminopeptidases (PepB, EC 3.4.11.23). 
LAPs are well studied and in the literature are referred to under several alternative 
names, e.g. cytosol aminopeptidase, leucine aminopeptidase and peptidase S. They 
are found in all kingdoms of life and species can have more than one M17 LAP. The 
eukaryotic LAPs have been characterised biochemically, mainly the porcine and 
bovine lens enzymes (Allen et al., 1983, Carpenter & Vahl, 1973, Cappiello et al., 
2006, Matsushima et al., 1991, Strater & Lipscomb, 1995b, a, Strater, Sun, et al., 
1999, Van Wart & Lin, 1981) and those of a number of plant species, (Gu & Walling, 
2002, Scranton et al., 2012). Protozoan LAPs have been studied in Babesia gibsoni 
(BgLAP, Jia et al., 2009), Leishmania spp. (Morty & Morehead, 2002), Plasmodium 
falciparum (PfLAP, Harbut et al., 2011), Toxoplasma gondii (TgLAP, Jia et al., 2010) 
and Trypanosoma cruzi (Cadavid-Restrepo et al., 2011). Bacterial enzymes were 
studied from E. coli (Stirling et al., 1989, Bhosale et al., 2010), Helicobacter pylori 
(Dong et al., 2005), Pseudomonas putida (Kale et al., 2010), P. aeruginosa 
(Woolwine et al., 2001), Vibrio cholerae (Behari et al., 2001) and Xanthomonas 
oryzae (Kim et al., 2013).  
The LAP structures of many species have been solved, e.g. bovine lens (blLAP, 
Burley et al., 1990, Kim & Lipscomb, 1993, Kim et al., 1993, Strater & Lipscomb, 
1995a, b), tomato (tLAP, DuPrez et al. unpublished), Caenorhabditis elegans (CeLAP, 
Patskovsky et al. unpublished) Coxiella burnetii (CbLAP, Minasov et al. unpublished), 
E. coli (EcLAP, PepA, Strater, Sherratt, et al., 1999), Francisella tularensis (FtLAP, 
Maltseva et al. unpublished), P. falciparum (PfLAP, Figure 4-1, McGowan et al., 
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2010), P. putida (PpLAP, Kale et al., 2010), Staphylococcus aureus (SaLAP, Hattne et 
al. unpublished), T. brucei (TbLAP, Wernimont et al. unpublished) and X. oryzae 
(XoLAP, Nataranjan et al. unpublished). All of these structures are homologous with 
overall RMSDs of 0.27 – 0.35 Å, while sequence identity towards the TriTryp LAPs is 
32-45 %. LAPs are bi-lobal proteins (Figure 4-1 A) with a highly conserved C-terminal 
domain, containing the active site, and a smaller N-terminal domain with lower 
sequence similarity between species. The C-terminal domain shows some structural 
homology to family M14 carboxypeptidases and the M20 and M28 families of 
metallopeptidases (Artymiuk et al., 1992), but the position of the metal binding 
sites between these families is not conserved. While the fold of the C-terminal 
domain is absolutely identical for all LAPs, the N-terminal domain shows 
differences, the secondary structure elements being conserved but their positioning 
towards each other differing among species. The overall LAP fold is represented as 
cartoon in Figure 4-1 B. All LAPs described so far form trimers (Figure 4-1 C) and 
hexamers (as dimers of trimers, Figure 4-1 D) in solution with the hexameric state 
being predominant.  
LAP activity is dependent on the presence of two co-catalytic zinc ions, but activity 
has been shown with a number of divalent metal ions, e.g. manganese and 
magnesium (Carpenter & Vahl, 1973). LAPs hydrolyse peptides and amino acyl 
substrates with N-terminal leucine efficiently, but the substrate specificity is broad 
and varies between species and between different LAPs within one species. These 
enzymes generally accept substrates with most amino acids as terminal residue and 
the penultimate residue plays a role in the catalytic efficiency of the enzyme (Gu & 
Walling, 2002).  
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Figure 4-1: Structure of PfLAP. 
 (A) Protomer; (B) Cartoon representation of PfLAP secondary structure elements coloured with a colour 
gradient from N-terminus (blue) to C-terminus (red) with β-sheets as arrows and α-heleces as tubes. (C) Half a 
hexamer (trimer); (D) Hexamer (dimer of trimers). For (A), (C) and (D): Protein in ribbon representation, 
ligand indicating the position of the active site as spheres. This and all subsequent structure figures were 
made with CCP4mg (McNicholas et al., 2011). The protein cartoon was generated using Pro-Origami (Stivala 
et al., 2011). 
 
PAPs were shown to be manganese-dependent aminopeptidases (Sarid et al., 1962, 
Nordwig & Mayer, 1973). Later studies showed the mammalian enzyme not to be 
restricted to prolyl bonds and functional characterisation suggested the PAPs are 
identical to LAPs (Turzynski & Mentlein, 1990). PepB, characterised in E. coli, is a 
zinc-dependent aminopeptidase cleaving preferentially acidic amino acid residues 
(aspartic and glutamic acid) off the peptide substrate (Mathew et al., 2000). It also 
accepts other amino acids, e.g. leucine, methionine, histidine cysteine and 
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glutamine. Its pH optimum is alkaline and the activity is stimulated by potassium 
ions. Like LAPs it forms homohexamers. 
 
4.1.2 M17 LAPs from the TriTryps 
Four distinct M17 family LAPs have been identified on the TriTryps genomes (Table 
4-1), classified according to their isoelectric points as acidic (LAP-A), neutral (LAP-N) 
or basic (LAP-B).  
 
Table 4-1: The TriTryp LAPs.  
The subcellular localisations were predicted with PSORT II, accessed on 22.6.2014 (Nakai & Horton, 1999), 
except those marked with an asterisk (*), which were determined experimentally; ER = endoplasmic 
reticulum. 
Name Gene ID (in TriTrypDB) 
Number 
of 
amino 
acids 
MW 
[Da] 
Isoelectric 
point 
Subcellular 
localisation 
LmLAP-A LmjF.11.0630 538 57 148 5.98 Cytoplasmic 
LmLAP-A2 LmjF.11.0620 292 31 229 5.91 Cytoplasmic 
LmLAP-N LmjF.33.2570 528 55 757 6.67 ER 
LmLAP-B LmjF.23.0950 565 60 267 9.21 Cytoplasmic* 
(Mitochondrial) 
TbLAP-A Tb427tmp.02.4440 521 55 400 6.04 Cytoplasmic 
TbLAP-A2 Tb11.v5.0360 216 23 376 5.67 Extracellular 
TbLAP-N Tb427tmp.02.0070 565 60 625 7.51 ER 
TbLAP-B Tb427.08.3060 671 71 455 9.33 Mitochondrial 
TcLAP-A TcCLB.508799.240 520 55 892 6.06 Cytoplasmic 
foci* TcLAP-A2 TCSILVIO_001670 217 23 512 5.44 Extracellular 
TcLAP-N TCSYLVIO_005560 557 59 915 6.98 ER 
TcLAP-B TCSILVIO_000171 584 62 309 9.19 ER 
 
Structure-based and sequence based multiple alignments clearly indicate a large 
divergence between the three distinct types, Figure 4-2, suggesting all three were 
present in a common ancestor of the TriTryps. The LAPs of most other species, 
including bacteria, plants and protozoa of other genera, are closest related to the B-
type LAPs with sequence identities between 34 and 45 %. The LAP with the highest 
identity to the TriTryp LAP-As and LAP-Ns is the human NPEPL1 with an overall 
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sequence identity of 37 % to LmLAP-A, 41 % to TbLAP-A and 51 % to TcLAP-A, while 
all other enzymes analysed showed lower identities between 28 % and 38 %. 
 
 
Figure 4-2: Phylogenetic tree of the M17 LAPs.  
HsLAP-NPEPL1 = human LAP called NPEPL1, HsLAP3 = human LAP3, HsLAP-u = human LAP, still classified as 
unknown product, BtLAP = bovine LAP, XoLAP = X. oryzae, PpLAP = P. putida LAP, EcPepA = E. coli LAP, TgLAP 
= T. gondii LAP, PfLAP = P. falciparum, BgLAP = B. gibsonii LAP, SlLAP = tomato LAP, AtLAP = A. thaliana LAP. 
Radial tree was drawn using TreeDyn 198.3 (Chevenet et al., 2006) after structure-based multiple sequence 
alignment using Expresso in T-coffee (Armougom et al., 2006). 
 
Alignment of the distinct TriTryp LAP types, e.g. all three LAP-As (Figure 4-3), shows 
a very high sequence similarity.  
Sequence alignment of the four LAPs (A, A2, N and B) from T. brucei, T. cruzi and 
L. major (Figure 4-4) shows low sequence identity, but common core secondary 
structure elements, interspaced with longer loop regions mainly for the LAP-Bs. It 
can be assumed that the core structures of the three long LAP types, LAP-A, LAP-N 
and LAP-B, are highly similar to one another and only differ in the length, 
conformation and charge of surface loops. The LAP signature sequence and active 
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site residues are conserved among all LAPs with the exception of the LAP-A2s, 
which are missing three of them. This work focuses on the LAP-As. This, together 
with analysis of the genomic surrounding of the lap-A2 genes, indicates the 
divergence of the LAP-As and LAP-A2s to be either an error in the annotation or 
alternatively non-functional gene duplication. 
Only two of the TriTryp LAPs have been characterised so far: LAP-B from L. major, 
L. donovani and L. amazonensis (Morty & Morehead, 2002) and LAP-A from T. cruzi 
(Cadavid-Restrepo et al., 2011). 
The LmLAP-Bs were shown to have very restricted substrate specificity, hydrolysing 
only substrates with leucine, cysteine and methionine residues as N-terminal amino 
acid efficiently. The peptidase activity was dependent on the metal ion with the 
catalytic efficiencies in the order Mn2+ >> Mg2+ > Co2+ > Ni2+ > Zn2+ and inhibition by 
Ca2+, Fe2+ and Cu2+. However, the physiological metal was determined to be zinc (by 
inductively coupled plasma atomic emission spectroscopy (ICP-AES)) (Morty & 
Morehead, 2002). Inhibition of the aminopeptidase function could be obtained by 
metal chelators, bestatin, apstatin, actinonin, L-leucinal and anti-porcine LAP IgG. 
Although analysis with PSORT II indicated mitochondrial localisation, Morty et al. 
suggested its localisation in the cytoplasm after immunocytochemical localisation 
experiments using anti porcine LAP IgG.  
TcLAP-A, like LmLAP-B, was shown to have limited substrate specificity with 
amidolytic activity only detected for amino coumarin substrates with N-terminal 
leucine (Leu-AMC) and none with N-terminal proline, aspartic acid, glycine-
phenylalanine, glycine-arginine, or glycine-proline and also did not accept bovine 
serum albumin, immunoglobulin G or gelatine as substrates. The enzyme showed a 
clear metal preference for Mn2+ > Ca2+ > Zn2+ with considerably less activity in the 
presence of Fe2+ and Mg2+ and almost none with Co2+ or Al3+. Inhibition could be 
obtained with metal chelators, bestatin and 1,10-phenanthroline. Interestingly, 
Cadavid-Restrepo et al. found distinct activity profiles for natively expressed and 
recombinant TcLAP-A with differences in temperature stability and activity optima. 
It was shown to be mainly hexameric in solution like other M17 LAPs. TcLAP-A is 
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localised in cytosolic foci or vesicles within the cytosol in T. cruzi amastigote, 
epimastigote and trypomastigote forms. 
Neither LmLAP-B, nor TcLAP-A has been validated as a potential drug target. 
 
 
Figure 4-3: Alignment of the TriTryp LAP-As.  
Consensus sequence (>70 %) is shown below the sequences, secondary structure of LmLAP-A above the 
sequences. Figure made with Espript 3.0 (Gouet et al., 2003) after sequence alignment in M-coffee 
(Notredame et al., 2000). 
 
                                                                      
LmLAP- A         1       P           S  V  C     NV FTD                    G   QLR       MSAMKR RSNSI VEETAV AY QT TNFKS  T   I SKVSCVA. . . . . . PHVLLV ALE   DNSLKSV
TbLAP- A         1       P           S  V  C     NV FTD                    G   QLR       M. . PTL KA. . . . EAKEL AF QS VEYKT  C   VAAYESNQKGVLSSGLAVLV THK   DPAVQRL
TcLAP- A         1       P           S  V  C     NV FTD                    G   QLR       . . . MNR PA. . . . TDSGA EF RS VNFET  E   VDAYKKTHTAGLASTFVVI L THA   EDALKEL
consensus>70 . . . . . . P. . . . . . . . . . . S. %V. . C. # %. . NV. FTD! . . . . . . . . . . . . . . . . . . . G. . . QLR# . . . . . .  
                                                                      
LmLAP- A        65  FY PAVAEA  RVK G T   L  E            V V   P   SR NCP R D       AA    L   C      LQ   A S VKT A VPG. . . RKGYTE M TAL ATT  T   Y A SMSEAVA  CGSV
TbLAP- A        65  FY PAVAEA  RVK G T   L  E            V V   P   SR NCP R D       AA    P  N      I E   E G YGV V GLANAAGSKFVR V GEV TKA  N   A P VVTXLVT  LDEV
TcLAP- A        64  FY PAVAEA  RVK G T   L  E            V V   P   SR NCP R D       AA    P  C      I Q   K E YAV A GVKNEANERFVR L GEV SEA  T   A P VVASLLS  LEEI
consensus>70 . FY. PAVAEA. # RVK. G. T. . . L . E. . . . . . . . . %. . V. V. . . P. . . SR. NCP. R. D. . . . . . . AA. . . !  
                                                                      
LmLAP- A       132        DV V   A      A A AR       AK G A   Y       L  VV               EEG. EVL  Y CAP GSETAV N V  AAPHSYT  A Q TKA MKQ. AMS N  MSSRAAFTQELVRGK
TbLAP- A       135        DV V   A      A A AR       AK G A   Y       L  VV               KEPNTTV  F LSN . . VLPI  A V  CGKHNFS  D A AAA NSGKVSR Q  FPEPPAI PPK. . . . .
TcLAP- A       134        DV V   A      A A AR       AK G A   Y       L  VV               KGPETKV  F RST . . ALAI  V A  SAKRNFT  E L TRG CDN. CVR T  FPTAPNPSPS. . . . .
consensus>70 . . . . . . . DV%V. . . A. . . . . ! A. A. AR. . . . . %. AK. G. A. . . Y. . . . . . . L . VV. . . . . . . . . . . . . . .  
                                                                      
LmLAP- A       200       L     TS QLCQRLVD P   L  T    E A  YA  LG    VI  G  L  E GYGGI Y VGK SVCVAE EAI C  V        T  PCM D VVYA I  AA  AE  VDMT  K DE R K      A   C
TbLAP- A       198       L     TS QLCQRLVD P   L  T    E A  YA  LG    VI  G  L  E GYGGI Y VGK . . . . . D EAVA  T        A PNL T ATFT I  QG  KA  FDVD  C DD C R      S   A
TcLAP- A       196       L     TS QLCQRLVD P   L  T    E A  YA  LG    VI  G  L  E GYGGI Y VGK . . . . . E AVVA  T        A TNL N ATFA V QS  KE  CAVD  C EE R R      S   C
consensus>70 . . . . . # L. . ! . TS. QLCQRLVD. P. . $ L. T. . %. E! A. . YA. . LG. . . . VI . G# # L. E. GYGGI Y. VGK.  
                                                                      
LmLAP- A       270 A     LVTL Y         K    VGKGI VYD GGL LKP   M  MK DMGG A VFC F   VR   QYPAH    R RNPNAAEGA NI AM        C   A   AAH TN  T    S G   A I AV  SM
TbLAP- A       263 A     LVTL Y         K    VGKGI VYD GGL LKP   M  MK DMGG A VFC F   VR   FEAPR    L  TPKG. . TPV KVSL        C   A   ADY KL  H    A A   G LTA  L.
TcLAP- A       261 A     LVTL Y         K    VGKGI VYD GGL LKP   M  MK DMGG A VFC F   VR   VEAPR    S KPKD. . ETR KVAL        S   S   TNF TG  R    A A   G LTA  L.
consensus>70 A. . . . . LVTL. Y. . . . . . . . . K. ! . $ VGKGI VYD. GGL. LKP. . . M. . MK. DMGG. A. VFC. F. . . VR. .  
                                                                      
LmLAP- A       340   Q          S TLCLAENAI GP  YRNDD    KSGK VEV NTDAEGR VLGDGV  AT E  F  KM RTHFSHI ANI  V           HS     VVVM    S   M       I       YY  G QD V
TbLAP- A       330   Q          S TLCLAENAI GP  YRNDD    KSGK VEV NTDAEGR VLGDGV  AT E  F  . .  Q. . . . P. VQL C           KS     I I VM    T    I        I       FH  N LS T
TcLAP- A       328   Q          S TLCLAENAI GP  YRNDD    KSGK VEV NTDAEGR VLGDGV  AT E  F  . .  M. . . . P. I EL C           DA     I LTL    T    N       L       FH  H I S K
consensus>70 . . Q. . . . . . . . # . S. TLCLAENAI GP. . YRNDD! . . $ KSGK. VEV. NTDAEGR. VLGDGV%. AT. E. . F .  
                                                                      
LmLAP- A       410 PDV  DMATLTGAQG ATG  HAG        E     AG  SG  C PVLYCPEYH     S  ADM N   L I           V   SK   VYASDAEA KDMI S  LQ  DL Y         EEVYK PC   R 
TbLAP- A       393 PDV  DMATLTGAQG ATG  HAG        E     AG  SG  C PVLYCPEYH     S  ADM N   VI           I    RH   LYVNEEGA AAMLR  RE  ET F         EPEFK NH   T  
TcLAP- A       391 PDV  DMATLTGAQG ATG  HAG        E     AG  SG  C PVLYCPEYH     S  ADM N   LV          I    HR   I FVNDEEE LSFLK  RA  ET F         VTEFR PV   R 
consensus>70 PDV. ! DMATLTGAQG! ATG. . HAG. %. . # . . . E. . . . . AG. . SG# . C%PVLYCPEYH. . . %. S. . ADM. N 
                                                                      
LmLAP- A       480        A  SC G F   HLS  F  G   HVD A P      ATG G  L   E  R             I ANSSSS GS  G Y VEQ   ER R PFV   M Y TSNTAG   Y VT VF FL QH.
TbLAP- A       463        A  SC G F   HLS  F  G   HVD A P      ATG G  L   E  R             LMERRDN GV  A Y I TT   PK T AHI    L  Y VFNSNG   F  PA LT YF KL.
TcLAP- A       461        A  SC G F   HLS  F  G   HVD A P      ATG G  L   E  R             SVKQVNN SV  A Q VAN   PD K KHI    M F AFENDK   F  PA LT YL NLR
consensus>70 . . . . . . . A. . SC. G. F! . . HLS. . F . G. . ! HVD$ A%P. . # . . . ATG%G. . L. . E%. R. . .  
a1 a2 b1 h1 b2 a3 h2 
a4 b3 b4 a5 h3 
b5 h4 a6 h5 b6 a7 
a8 a9 b7 a10 a11 
b8 b9 a12 h6 a13 
b10 b11 b12 a14 
b13 a15 b14 a16 b15 a17 b16 
a18 b17 b18 b19 a19 
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Figure 4-4: Consensus sequence (> 70 %) of the TriTryps LAPs.  
LAP signature sequence is underlined in orange, red asterisks indicate active site residues. Conserved residues 
are written as capital letters, partially conserved residues in small letters, and secondary structure of LmLAP-
A above the sequences. Figure made with Espript 3.0 (Gouet et al., 2003) after sequence alignment in M-
coffee (Notredame et al., 2000). 
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4.1.3 Mechanism of LAPs 
The amidolytic mechanism of M17 LAPs was characterised using structural 
information gained from the bovine lens LAP (Strater, Sun, et al., 1999) and led to 
the now commonly accepted model for catalysis, Figure 4-5.  
In brief, the active site contains two divalent metal ions in two non-equivalent 
binding sites. One site is reported to have a higher affinity for the metal as it is 
buried deeper within the protein than the other, which is closer to the surface. The 
physiological metal is believed to be zinc, but it can be exchanged in vitro for some 
other divalent ions preserving the activity (Kim & Lipscomb, 1993, Jia et al., 2010, 
Morty & Morehead, 2002, Cadavid-Restrepo et al., 2011). Depending on the 
species, LAPs seem to have different metal preferences. Besides the two zinc ions 
the active site contains a HCO3
- in most but not all structures. The two metal ions 
coordinate the substrate and are involved in stabilisation of the gem-diolate 
intermediate (middle panel in Figure 4-5) by polarisation of the substrate carbonyl 
group. The HCO3
- coordinated by R375 (in TbLAP-A) functions as a general base in 
the catalysis by accepting a proton from the metal-bridging water (the catalytic 
nucleophile). Then the HCO3
- transfers a proton to the leaving amino group of the 
peptide, which results in breakage of the gem-diolate intermediate. The residues 
involved in metal coordination and HCO3
- binding are conserved in all LAPs.  
 
 154
 
Figure 4-5: LAP mechanism.  
Amino acid residues numbered after TbLAP-A. Figure made with MarvinSketch (ChemAxon). 
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4.1.4 Physiological Functions of LAPs 
The physiological functions proposed for LAPs are diverse and differ between 
species. In animals, LAPs were implicated to play a role in proteolytic degradation 
and protein turnover based on the accumulation of peptides in rat liver cells after 
treatment with the aminopeptidase inhibitor bestatin (Botbol & Scornik, 1991). 
Whether this peptide accumulation was caused by inhibition of LAP or another 
bestatin-sensitive aminopeptidase is not clear. Another study (Cappiello et al., 
2006) proposed a role in maintenance of the cell redox status based on the 
observation that rat liver and bovine lens LAPs are able to cleave Cys-Gly bonds, 
which are components of glutathione, the cellular response against oxidative stress. 
Although E. coli and porcine LAP also utilise this substrate, plant LAPs show limited 
activity against it (Gu & Walling, 2002), arguing against this role in plants. Chaerkady 
and Sharma (Chaerkady & Sharma, 2004) suggested LAP plays a role in the 
formation of cataracts, due to the correlation of accumulation of partially degraded 
proteins and subsequent formation of opaque protein aggregates with the decline 
of LAP activity during lens maturation and aging. Mammalian LAPs are involved in 
MHC-1 antigen presentation by the trimming of the N-terminus of the peptides to 
be presented (Beninga et al., 1998, Stoltze et al., 2000, Kloetzel & Ossendorp, 
2004), but LAP is not essential for antigen presentation in vivo (Towne et al., 2005). 
Plants encode a varying number of LAPs, which are classified by their isoelectric 
points with LAP-As having acidic, LAP-Ns neutral and LAP-Bs basic pIs. Some plant 
LAPs are expressed as 65 kDa pre-proteins and subsequently processed to their 
mature 55 kDa form. LAP-As are transcriptionally regulated (Chao et al., 1999)  
responding to biotic and abiotic stresses (Gu & Walling, 2002). LAPs in tomato 
(SlLAP) and A. thaliana (AtLAP) are bifunctional, showing aminopeptidase activity 
and in addition acting as molecular chaperones (Scranton et al., 2012). These two 
functions are independent from each other with active site mutations eliminating 
peptidase activity having no adverse effect on the ATP-independent chaperone 
activity. Also, disruption of LAP’s hexamer formation (by introduction of point 
mutations) increased the chaperone activity. 
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Bacterial LAPs have rather broad substrate specificities and were proposed to be 
housekeeping enzymes facilitating amino acid recycling within the cell. The N-
terminal domain of E. coli LAP, called aminopeptidase A, EcPepA or EcXerB, was 
shown to have an additional, completely unrelated function. EcPepA (XerB) aids 
site-specific recombination events between directly repeated cer sites on ColE1 
plasmids and psi sites in pSC101 (Gourlay & Colloms, 2004) by binding to specific 
sites and bending the DNA to allow other proteins to interact. In addition, EcPepA 
was shown to be involved in cre-Lox recombination, which maintains the lysogenic 
state of the bacteriophage P1 (Paul & Summers, 2004). Another proposed function 
of EcPepA is transcriptional repression of the carAB operon, encoding an essential 
protein in the pyrimidine biosynthesis pathway (reviewed in Gourlay & Colloms, 
2004), and is working as a repressor of its own transcription. V. cholera PepA was 
shown to be involved in expression regulation of the toxT-dependent virulence 
genes (Behari et al., 2001, Woolwine et al., 2001), repressing them under non-
inducing pH conditions. The P. aeruginosa LAP, called PhpA, causes transcriptional 
repression of algD, which encodes for the first enzyme in the alginate biosynthesis 
pathway (Woolwine et al., 2001). Unlike EcPepA, PhpA’s aminopeptidase function 
and transcriptional repression are coupled, so that mutations abolishing the 
aminopeptidase function hamper the transcriptional repression.  
In summary, the physiological functions of M17 family LAPs are extremely diverse 
and vary with the species. This makes it very difficult, if not impossible, to predict 
the function in other species not characterised so far, e.g. kinetoplastid parasites.  
 
4.1.5 LAPs as drug targets and vaccine candidates 
As peptidases are central enzymes in protein and amino acid metabolism, there has 
been lots of interest in them as drug targets. For example, broad-spectrum 
aminopeptidase and 1,2-aminoalcohol-based LAP inhibitors were shown to have 
anti-malarial activity (Nankya-Kitaka et al., 1998, Howarth & Lloyd, 2000) and 
arphamenine-A proved to have anti-trypanosomal properties (Knowles, 1993). 
More recently, P. falciparum LAP (PfLAP), involved in haemoglobin digestion, was 
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identified as an essential enzyme and hence a potential drug target (Stack et al., 
2007, Harbut et al., 2011).  
In addition, LAPs have potential in vaccine development. Thus Fasciola hepatica LAP 
(FhLAP) was shown to be a vaccine candidate against ruminant fasciolosis (Acosta et 
al., 2008, Marcilla et al., 2008) and when combined with different adjuvants 
conferred a high level of immunity in sheep (Maggioli et al., 2011). 
 
4.1.6 Aims  
The primary aim was to evaluate the cytosolic M17 LAP-A as a potential drug target 
in T. brucei and additional experiments were to shed light on the physiological 
function of the LAP-As. The crystal structures of the LAP-As of the TriTryps in apo 
form and in complex with ligands were to be determined, and the oligomeric state 
in solution to be confirmed.  
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4.2 Experimental 
4.2.1 Cloning of LAP-A constructs for structural studies 
The genes encoding for the LAP-As were amplified from genomic DNA (T. brucei 
Lister427, T. cruzi Sylvio X10/1 and L. major Friedlin) and cloned into the YSBLIC3C 
vector using ligase independent cloning (LIC, Aslanidis & de Jong, 1990, Fogg et al., 
2006). PCR amplification and cloning of the LAP-As followed the protocol used for 
TbAK (Table 2-1 and Table 2-2) including identical reaction composition and 
temperature profile with primer sequences listed in appendix A.2.3. The resulting 
constructs (TbLAP-3C, TcLAP-3C and LmLAP-3C) encoded the LAP-As with an N-
terminal fusion to a hexahistidine tag, separated from the N-terminus of the protein 
by the recognition site of the HRV 3C protease. Cloning of the LmLAP-A construct 
was carried out by Nam Duong (a student of the Minority Health and Health 
Disparities International Research Training (MHIRT) program). The TbLAP-A gene 
was cloned into the YSBLIC vector by Dr. Javier Garcia Nafria using LIC, resulting in a 
construct encoding TbLAP-A with a non-cleavable N-terminal fusion to a 
hexahistidine tag (TbLAP-A-LIC). The success of the cloning was confirmed by 
restriction endonuclease digestion after plasmid propagation. The restriction 
endonuclease digestion was carried out using Nco1 and Nde1 (NEB). Reaction 
conditions are specified in Table 4-2 and were incubated for 1.5 h at 37°C. 
Subsequently, samples were analysed via agarose gel electrophoresis. Positive 
clones were further verified by sequencing. 
 
Table 4-2: Condition of control digests used to confirm cloning success. 
Reagent Volume per reaction [μL] 
10x NEB buffer 4 2 
ddH2O 6 
Nco1 (10 U/μL, NEB) 1 
Nde1 (20 U/μL, NEB) 1 
DNA (= ~50-100 ng/μL) 10 
Total volume 20 
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4.2.2 Expression of LAP-As in E. coli 
The TbLAP-LIC and TbLAP-3C constructs were transformed into E. coli BL21 (DE3) 
gold cells and plated on LB plates containing 35 µg mL-1 kanamycin. The TcLAP-3C 
and LmLAP-3C constructs were transformed into pLEMO (DE3) cells and plated on 
LB plates supplemented with 35 µg mL-1 kanamycin and 34 µg mL-1 
chloramphenicol. For all constructs, the next day the colonies were washed off with 
3 mL LB each and used for inoculation of fresh LB containing the appropriate 
antibiotics. The cells were grown at 37°C with shaking at 180 rpm (Innova44, New 
Brunswick Scientific) till they reached an optical density of 0.4 at 600 nm, where 
TbLAP-A-LIC and -3C expression was induced by addition of 1 mM IPTG for 4 h and 
TcLAP-A-3C and LmLAP-A-3C cultures transferred to 20°C with shaking at 251 rpm. 
TcLAP-A-3C and LmLAP-A-3C expression was induced at 20°C at an optical density of 
~ 0.6 at 600 nm over night (~ 16 h) also by addition of 1 mM IPTG. Cells were 
harvested by centrifugation at 5000 rcf for 30 min and washed with PBS prior to 
freezing. 
 
4.2.3 Purification of LAP-As 
Cells of 1 L culture were thawed on ice and lysed in 35 mL buffer A (20 mM Tris 
pH8.0, 300 mM NaCl, 30 mM imidazole, 1 mM DTT and 110 µM PMSF) by 
sonication. Cell debris was removed by centrifugation at 5000 rcf for 30 min and 
supernatant was loaded onto an equilibrated 5 mM HisTrap FF crude column (GE 
Healthcare). The column was washed with 3 column volumes of buffer A before the 
protein was eluted using an imidazole gradient from 30 mM to 500 mM in buffer A. 
For LAP-As containing a HRV 3C cleavable histidine-tag the protein fractions were 
pooled and concentrated to a volume of ~ 30 mL before addition of HRV 3C 
protease in a ratio 1:100 (protease:LAP-A). The proteolysis was monitored by SDS-
PAGE and reached completion after incubation overnight at 4°C. In order to remove 
the histidine-tag and non-cleaved LAP, the protein was exchanged into buffer A 
using Centrifuge filters (Amicon® Ultra Centrifugal Filter from Millipore or Vivaspin6 
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from SartoriumStedim biotech, 50 kDa cutoff) and another Nickel affinity 
purification was performed using the same conditions as before. The flowthrough 
contained untagged LAP-A. The resulting protein was concentrated and loaded onto 
a Superdex200 16/60 column (GE Healthcare), and run in buffer containing 10 mM 
Tris pH 8.0, 200 mM NaCl and 1 mM DTT (Figure 4-6 A) at a flowrate of 0.5 mL min-1. 
The TbLAP-A fused to a non-cleavable histidine-tag was concentrated and loaded 
onto a Superdex 200 16/60 column directly after the first nickel affinity column. The 
purifications of the LAP-As were monitored by SDS-PAGE (Figure 4-6 B).  
Purified LAP-As were buffer exchanged into 20 mM Tris pH 8.0, 300 mM NaCl and 
1 mM DTT concentrated, flash frozen in liquid nitrogen and stored at -80°C.  
 
 
Figure 4-6: LAP-A purification.  
(A) Overlay of the size exclusion chromatography traces of TbLAP-A, TcLAP-A and LmLAP-A. (B) SDS-PAGE 
analysis of purified LAP-As (Tb = T. brucei, Tc = T. cruzi, Lm = L. major). 
 
4.2.4 Native PAGE zymography 
The pure LAP-As were mixed with native gel loading buffer (100 mM Tris pH 6.8, 
20 % (v/v) glycerol, 0.1 % (w/v) bromophenol blue) and loaded on a 5 % 
polyacrylamide gel. Each LAP-A was loaded three times on the same gel, which was 
run at 100 V for 2 h at 4°C to prevent heat denaturation during the electrophoresis. 
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Subsequently, the gel was washed 3 x 20 min with 50 mM Tris pH 8.0 and cut into 
three pieces (each containing all three LAP-As). Each piece was incubated with 
activity assay buffer containing 50 mM Tris pH 8.0, 100 mM KCl and 1 mM MnCl2, 
supplemented with 7.5 μM fluorescent substrate for 10 min at 37°C. The 
fluorescent substrates tested were L-Leucine-(4-methyl-7-coumarinylamide) (Leu-
AMC), L-Valine-7-amido-4-methylcoumarin (Val-AMC) and L-Proline-7-amido-4-
methylcoumarin (Pro-AMC). The fluorescent products were detected using an UV 
light imager. Subsequently the same gel pieces were stained with Coomassie. 
 
4.2.5 Generation of anti-TbLAP-A antisera in rabbit and affinity 
purification of polyclonal anti-TbLAP-A antibody 
Ten mg of purified TbLAP-A were lyophilised and resuspended in PBS and mixed 
with Freud’s adjuvant prior to injecting into a rabbit. Four inoculations of ~ 400 μg 
of protein were carried out and antisera were extracted prior to the inoculations 
and tested for recognition of LAP-A in T. brucei lysates and purified protein. For 
antiserum preparation, rabbit blood was taken and incubated at room temperature 
for 2 h. Subsequently the blood was incubated at 37°C for 20 min and on ice for 4 h. 
After the incubations the antisera were separated from cells and insoluble material 
by centrifugation (4°C, 3000 rpm, 15 min). Sodium azide was added for 
preservation. The antisera were stored in 500 μL aliquots at 4°C, -20°C and -80°C. To 
increase specificity, the polyclonal antibody was affinity-purified using pure TbLAP-A 
coupled to an Affi-Gel® 15 Gel resin (Biorad) following the manufacturer’s 
instructions. Anti-TbLAP-A antiserum was bound to the TbLAP-A coupled to the Affi-
Gel® 15 Gel resin, washed and eluted in 1 mL fractions. Elution fractions were 
tested for sensitivity and specificity via western blot analysis as mentioned below. 
The injections into the rabbit and the extraction of the blood were done in 
collaboration with the staff of the Instituto de Parasitologia y Biomedicina “Lopez-
Neyra” in Granada, Spain.  
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4.2.6 Validation of polyclonal anti-TbLAP-A antibody 
To test sensitivity 2.5 x 106 lysed T. brucei bloodstream form and procyclic parasites 
were loaded in alternating lanes of one SDS-gel and after separation the proteins 
were transferred to a nitrocellulose membrane. After the blocking step, the 
membrane was cut in pieces (two lanes each) and incubated in different dilutions 
(1:50 000, 1:75 000, 1:100 000 and 1:200 000) of primary antibody. This ensures 
comparability between the different antibody dilutions tested. For secondary 
antibody incubation the same dilution was used for all membrane pieces. For 
imaging, the pieces were recombined and the cut sites together with lane marks 
and marker were marked on the developed film. As control, prepared pre-immune 
serum was treated as the anti-TbLAP-A antiserum from the other extraction. 
To test specificity anti-TbLAP-A antiserum was saturated with a 30-fold excess of 
purified TbLAP-A protein in blocking solution overnight at 4°C. Western blot analysis 
of 50, 100 and 500 ng pure TbLAP-A as well as 2.5 x 106 bloodstream and procyclic 
parasites was carried out using untreated and the saturated anti-TbLAP-A antiserum 
at a dilution of 1:100 000 for incubation. As for the sensitivity test, all samples were 
loaded onto the same SDS-gel, which was cut into pieces after blocking for 
incubation with the two different primary antibody solutions.  
The cross-reactivity against T. cruzi and L. major LAP-As was determined by loading 
5 x 106 and 10 x 106 lysed T. cruzi trypomastigotes, 10 x 106 T. cruzi amastigotes 
(plus host cell background) and 5 x 106 lysed L. major promastigotes and analysing 
the western blot. For this anti-TbLAP-A antiserum from the second extraction was 
used in a dilution of 1:15 000.  
 
4.2.7 SDS-PAGE and Western blots 
For the preparation of T. brucei lysates (bloodstream form or procyclic), parasites 
were harvested by centrifugation, washed in PBS and lysed. In each lane of a 12 % 
SDS gel 2.5 x 106 lysed parasites were loaded. After separation on the SDS gel, 
proteins were transferred to a nitrocellulose membrane. The membranes were 
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blocked in 5 % (w/v) defatted milk in wash buffer (PBS + 0.1 % (v/v) Tween20®) for 
30 min at room temperature, before being incubated for 1 h at room temperature 
with anti-TbLAP-A primary antibody from the second extraction after immunisation 
in a dilution of 1:15 000 or anti-TbLAP-A primary antibody of the final extraction in a 
dilution of 1:200 000. Subsequently, the membranes were washed three times for 
10 min in wash buffer and incubated with HRP-conjugated anti-rabbit secondary 
antibody (Promega) in a dilution of 1:5000 for 1 h at room temperature. The 
membranes were then developed using chemiluminescence, detected by exposure 
to photo film. 
To compare the amount of LAP-A in different samples, TbSMT was chosen as 
loading control because its expression level is independent from the one from LAP-
A and it is clearly distinguishable on SDS-PAGE and Western blot by its molecular 
weight. For this, rabbit anti-TbSMT antiserum in 1:10 000 dilution was added with 
the primary anti-TbLAP-A antibody.  
 
4.2.8 Generation of the construct for ectopic expression of LAP-A 
The TbLAP-A gene (Tb427tmp.02.4440) was amplified from genomic DNA (T. brucei 
Lister427) by PCR using the same reaction conditions and temperature profle as 
described in Table 2-1 and Table 2-2 with the annealing temperature increased to 
65°C. The primer sequences can be found in appendix A.2.3 and contained 
overhangs with the recognition sites for the restriction endonucleases Nde1 
(forward primer) and BamH1 (reverse primer). PCR product and the pGRV23b 
vector (Castillo-Acosta et al., 2012) were digested for 5 h at 37°C using the 
restriction endonucleases for Nde1 and BamH1 following the composition 
summarised in Table 4-3. The vector backbone of pGRV23b was purified from a 
1.6 % agarose gel after separation from its previous insert by electrophoresis using 
the Gel extraction Kit (Qiagen) and manufacturers instructions. The insert was 
purified using the PCR purification Kit (Qiagen). Subsequently vector backbone and 
insert were ligated using the reaction conditions summarised in Table 4-4, which 
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were incubated at room temperature for 24 h before transformation into 
competent E. coli (NEB5α) cells. 
 
Table 4-3: Compositions of the resitriction digests for the pGRV23b construct. 
Reagent TbLAP-A pGRV23b 
10x NEB buffer 4 5 μL 5 μL 
DNA  39.5 μL (= ~0.5 μg) 10 μL (= ~2 μg) 
BSA (10 μg/μL, NEB) 0.5 μL 0.5 μL 
ddH2O - 30 μL 
Nde1 (20 U/μL, NEB) 3 μL 3 μL 
BamH1 (20 U/μL, NEB) 2 μL 2 μL 
Total volume 50.5 μL 50.5 μL 
 
Table 4-4:  Composition of the ligations for TbLAP-A constructs. 
Reagent Volume [μL] 
10x T4 ligase buffer (NEB) 2 
Vector (digested) 8.5 (= ~100 ng) 
Insert (digested) 8.5 (= ~100 ng) 
T4 ligase (400 U/μL, NEB) 1 
Total volume 20 
 
The cloning success was confirmed by restriction endonuclease digestion after 
plasmid propagation using the same enzymes as for the cloning and subsequent 
verification via sequencing. 
 
4.2.9 Generation of constructs for LAP-A RNAi  
To create a hairpin structure of the transcribed RNA from this vector, the same 
fragment was inserted into the vector in both 5’  3’ and 3’  5’ orientation at 
locations separated from eachother by a non-coding linker region. A 465 bp 
fragment of the TbLAP-A gene (bp 10-475) was selected using the server 
http://trypanofan.path.cam.ac.uk/software/RNAit.html (Redmond et al., 2003), 
accessed on 20. 8. 2012) and amplified from genomic DNA (T. brucei Lister427) 
using primers containing the recognition sites for BamH1 and Hind3 (forward 
primer) and for Hpa1 and Apa1 (reverse primer). PCR conditions and temperature 
profile were identical to the ones used for the previous LAP-A constructs. Firstly, the 
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fragment was cloned into the pGR19 vector (Clayton et al., 2005) using the 
restriction sites Hind3 and Apa1. As these two enzymes require buffer conditions 
not compatible to oneanother the resitriction digests were carried out separately 
and the DNA was purified between each step using the PCR purification Kit 
(Qiagen). Both restriction digests were incubated for 3 h, Hind3 at 37°C and Apa1 at 
room temperature. The reaction conditions are summarised in Table 4-5 and Table 
4-6. Additionally the vector (pGR19) was dephosphorylated by incubation at 37°C 
for 1 h after addition of 10 μL 10x alkaline phosphatase buffer (Promega), 10 μL 
alkaline phosphatase (= 10 U, Promega) and 30 μL ddH2O to the last digest. After 
DNA purification, digested vector and insert were ligated using the same conditions 
as described for the construct for ectopic expression of LAP-A in T. brucei (section 
4.2.8) and the successful insertion was confirmed by restriction digest (with Hind3 
and Apa1) after plasmid propagation. 
 
Table 4-5: Conditions of Hind3 digests for first RNAi fragment insertion. 
 RNAi fragment pGR19 
DNA (= ~ 2 μg) 40 μL 10 μL 
10 x NEB buffer 2 5 μL 5 μL 
ddH2O 2.5 μL 32.5 μL 
Hind3 (NEB) 2.5 μL 2.5 μL 
Total volume 50 μL 50 μL 
 
Table 4-6: Conditions of Apa1 digests for first RNAi fragment insertion. 
 RNAi fragment 
(cut with Hind3) 
pGR19           
(cut with Hind3) 
DNA  44 μL 44 μL 
10 x NEB buffer 4 5 μL 5 μL 
BSA (NEB) 0.5 μL 0.5 μL 
Apa1 (NEB) 0.5 μL 0.5 μL 
Total volume 50 μL 50 μL 
 
To insert the fragment in opposite orientation from the first insert, 2 μg of each, 
insert and previous vector, were incubated for 3 h at 37°C with BamH1 and Hpa1 
under the conditions specified in Table 4-7. The vector was dephosphorylated as 
described above and both (digested vector and insert) were ligated after DNA 
purification using the same protocol as above (section 4.2.8). 
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Table 4-7: Conditions of restriction digests for second RNAi fragment insertion. 
 RNAi fragment pGR19 + first insert 
DNA (= ~ 2 μg) 39.5 μL 10 μL 
10 x NEB buffer 4 5 μL 5 μL 
BSA (NEB) 0.5 μL 0.5 μL 
ddH2O - 29.5 μL 
Hpa1 (NEB) 2.5 μL 2.5 μL 
BamH1 (NEB) 2.5 μL 2.5 μL 
Total volume 50 μL 50 μL 
 
Cloning success was confirmed by restriction digestion (with Hpa1 and BamH1) 
after plasmid propagation. A plasmid map of the final vector is shown in appendix 
A.2.5.4. 
 
4.2.10  Generation of LAP-A cMyc-fusion constructs for 
overexpression in T. brucei 
The LAP-A gene from T. brucei was amplified by PCR and cloned into the backbone 
of the pGRV33 vector (Castillo-Acosta et al., 2012) using the restriction 
endonucleases Nde1 and Hpa1 and ligation with T4 ligase, following the same 
protocol as described for the construct for ectopic expression of LAP-A in T. brucei 
(section 4.2.8) with the exception of the restriction digest which was incubated over 
night at 37°C. The primer sequences are listed in appendix A.2.3. Cloning success 
was confirmed by restriction endonuclease digestion (with Nde1 and Hpa1) and 
sequencing.  
 
4.2.11  Generation of T. brucei LAP-A knockout cell lines 
To generate the two replacement cassettes for the double knockouts, untranslated 
regions (UTRs) upstream (5’) and downstream (3’) of the TbLAP-A gene on the 
genome were chosen and cloned into a vector each side of a blasticidin resistance 
marker. To create the second vector (for removal of the second allel on the 
genome) the blasticidin resistance cassette was exchanged for a hygromycin 
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resistance cassette. Transfection of the final vectors into T. brucei cells results in the 
exchange of the TbLAP-A gene from the genome for the antibiotic resistances by 
homologous recombination.  
For this a 538 bp fragment of the 5’UTR upstream of the TbLAP-A gene (-61 - -599) 
and a 467 bp fragment of the 3’UTR downstream of the TbLAP-A gene (+7 - +475) 
were amplified from genomic DNA (T. brucei Lister427) by PCR using the same 
conditions as described in Table 2-1 and Table 2-2. The primers used for the 5’UTR 
fragment contained a Not1 site (forward) and a Xho1 site (reverse) and the primers 
used for the 3’ UTR fragment contained a Stu1 site (forward) and Nhe1 and Not1 
sites (reverse). The primer sequences can be found in appendix A.2.3. Firstly, the 
5’UTR fragment was inserted into the pHD887 vector (kindly provided by V. Castillo-
Acosta, Instituto de Parasitologia y Biomedicina “Lopez-Neyra”, Granada, Spain) 
using incubation with the endonucleases Xho1 and Not1 for 2 h at 37°C under the 
conditions specified in Table 4-8. This was followed by dephosphorylation of the 
vector and DNA purification of vector and insert using the PCR purification Kit 
(Qiagen). Insert and vector were ligated overnight at room temperature following 
the conditions in Table 4-9.  
 
Table 4-8: Conditions of restriction digests for 5’-UTR fragment insertion. 
 5’-UTR pHD887 
DNA (= ~ 2 μg) 42.5 μL 13 μL 
10 x NEB buffer 3 5 μL 5 μL 
BSA (NEB) 0.5 μL 0.5 μL 
ddH2O - 29.5 μL 
Not1 (NEB) 1 μL 1 μL 
Xho1 (NEB) 1 μL 1 μL 
Total volume 50 μL 50 μL 
 
Table 4-9:  Composition of ligations for 5’-UTR construct. 
Reagent Volume [μL] 
10x T4 ligase buffer (NEB) 2 
Vector (digested) 8 (= ~100 ng) 
Insert (digested) 4.25 (= ~100 ng) 
ddH2O 4.75 
T4 ligase (400 U/μL, NEB) 1 
Total volume 20 
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Ligated vector was transformed into E. coli cells and the successful insertion of the 
5’-UTR was confirmed by control digests with Xho1 and Not1. 
Subsequently, the 3’UTR fragment was cloned into the resulting vector from the 
previous step using the restriction endonucleases Stu1 and Nhe1. The incubation of 
digests was at 37°C and the reaction conditions are summarised in Table 4-10. As 
the Stu1 stock was very old, it was added to the reaction 3 h earlier than the Nhe1, 
which was incubated for 2 h with the DNA (so the total reaction time was 5 h for 
Stu1 and 2 h for Nhe1). The vector was dephosphorylated as described before. 
Ligations were carried out using incubation with T4 ligase over night at room 
temperature following the conditions summarised in Table 4-9. Cloning was 
confirmed by restriction endonuclease digestion.  
 
Table 4-10: Conditions of restriction digests for 3’-UTR fragment insertion. 
 3’-UTR pHD887-5’-UTR 
DNA (= ~ 2 μg) 30 μL 30 μL 
10 x NEB buffer 4 5 μL 5 μL 
BSA (NEB) 0.5 μL 0.5 μL 
ddH2O 9.5 μL 9.5 μL 
Stu1 (NEB) 3 μL 3 μL 
Nhe1 (NEB) 2 μL 2 μL 
Total volume 50 μL 50 μL 
 
In the resulting vector (pHD887B/UTRs) the two UTR fragments flank the blasticidin 
S transferase (BSD) resistance gene and it was used to transform parental 
bloodstream form and procyclic cells as described below. To remove the second 
TbLAP-A allele from the genome, the hygromycin phosphotransferase (HYG) 
selectable marker from pGR19 (Clayton et al., 2005) was sub-cloned into 
pHD887B/UTRs. For this pHD887B/UTRs and pGR19 were digested with the 
restriction endonuclease SnaB1 for 3 h at 37°C under the conditions specified in 
Table 4-11. The pHD887B/UTRs backbone and HYG from pGR19 were purified from 
a 2 % agarose gel using the Gel extraction Kit (Qiagen). The vector backbone was 
dephosphorylated as described above and purified using a PCR purification kit 
(Qiagen). HYG and vector were ligated using the same protocol as in Table 4-4 in 
section 4.2.8.  
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Table 4-11: Conditions of restriction digests for antibiotic resistance exchange. 
 pGR19 pHD887B/UTRs 
DNA (= ~ 2 μg) 10 μL 5 μL 
10 x NEB buffer 4 5 μL 5 μL 
BSA (NEB) 0.5 μL 0.5 μL 
ddH2O 34 μL 39 μL 
SnaB1 (NEB) 1 μL 1 μL 
Total volume 50 μL 50 μL 
 
Positive clones were identified by control digests with SnaB1 and propagated. To 
confirm the right orientation of HYG, the clones were digested with Xho1 and Nco1 
for 2 h at 37°C. The reaction condition is summarised in Table 4-12. This restriction 
digest led to a 740 bp or a 1055 bp fragment for plasmids containing HYG in the 
correct or the wrong orientation respectively, which were distinguished by agarose 
gel electrophoresis. Additionally, successful construction of the vectors was 
confirmed by sequencing and plasmid maps can be found in appendix A.2.5.5. 
 
Table 4-12: Conditions used to confirm HYG orientation. 
 Volume/reaction [μL]  
DNA  5  
10 x NEB buffer 4 1.5  
ddH2O 8  
Xho1 (NEB) 0.25  
Nco1 (NEB) 0.25  
Total volume 15  
 
The resulting vector pHD887H/UTRs was used to transfect the positive single 
knockouts as described below.  
 
4.2.12  Trypanosoma brucei cell lines, culture and transfections 
The cell lines used in this work were Trypanosoma brucei brucei bloodstream form 
S16 (Wirtz et al., 1999) and the procyclic cell line 449 (Estevez et al., 2001). The 
blood stream parasites were cultured at 37°C and 5 % CO2 in HMI-9 media, 
containing 10 % (v/v) fetal bovine serum (FBS) (Hirumi & Hirumi, 1994). The 
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procyclic trypanosomes were cultured at 28°C in SDM-79 media supplemented with 
10 % (v/v) FBS and 7.5 g mL-1 Haemin (Brun & Schonenberger, 1979).  
To generate double knockout and knockdown (RNAi) parasite cells lines as well as a 
parasite line overexpressing LAP-A and LAP-A cMyc-fusion protein, parental cell 
lines of bloodstream form and procyclics were transfected with the respective 
targeting vectors. Firstly, the circular plasmids were linearised by digestion with 
endonuclease NotI and subsequently purified by ethanol precipitation. For each 
transfection 24 x 106 parasites were transfected with 3-10 g of linearised targeting 
vectors using electroporation as previously described (Wirtz et al., 1998, Wirtz et 
al., 1999). Selection of positive clones was carried out by limited dilution in 24-well 
cell culture plates in the presence of selection drugs, Table 4-13. Each transfection 
led to 1-3 clones (bloodstream form) or 6-12 clones (procyclics), respectively. 
Selection of clones was completed after 7-14 days.  
Growing clones were tested by determination of the LAP-A amount in the cells in 
comparison with the parental cell lines using western blot analysis after induction of 
RNAi or overexpression of the LAP-A. Positive RNAi clones did show a significant 
reduction of LAP-A upon induction, overexpressing clones showed a strong increase 
of LAP-A (with and without cMyc-fusion). Uninduced RNAi and overexpression 
clones showed the same amount of LAP-A than the parental cells. 
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Table 4-13: Selection drugs used for the different T. brucei parasite strains. 
TbBF: bloodstream form, Tb449: procyclic form 
Targeting vector – 
purpose 
Selective antibiotics Concentration for 
TbBF [µg mL-1] 
Concentration for 
Tb449 [µg mL-1] 
Replacement of first 
LAP-A allele from 
the genome (sKO) 
Blasticidin 10 20 
Replacement of 
second LAP-A allele 
from the genome 
(dKO) 
Hygromycin 
(Additionally to the 
blasticidine from the 
sKO) 
5 50 
LAP-A RNAi Hygromycin 5 50 
Ectopic copy control 
vector for LAP-A 
overexpression 
Puromycin 0.1 1 
Ectopic copy control 
for expression of 
LAP-A cMyc fusion 
Puromycin 0.1 1 
 
4.2.13  T. brucei cultures in minimal media 
Bloodstream form parasites were cultured in HMI-9 media, containing 10 % (v/v) 
dialysed FBS to reduce the amount of undefined small molecule components. 
For further investigations into the physiological role of LAP-A, procyclic parasites 
were cultured in minimal essential media (MEM) containing 7.5 g mL-1 haemin and 
10 % (v/v) FBS or dialysed FBS to remove glucose as energy source and other 
undefined small molecules from the media. To test the influence of amino acid 
limitation the same MEM with dialysed FBS was prepared either without leucine or 
without the “Non-essential amino acids”-mix (100x, Sigma M7145), thus omitting L-
alanine, L-asparagine, L-aspartic acid, L-glutamic acid, glycine and L-serine, and 
reducing the amount of L-proline. The exact composition of the media can be found 
in appendix A.3.  
Generally, when culture media or volume was changed, the parasites were cultured 
for 6-9 days (2-3 dilutions) to give them time to adapt to the new conditions and 
reach a reproducible growth rate. Growth rates in media with dialysed FBS were 
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lower, so cultures were incubated at culture temperature for 3 days (instead of 2) 
before the next dilution. For the procyclic parasite cultures in amino acid depleted 
MEM the cultures were diluted to 1 000 000 parasites mL-1 and incubated for 3 days 
for adaptation. 
 
4.2.14  Determination of parasite growth upon RNAi induction 
and overexpression of LAP-A 
The targeting vectors of RNAi and ectopic copy control contained the tetracycline-
inducible promotor. RNAi and overexpression were induced by the addition of 
1 g mL-1 doxycycline to the cultures directly after dilution in fresh media.  
For recording the growth curves, all procyclic cultures (induced, un-induced and 
parental cell lines) were diluted to and induced at 200 000 parasites mL-1 and 
cultured for two days before counting and dilution in fresh media. The cell growth 
was followed for 6-10 days. For the growth curves of bloodstream form cultures the 
cells were diluted to and induced at 5 000 parasites mL-1 and cultured for two days 
before the next dilution. Additionally, the growth curves for bloodstream form 
parasites were recorded when diluting to and inducing RNAi/over-expression at 
100 000 parasites mL-1 and letting the cultures grow for 24 h before the next 
dilution. The two different protocols addressed the possible influence of the high 
dilution itself on parasite growth.  
 
4.2.15 Statistical analysis of changes in parasite growth 
The significance of changes in generation times of T. brucei dKO clones and upon 
induction of RNAi and overexpression was evaluated using the Welch’s t-test (two-
sample, unpaired) in GraphPad Prism (version 6). Results giving p ≤ 0.05 were 
considered significant. 
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4.2.16 Glycerol stocks of T. brucei clones 
All clones generated were frozen at -80°C. For each frozen aliquot (bloodstream 
form and procyclics) 20 - 30 x 106 parasites were harvested by centrifugation at 
1400 rcf for 10 min and resuspended in 250 μL HMI-9 media, containing 10 % (v/v) 
FBS and 10 % Glycerol (bloodstream form) or 250 μL SDM-79 media with 10 % (v/v) 
FBS, 7.5 g mL-1 Heamin and 10% Glycerol (procyclic form). 
 
4.2.17  Cell cycle analysis by flow cytometry 
Bloodstream form and procyclic parasites (5-20 x 106) were harvested by 
centrifugation at 1400 rcf for 10 min and washed twice with PBS before being fixed 
overnight at -20°C in 70 % ethanol (in PBS). Fixed parasites were washed twice in 
PBS, resuspended in 500 μL PBS containing 40 μg mL-1 propidium iodide and 
10 μg mL-1 RNase A and incubated for 30 min at 37°C in the dark. The propidium 
iodide intercalates into the DNA of the cells and the DNA content of the cells was 
analysed using a FACSCalibur (Becton Dickinson, USA) analytical flow cytometer and 
the CellQuest software. The fluorescence signals were recorded in FL3-H for the cell 
population gated in SSC-H vs. FSC-H. Data were analysed using FlowJo software 
v7.6.1 calculating the percentages of each cell cycle stage (Sub-G1, G1, S, G2/M and 
Super-G2). After normalisation, data from three independent cultures per condition 
and strain were averaged and the standard deviation calculated. The analysed data 
were plotted using Microsoft Excel 2010.  
 
4.2.18  Cell cycle analysis by fluorescence microscopy 
Bloodstream form and procyclic parasites were harvested by centrifugation, 
washed in PBS and fixed in 4 % p-formaldehyde in wash solution (PBS + 0.2 % (v/v) 
Tween20®) on a poly-L-lysine coated glass slide for 20 min at room temperature. 
After washing twice the slides were dehydrated in 100 % methanol for 1 min. Once 
the methanol had evaporated the slides were stained and mounted with 
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Vectashield-DAPI (Vector Laboratories, Inc.), covered with cover slips and sealed 
with nail polish. Images were taken using a Zeiss Axiophot microscope (Carl Zeiss, 
INC) and the percentages of 1N1K, 1N2K, 2N2K and pathological (0N1K 1N0K, 2N1K 
and xNxK) cells were analysed manually.  
 
4.2.19  Immunofluorescence 
For preparation of immunofluorescence in bloodstream and procyclic forms, 
10 x 106 parasites from mid-log cultures were harvested by centrifugation at 
1400rcf for 10 min. Cells were resuspended in 1 mL PBS containing MitoTracker® 
(Invitrogen) and incubated in the dark at culture temperature for 15 min. After 
incubation the cells were pelleted by centrifugation and washed with 1 mL PBS 
before resuspension in a solution of 4 % p-formaldehyde and wash solution (PBS + 
0.2 % (v/v) Tween20®). The cells were fixed on a poly-L-lysine coated glass slide for 
20 min at room temperature, washed twice and incubated for 75 min in a mixture 
of wash solution with 1 % Blocking Reagent (Roche) and 1 % IGEPAL (Sigma) in order 
to block and permeabilise the cells. The slides were incubated for 1 h at room 
temperature with primary rabbit anti-TbLAP-A antibody (affinity-purified, diluted 
1:500 for over-expressing cells, 1:100 for all others in blocking solution) or 
monoclonal anti-cMyc antibody (Sigma, 1:100 in blocking solution) to find the 
optimal conditions. After 6 washes of 5 min with wash solution, the slides were 
incubated with secondary antibody for 1 h at room temperature: FITC-conjugated 
anti-rabbit antibody (Sigma, 1:40 diluted in blocking solution) for anti-TbLAP-A 
primary antibody or AlexaFluor488-conjugated anti-mouse antibody (Sigma, 1:40 
diluted in blocking solution). Subsequently, the slides were washed 6 times for 
5 min and dehydrated by incubation in 100 % methanol for 1 min. After evaporation 
of the methanol the slides were stained and mounted with Vectashield-DAPI 
(Vector Laboratories, Inc.), covered with cover slips and sealed with nail polish. 
Vertical stacks of 20 slices (0.2 μm steps) were taken with a Leica TCS SP5 confocal 
microscope with 63x magnification. Image preparation and analysis were carried 
out with the LAS-AF software (Leica) and ImageJ (version 1.37; National Institutes of 
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Health). The confocal microscopy images of bloodstream forms and procyclics 
(parental and LAP-A-cMyc overexpressing, 12 images each) were analysed for 
colocalisation of LAP-A with DAPI and MitoTracker using Li’s approach (Li et al., 
2004) with the JACoP Plugin (Bolte & Cordelieres, 2006) in ImageJ. 
 
4.2.20  Crystallisation of the LAP-As 
Prior to setting up crystallisation screens, the LAP-As were thawed at room 
temperature and pre-incubated with the desired metal salts for 2 h and 
subsequently with ligand for another 2 h on ice. Precipitated protein was removed 
by centrifugation and protein concentration was determined from the absorbance 
at 280 nm. Concentrations of proteins and ligands used in crystallisation as well as 
the initial commercially available screens used are summarised in Table 4-14. The 
initial screens were pipetted in sitting drop vapour diffusion using a Mosquito robot 
(TTP Labtech, UK) with a drop size of 150 nL protein plus an equal amount of well 
solution.  
 
 
 
 
 
 
 
 
 
 
 
 176
Table 4-14: Concentrations and screens used for crystallisation screening. 
Protein Protein 
concentration 
[mg mL-1] 
Additives [mM] Inhibitors/Ligands 
and concentrations 
[mM] 
Initial screens 
TbLAP-A 
(tagged) 
20, 30, 50 5, 20 mM CaCl2, 
5, 20 mM CoSO4, 
5, 20 mM MgCl2, 
5, 20 mM MnSO4, 
1, 5 mM MnCl2, 
1 μM ZnSO4, 
1, 5 mM ZnSO4, 
1 μM ZnCl2 
5, 10 mM Actinonin, 
5, 10 mM Amastatin, 
5, 10 mM Bestatin, 
1, 10 mM L-leucine 
PACT, JCSG, 
Index, MPD, 
Ammonium 
sulfate 
TbLAP-A 
(not 
tagged) 
30 1 mM MnCl2, 
1 μM ZnCl2 
5 mM Bestatin, 
1 mM L-Leucine 
JCSG, 
Ammonium 
sulfate 
TcLAP-A 16.6 
48.8 
5 mM MnSO4, 
1 mM MnCl2, 
1 μM ZnSO4/ 
ZnCl2 
5, 10 mM Actinonin, 
5, 10 mM Amastatin, 
5, 10 mM Bestatin 
JCSG, Index, 
Ammonium 
sulphate, 
Morpheus, 
MPD 
LmLAP-A 26 5 mM MnSO4, 
1 mM MnCl2, 
1 μM ZnSO4 
5, 10 mM Actinonin, 
5, 10 mM Amastatin, 
5, 10 mM Bestatin 
JCSG, 
Ammonium 
sulfate 
 
Hits were optimised using sitting and hanging drop vapour diffusion with a drop size 
of 1 μL protein plus 1 μL well solution set up manually. For the LmLAP-A the additive 
screen (Hampton Research) was used to identify a compound that enhanced the 
diffraction of the crystals. All crystals were grown at 20°C. The crystallisation 
conditions leading to LAP-A crystals that allowed structure solution, as well as the 
ligands bound in the active sites of these structures are listed in Table 4-15. 
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Table 4-15: Crystallisation conditions of the LAP-As and ligands bound. 
Protein Crystal name Crystallisation 
condition 
Ligand bound in the active 
site in the structure 
TbLAP-A apo TbLAP-A 0.8 M Na citrate pH 7.0, 
5 mM CoSO4 
- 
TbLAP-A TbLAP-A-Mn-
bestatin 
0.1 M HEPES pH 7.0, 
40 % (v/v) MPD, 
5 mM MnCl2, 
5 mM bestatin 
Mn2+, HCO3
-, bestatin 
TbLAP-A TbLAP-A-Mn-
actinonin 
0.1 M Tris pH 8.0, 
2.4 M (NH4)2SO4, 
5 mM MnSO4, 
5 mM actinonin 
Mn2+, actinonin 
TbLAP-A TbLAP-A-Mn 0.1 M Tris pH 6.8, 
0.2 M MgCl2, 
11 % (w/v) PEG 8000,  
10 μM ZnCl2,     
10 mM L-leucine 
Mn2+, HCO3
- 
TcLAP-A TcLAP-A-Mn-
citrate 
0.1 M Phosphate-citrate 
pH 4.2, 
40 % (v/v) PEG 300, 
5 mM MnSO4,  
5 mM amastatin 
Mn2+, SO4
2-, citrate 
TcLAP-A apo TcLAP-A 0.1 M Citric acid pH 4.0, 
1.6 M (NH4)2SO4, 
1 mM MnCl2, 
5 mM actinonin 
SO4
2- 
LmLAP-A LmLAP-A-Mn-
actinonin 
0.8 M Succinic acid 
pH 7.0,       
3 % (w/v) 1,5-Diamino-
pentane di-
hydrochloride, 
5 mM MnSO4, 
5 mM actinonin 
Mn2+, HCO3
-, actinonin 
 
4.2.21  Data Collection and Structure Solution of the LAP-As 
Unless otherwise indicated, all computations were performed using programs of 
the CCP4 suite (Winn et al., 2011). The data were processed with MOSFLM (Battye 
et al., 2011) and AIMLESS (Evans & Murshudov, 2013). The crystal of apo TbLAP-A 
was cryo-protected in well solution containing 20% (v/v) glycerol prior to 
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vitrification. The other LAP-A crystals were not cryo-protected. Crystallographic 
data and statistics are shown in Table 4-16 - 8. 
The structures were solved by molecular replacement (MR) using PHASER (McCoy, 
2007) and MOLREP (Vagin & Teplyakov, 1997). The highest structural homology to 
the TbLAP-A was predicted to be the C. elegans LAP using BLAST searching against 
entries in the PDB, and the protomer was used in MR to generate initial phases 
from which the TbLAP-A model was built. For all subsequent LAP-A structures the 
first TbLAP-A model (apo) was used for MR. Model building was carried out using 
BUCCANEER (Cowtan, 2006). Manual fitting of the electron-density maps, as well as 
model building and fitting of the ligands were carried out with COOT (Emsley et al., 
2010). The structures were refined using REFMAC5 (Murshudov et al., 2011) and 
validated using COOT and Molprobity (Chen et al., 2010).  
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Table 4-16: Crystallographic data and statistics for TbLAP-A crystals. 
In this and all subsequent data tables: Data for the highest resolution shell shown in brackets, the 
Ramachandran Plot was calculated using COOT (Emsley et al. 2010), the poor rotamer analysis was carried 
out in Molprobity (Chen et al. 2010). 
 apo TbLAP-A TbLAP-A-Mn 
Data collection   
Diffraction Source DLS beamline I04 DLS beamline I04 
Wavelength (Å) 0.9795 0.9795 
Temperature (K) 100 100 
Detector Pilatus 6M-F Pilatus 6M-F 
Rotation range per image (°) 0.5 0.2 
Total Rotation range (°) 180 220 
Crystal data   
Space group P212121 P21 
a, b, c (Å) 162.33, 162.45, 176.99 87.37, 143.8, 270.1 
α, β, γ (°) 90, 90, 90 90, 95.47, 90 
Resolution (Å) 72.61-2.60 (2.64-2.60) 32.73-2.40 (2.44-2.40) 
Total Reflections 1065695 (53405) 803022 (32773) 
Unique Reflections  143992 (7106) 244412 (11362) 
Completeness (%) 100 (100) 94.5 (88.7) 
Redundancy 7.4 (7.5) 3.3 (2.9) 
Rmerge  0.165 (1.019) 0.117 (0.351) 
[I/σ (I)] 9.5 (2.0) 5.7 (2.0) 
Matthew’s coefficient 3.51 2.40 
Refinement statistics   
Reflections, working set 136637 232199 
Reflections, test set 7257 11981 
Resolution Range (Å) 72.61-2.60 32.73-2.40 
R-factor 0.1742 0.1877 
Rfree 0.1934 0.2062 
No. of non-H atoms   
Protein 22152 45624 
Ligands - 72 
Water 500 661 
Mean B factors (Å
2
)   
Protein 29.0 25.7 
Ligands - 30.5 
Water 31.4 28.9 
RMS deviation from ideal   
Bond length (Å) 0.0119 0.0096 
Bond angles (°) 1.4252 1.2938 
Ramachandran Plot
 
(%)   
Residues in favored region 97.88 97.68 
Residues in allowed region 2.02 2.06 
Outliers  0.10 0.26 
Molprobity score  0.92 1.14 
Poor Rotamers (%) 1.19 2.04 
PDB ID   
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Table 4-17: Crystallographic data and statistics for TbLAP-A-complex crystals. 
 TbLAP-A-Mn-bestatin TbLAP-A-Mn-actinonin 
Data collection   
Diffraction Source DLS beamline I03 DLS beamline I04-1 
Wavelength (Å) 0.97625 0.9200 
Temperature (K) 100 100 
Detector Pilatus 6M Pilatus 2M 
Rotation range per image (°) 0.2 0.2 
Total Rotation range (°) 220 180 
Crystal data   
Space group P21 P21 
a, b, c (Å) 87.26, 143.45, 268.03 95.91, 165.73, 121.98 
α, β, γ (°) 90, 95.54, 90 90, 112.45, 90 
Resolution (Å) 80.33-2.30 (2.34-2.30) 41.50-3.00 (3.07-3.00) 
Total Reflections 1132102 (52607) 217196 (14160) 
Unique Reflections  290030 (14130) 68219 (4424) 
Completeness (%) 99.7 (99.0) 97.0 (98.0) 
Redundancy 3.9 (3.7) 3.2 (3.2) 
Rmerge  0.091 (0.523) 0.166 (0.440) 
[I/σ (I)] 9.1 (2.1) 4.5 (2.0) 
Matthew’s coefficient 2.51 2.70 
Refinement statistics   
Reflections, working set 275670 63948 
Reflections, test set 14322 3327 
Resolution Range (Å) 80.33-2.30 41.50-3.00 
R-factor 0.1649 0.2531 
Rfree 0.1910 0.2710 
No. of non-H atoms   
Protein 45631 22529 
Ligands 436 174 
Water 2798 7 
Mean B factors (Å
2
)   
Protein 22.3 2.0 
Ligands 47.3 5.5 
Water 37.2 2.0 
RMS deviation from ideal   
Bond length (Å) 0.0120 0.0120 
Bond angles (°) 1.4022 1.3810 
Ramachandran Plot (%)   
Residues in favored region 97.27 97.75 
Residues in allowed region 2.52 2.06 
Outliers  0.21 0.19 
Molprobity score  1.21 1.15 
Poor Rotamers (%) 2.37 1.77 
PDB ID   
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Table 4-18: Crystallographic data and statistics for the TcLAP-A crystals. 
 TcLAP-A-Mn-citrate apo TcLAP-A 
Data collection   
Diffraction Source DLS beamline I04 DLS beamline I04 
Wavelength (Å) 0.9795 0.9795 
Temperature (K) 100 100 
Detector Pilatus 6M-F Pilatus 6M-F 
Rotation range per image (°) 0.5 0.2 
Total Rotation range (°) 180 180 
Crystal data   
Space group H32 / R32 H32 / R32 
a, b, c (Å) 160.12, 160.12, 203.67 161.42, 161.42, 205.11 
α, β, γ (°) 90, 90, 120 90, 90, 120 
Resolution (Å) 57.31-2.32 (2.40-2.32) 48.14-2.30 (2.38-2.30) 
Total Reflections 477971 (47316) 380916 (39032) 
Unique Reflections  43546 (4249) 43976 (4437) 
Completeness (%) 100 (100) 96.2 (100) 
Redundancy 11.0 (11.1) 8.7 (8.8) 
Rmerge  0.188 (1.202) 0.181 (0.987) 
[I/σ (I)] 11.0 (2.1) 9.1 (2.4) 
Matthew’s coefficient 2.28 2.34 
Refinement statistics   
Reflections, working set 41361 41496 
Reflections, test set 2183 2061 
Resolution Range (Å) 57.31-2.32 48.14-2.30 
R-factor 0.1652 0.2052 
Rfree 0.2076 0.2558 
No. of non-H atoms   
Protein 7648 7537 
Ligands 51 20 
Water 382 139 
Mean B factors (Å
2
)   
Protein 26.89 26.07 
Ligands 47.69 41.65 
Water 33.17 25.54 
RMS deviation from ideal   
Bond length (Å) 0.0101 0.0111 
Bond angles (°) 1.4295 1.3625 
Ramachandran Plot (%)   
Residues in favored region 95.95 96.27 
Residues in allowed region 3.85 3.54 
Outliers  0.20 0.20 
Molprobity score  1.31 1.21 
Poor Rotamers (%) 1.86 0.90 
PDB ID   
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Table 4-19: Crystallographic data and statistics for the LmLAP-A-Mn-actinonin. 
 LmLAP-A-Mn-actinonin 
Data collection  
Diffraction Source DLS beamline I24 
Wavelength (Å) 0.97781 
Temperature (K) 100 
Detector Pilatus 6M 
Rotation range per image (°) 0.2 
Total Rotation range (°) 100 
Crystal data  
Space group P321 
a, b, c (Å) 116.44, 116.44, 91.49 
α, β, γ (°) 90, 90, 120 
Resolution (Å) 38.11-2.50 (2.60-2.50) 
Total Reflections 125585 (14243) 
Unique Reflections  21850 (2528) 
Completeness (%) 87.8 (90.2) 
Redundancy 5.7 (5.6) 
Rmerge  0.150 (0.747) 
[I/σ (I)] 8.2 (2.0) 
Matthew’s coefficient 3.09 
Refinement statistics  
Reflections, working set 20818 
Reflections, test set 1031 
Resolution Range (Å) 38.11-2.50 
R-factor 0.1877 
Rfree 0.2408 
No. of non-H atoms  
Protein 3893 
Ligands 33 
Water 50 
Mean B factors (Å
2
)  
Protein 23.8 
Ligands 43.1 
Water 27.5 
RMS deviation from ideal  
Bond length (Å) 0.0134 
Bond angles (°) 1.6575 
Ramachandran Plot (%)  
Residues in favored region 95.14 
Residues in allowed region 4.67 
Outliers  0.19 
Molprobity score  1.76 
Poor Rotamers (%) 2.26 
PDB ID  
 
 
 183 
4.2.22 Identification of metal ions in the TbLAP-A structure  
X-ray fluorescence (XRF) scans were collected for the crystal grown in the presence 
of ZnCl2 and L-leucine. These crystals were set up using protein treated with EDTA 
during purification to remove any metals and no other metal except ZnCl2 was 
added prior to crystallisation. The XRF scans were analysed using the PyMca 
software (Sole et al., 2007). A specific edge scan for zinc did not give a signal.  
X-ray data were collected at each side of the theoretical zinc edge at wavelengths of 
0.9795 Å and 1.3051 Å. After data processing with Xia2 (Winter, 2010) and structure 
solution and refinement as described above, reflection data from REFMAC5 
(including the phases) were combined with the Friedel difference (DANO) and the 
standard deviation of F2 (SIGDANO) from the unmerged data file (from Xia2) using 
CAD from CCP4. Anomalous difference maps were generated using the FFT program 
in CCP4. 
 
4.2.23  SEC-MALLS 
Purified and frozen TbLAP-A, TcLAP-A and LmLAP-A were thawed and diluted to 
concentrations of 0.1, 0.5, 1.0 and 3.0 mg mL-1. Additionally TbLAP-A was diluted to 
5 mg mL-1. The LAP-As were incubated at the respective concentrations for a 
minimum of 3 h at room temperature before automatic injection into a SEC-MALLS 
system (Wyatt Dawn HELEOS-II 18-angle light scattering detector and Wyatt Optilab 
rEX refractive index monitor linked to a Shimadzu HPLC system comprising LC-20AD 
pump, SIL-20A Autosampler and SPD20A UV/Vis detector) using a Superdex200 
10/300 size exclusion column and a running buffer containing 10 mM Tris pH 8.0, 
200 mM NaCl and 1 mM DTT. In addition, TbLAP-A was run in a buffer containing 50 
mM Tris pH 8.0, 100 mM KCl, 1 mM MnCl2 and 1 mM DTT.  
The sample preparation of TcLAP-A and LmLAP-A and part of the data analysis were 
carried out by Michael Norris (MChem undergraduate project student). The data 
were analysed using the ASTRA software (version 5.3.4.14) and the molecular 
masses were calculated for each sample. 
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4.3 Results 
The first aim was to explore the essential character of LAP-A and its potential as a 
drug target in T. brucei parasites. For this purpose two different life cycle stages of 
the parasites, bloodstream form and procyclic, were cultured and used for 
generation of LAP-A knockout, knock down and overexpression strains, which were 
subsequently characterised. TbLAP-A-specific polyclonal antibody was generated 
and purified for determination of the intracellular LAP-A amount and its localisation 
and characterisation. Secondly, structural studies of the TriTryp LAP-As and the 
determination of their oligomeric states in solution were to aid rational drug design. 
 
4.3.1 Overexpression and purification of active protein 
The TriTryp LAP-As were expressed and purified successfully as described above. 
The activities against the substrate analogues Leu-AMC, Val-AMC and Pro-AMC 
were confirmed by native gel zymography (Figure 4-7). All three LAP-As were active 
against Leu-AMC. TbLAP-A showed activity against Val-AMC and Pro-AMC, though 
much less than for Leu-AMC. For TcLAP-A and LmLAP-A no activity against Val-AMC 
and Pro-AMC could be detected.  
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Figure 4-7: Native gel zymography of recombinant TriTryp LAP-As.  
The figure shows the native gel pieces containing the LAP-As, which were incubated with Leu-AMC, Val-AMC 
or Pro-AMC for 10 min at 37°C. (A) Visualisation of the gel pieces using UV light, showing the AMC products 
hydrolysed by the LAP-As. (B) Coomassie staining of the same native gel pieces. 
 
4.3.2 Validation of anti-TbLAP-A antiserum  
The generated anti-TbLAP-A antiserum recognises TbLAP-A in cell extracts of 
bloodstream forms and procyclics indicated by a strong band at the expected 
molecular weight, Figure 4-8 A. In western blots the anti-serum gives strong signals 
in dilutions up to 1:200 000 and recognises an additional product of ~ 33 kDa in the 
cell lysates, especially when used at lower dilutions. This additional product is 
recognised in the lysate of bloodstream form parasites, and less in procyclics. As it is 
recognised also in the procyclic double knockout and bloodstream and procyclic 
knock down parasites, it can be assumed to be a different protein and not a 
degradation product of LAP. Saturation experiments with recombinant, purified 
TbLAP-A, Figure 4-8 B, identify the band at ~ 55 kDa as TbLAP-A. The antibody 
recognises the purified TbLAP-A loaded in spite of the saturation due to the high 
concentration on the blot. 
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Figure 4-8: Validation of anti-TbLAP-A by western blot analysis.  
(A) Sensitivity of anti-TbLAP-A: western blot analysis with anti-TbLAP-A as primary antibody in dilutions 
1:50 000 (1), 1:75 000 (2), 1:100 000 (3) or 1:200 000 (4); each lane contains 2.5 x 10
6
 parasites 
(BF = bloodstream forms, PF = procyclics); the dotted line indicates where the membrane was cut after the 
blocking step. (B) Specificity of anti-TbLAP-A: western blot analysis with saturated or untreated anti-TbLAP-A 
in dilution 1:100 000 and anti-TbSMT 1:15 000. The lanes contain either 50, 100 or 500 ng pure TbLAP-A or 
2.5 x 10
6
 parasites; the dotted line indicates where the membrane was cut after the blocking step. (C) Cross-
reactivity of anti-TbLAP-A: western blot analysis with anti-TbLAP-A (1:15 000) as primary antibody. The lanes 
contain 2.5 x 10
6
 T. brucei (bloodstreams and procyclics), 5 x 10
6
 L. major promastigotes (L.m. P), 5 x 10
6
 or 
10 x 10
6
 T. cruzi trypomastigotes (5T and 10T respectively) or 10 x 10
6
 T. cruzi amastigotes (with host cell 
background). (D) Analysis of affinity purified polyclonal anti-TbLAP-A antibody: western blot analysis with 
antibody elution fractions 4 and 5 (from affinity purification) used in 1:100 000 dilution. Each lane contains 
2.5 x 10
6
 parasites. 
 
Cross-reactivity with L. major LAP-A was shown, Figure 4-8 C, although the signal is 
much weaker, and could indicate poor recognition or a generally lower expression 
level of LAP-A. L. major also shows a lower molecular weight product being 
recognised, like that detected in T. brucei cell lysates. No cross-reactivity could be 
detected towards LAP-A in T. cruzi cell lysates although unfortunately the amount 
of protein loaded was very low as indicated by Ponceau red staining of the 
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membranes (data not shown), and therefore a certain level of cross-reactivity 
cannot be ruled out. 
After affinity purification with purified recombinant TbLAP-A, the elution fractions 4 
and 5 contained the anti-TbLAP-A antibody as shown by western blot against cell 
lysates of blood stream and procyclic T. brucei (Figure 4-8 D). At an antibody 
dilution of 1:100 000 the additional low molecular weight band was recognised only 
very weakly. 
 
4.3.3 Trypanosoma brucei brucei cell lines, culture and 
transfections 
For confirmation of the successful generation of the strains, the LAP-A levels in 
induced and un-induced cultures were determined by western blots using TbLAP-A-
specific antiserum. In bloodstream form parasites, strains with inducible LAP-A RNAi 
and overexpression, as well as strains overexpressing a LAP-A-cMyc fusion protein, 
were generated successfully. However, the generation of a LAP-A double knockout 
was not successful. Parasites exhibiting resistance to the drugs used for selection 
were attained, yet it is not possible to say at this point whether spontaneous 
resistance was generated, if the marker integrated into the wrong locus, and 
therefore did not replace the LAP-A gene, or if gene arrangements or duplications 
have occurred thus generating an additional copy of the LAP-A gene. All 
bloodstream form strains grew in HMI-9 with generation times of ~ 6 h. 
In procyclic parasites, strains with LAP-A RNAi, double knockouts and cells 
overexpressing LAP-A and a LAP-A-cMyc fusion protein were generated. 
Interestingly, the double knockout was created using the same constructs as for the 
bloodstream form parasites, where they had not been successful. All the procyclic 
strains grew in SDM-79 with generation times of ~ 8 h.  
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4.3.4 Growth and adaptation to media 
Growth variability was observed according to culture conditions and batches of 
media. Also, for culture of bloodstream forms in dialysed serum and changes in 
culture volumes a period of adaptation was required for obtaining constant growth 
rates (Figure 4-9).  
Cells were adapted to different media and culture volumes (until they showed 
constant generation times), before RNAi or overexpression were induced and 
growth curves were recorded.  
 
 
Figure 4-9: T. brucei growth adaptation.  
Given are the generation times in hours with error bars indicating the standard deviation of three 
independent cultures. (A) Bloodstream parasite cultures (parental and RNAi) in HMI-9 media with dialysed 
FBS after transfer from HMI-9 with non-dialysed FBS. (B) Procyclic parasite cultures (parental, double 
knockout clones 3,4 and 9 (KOBH3, KOBH4, KOBH9) and overexpression (induced and un-induced)) in SDM-79 
after transfer from 5 mL cultures in flasks into 3 mL cultures in 6-well cell culture plates. 
 
While there is no glucose available in the tsetse fly and procyclic T. brucei use 
proline as the main energy source (Bringaud et al., 2006), standard SDM-79 media 
contains high concentrations of glucose, which provides the parasites with an 
additional energy source, changing their energy metabolism (Lamour et al., 2005, 
Coustou et al., 2008). Glucose-free MEM media attempts to mimic the in vivo 
conditions more closely. Adaptation to MEM with dialysed FBS had to be performed 
step-wise with lower dilutions. Generally, the generation time observed in the 
 189 
glucose-free minimal media (MEM with dialysed FBS) was considerably longer than 
in SDM-79 media for all procyclic strains. 
The generation times observed for bloodstream form parasites were significantly 
longer in HMI-9 with dialysed serum (~ 11 h) than with non-dialysed FBS (6-7 h). 
 
4.3.5 Cell cycle analysis: flow cytometry and fluorescence 
microscopy analysis 
To determine the effect of LAP-A depletion and overexpression on the cell cycle, 
cells were analysed by flow cytometry and fluorescence microscopy.  
Flow cytometry allows determination of the DNA content per parasite cell, and to 
distinguish parasites in G1-, S- and G2/M-phase by measuring the fluorescence signal 
of the stained DNA compared to the particle size and internal complexity. Cells in 
M-phase have the same DNA content as G2-phase cells and therefore cannot be 
distinguished from these. Cells having lower DNA content, usually fragmented, are 
identified as the Sub-G1 population. Cell fragments are not detected, because data 
were recorded of a gated cell population, which shows overall size and inner 
complexity of trypanosomal cells. Cells containing the same amount of DNA as one 
of the other cell cycle stages will be misinterpreted as such. 
Using fluorescence microscopy of DAPI-stained cells, it is possible to gain more 
details about the cell cycle stage M and cytokinesis since cells with modifications in 
the kinetoplast or nuclear DNA content can be identified.  
Both, flow cytometry cell cycle analysis and DAPI staining were employed for 
analysis of the effects by growth conditions and LAP-A depletion and 
overexpression.  
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4.3.6 RNAi mediated depletion of LAP-A in bloodstream forms of 
T. brucei 
In bloodstream form T. brucei LAP-A knockdown over the whole time of the 
experiment was confirmed by western blots (Figure 4-10). LAP-A depletion 
approached 95 % and was maintained throughout the experiment.  
 
 
Figure 4-10: Western blot analysis of RNAi-mediated LAP-A depletion in bloodstream T. brucei. 
Western blot analysis of LAP-A knockdown with RNAi over 7 days. P = parental cell line, all other lanes TbBF 
RNAi clone, +/- doxycycline (Dox), cultures diluted and samples taken daily (days 1-7); Loading control = 
rabbit anti-TbSMT 1:10 000 dilution. Each lane contains 2.5 x 10
6
 parasites.   
 
Bloodstream form parasites were cultured in HMI-9 media containing FBS or 
dialysed FBS and after adaptation and observation of constant growth the 
generation time was calculated and averaged over time (Figure 4-11 A). The 
average generation time of parental bloodstreams in the presence and absence of 
doxycycline was recorded, as well as the generation times of RNAi induced and un-
induced parasites. The generation times of cultures containing doxycycline were 
marginally longer compared to cultures without it, independent of LAP-A depletion. 
In both media, the increase in generation time upon LAP-A depletion was identical 
to that of parental cells upon doxycycline addition and is considered not significant 
(evaluated using Welch’s t-test). Additionally, the cell cycle was analysed via flow 
cytometry and fluorescence microscopy. Neither in HMI-9 with FBS (Figure 4-11 B) 
 191 
nor with dialysed FBS (Figure 4-11 C), did cells display cell cycle defects upon LAP-A 
depletion and no increase in cell numbers with pathological nuclei or kinetoplast 
numbers was detected with fluorescent microscopy. Therefore, it can be concluded 
that LAP-A is not essential in bloodstream T. brucei under the culture conditions 
used. 
 
 
Figure 4-11: Growth and cell cycle analysis of RNAi-mediated LAP-A depletion in bloodstream T. brucei. 
 (A) Generation times calculated for bloodstream parasites with RNAi induced and un-induced, in HMI-9 
media containing FBS or dialysed FBS. Given are the generation times in hours with error bars indicating the 
standard deviation of three independent cultures. Cell cycle analysis via flow cytometry of parental (= WT) 
and RNAi grown in HMI-9 containing FBS (B) and HMI-9 containing dialysed FBS (C). 
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4.3.7 RNAi mediated depletion of LAP-A and generation of LAP-A-
dKO cells in procyclic forms of T. brucei 
In procyclic LAP-A knockdown via RNAi as well as the generation of double knockout 
(LAP-A-dKO) strains was successful and confirmed by western blots (Figure 4-12). 
The RNAi-mediated depletion of LAP-A approached 100 % and could be maintained 
over more than 10 days. 
 
 
Figure 4-12: Western blot analysis of RNAi-mediated LAP-A depletion and dKO in procyclic T. brucei. 
 (A) Western blot analysis of single knockout (sKO) and LAP-A knock down via RNAi in comparison to parental 
(P) procyclic T. brucei. The lanes contain 2.5 x 10
6
 parasites each, either induced or un-induced RNAi (+/-
 doxycycline) over 10 days with dilution of cultures every 2 days. Anti-TbLAP-A antiserum from the second 
extraction was used in a dilution 1:15 000, anti-TbSMT (as loading control) in 1:10 000 dilution. (B) Western 
blot analysis of double knockout (dKO) clones 3, 4, 8 and 9, compared to the parental (P) cells. Anti-TbLAP-A 
was used in 1:15 000 dilution, anti-TbSMT in 1:10 000.  
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Neither knockdown (data not shown) nor LAP-A-dKO showed a strong effect  on the 
growth profile (> 10 % increase in generation time, Figure 4-13 A) or the cell cycle 
(Figure 4-13 B), either in standard SDM-79 or in MEM media with dialysed FBS. 
However, the increase of generation times of LAP-A-dKO clones 3 and 9 in MEM 
media were considered significant based on the Welch’s t-test. No increase in cell 
numbers with pathological numbers of nuclei or kinetoplast was detected with 
fluorescent microscopy. Therefore it can be assumed that LAP-A is not essential in 
procyclic forms of T. brucei under the conditions tested.  
 
 
Figure 4-13: Growth curve and cell cycle analysis of RNAi and dKO in procyclic T. brucei. 
 (A) Generation times in hours of parental procyclics compared with dKO clones 3, 4 and 9 in SDM-79 (+ 10% 
FBS, + Haemin) and MEM media with dialysed FBS (+ Haemin). Given are the generation times in hours with 
error bars indicating the standard deviation of three independent cultures. ** indicates significant differences 
between samples (p ≤ 0.05). (B) Cell cycle analysis via flow cytometry of procyclic parasites (parental and dKO 
clone 4) in different media (SDM-79 and MEM with dialysed FBS). 
  
 
4.3.8 Overexpression of LAP-A in bloodstream and procyclic 
forms of T. brucei 
Overexpression of LAP-A in bloodstream form and procyclic parasites was induced 
by addition of doxycycline and confirmed by western blot analysis (Figure 4-14).  
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Figure 4-14: Western blot analysis of LAP-A overexpression in T. brucei. 
Western blot analysis of (A) bloodstream and procyclic (B) T. brucei with LAP-A overexpression induced by 
addition of doxycycline over 10 days with dilutions of cultures and samples taken every 2 days. Uninduced 
cultures were treated identical to induced ones. The anti-TbLAP-A from the second extraction was used in 
1:15 000 dilution, anti-TbSMT 1:10 000.  
 
 LAP-A overexpression in bloodstream parasites grown in HMI-9 media did not 
effect the growth rate of the parasites (Figure 4-15 A). LAP-A overexpressing 
procyclic parasites in SDM-79 media show a significant reduction of growth (longer 
generation time) even if not induced (p ≤ 0.05, Figure 4-15 B). This might be caused 
by the selective marker (puromycin) or by leakiness of the construct, although the 
latter was not observed in comparison to the parental cell line on the western blot. 
Cell cycle analysis using flow cytometry and fluorescence microscopy did not reveal 
adverse effects of LAP-A overexpression on the cell cycle in these media. 
 
 
Figure 4-15: Growth of LAP-A overexpressing T. brucei in standard media. 
 Shown are the parasite counts per mL of LAP-A overexpressing bloodstream (A) and procyclic (B) parasites 
over the course of 10/12 days with dilution of the cultures every 2 days. Error bars indicate the standard 
deviation. 
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When procyclic forms were grown in minimal essential medium (MEM), LAP-A 
overexpression had no immediate adverse effects, but growth of induced and un-
induced cultures was reduced significantly (p ≤ 0.05) after subsequent dilutions, 
possibly due to the puromycin (Figure 4-16 A). Compared to parental cells no 
increase of LAP-A expression for un-induced cells could be detected by western 
blots. After six days of culture (two dilutions) the induced cells show a reduction in 
growth rate and after 12 days (three dilutions) a proportion of the LAP-A 
overexpressing cells died, shown most clearly by the increase of sub-G1 cells in cell 
cycle analysis via flow cytometry (Figure 4-16 B).  
 
 
Figure 4-16: Growth and cell cycle analysis of LAP-A overexpression in procyclic T. brucei in MEM.  
 (A) Culture growth: cells counted every three days (Dilution 1 = day 3, dilution 2 = day 6, etc.) as parasites per 
mL before cultures were diluted again to 200 000 parasites mL
-1
. The error bars indicate the standard 
deviation, * indicates the cultures that were harvested for cell cycle analysis by flow cytometry, ** indicates 
statistical significance between samples (p < 0.05). ECC8 = OE8 = clone name. (B) Cell cycle analysis by flow 
cytometry. The red arrow indicates the strong increase in Sub-G1 = dead cells of the LAP-A overexpressing 
culture after 12 days (4 dilutions).  
 
4.3.9 Amino acid limitation in procyclic forms of T. brucei 
LAPs cleave amino acids, preferentially leucine, from the N-terminus of proteins or 
peptides and therefore play a role in protein recycling and turnover and the 
depletion or overexpression of an aminopeptidase is expected to have an increased 
effect on the cells wellbeing under suboptimal extracellular amino acid conditions. 
In the case of LAP-A depletion, the extracellular leucine levels might be particularly 
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important. To test the effect of leucine limitation on the growth and cell cycle of 
procyclic forms of T. brucei, cultures were grown in glucose-free MEM prepared 
without leucine and with dialysed FBS to make sure no peptides and undefined 
amino acids are present. Parental and LAP-A-dKO cells from cultures grown in MEM 
containing leucine (with dialysed FBS) were transferred to MEM without leucine 
and incubated at culture temperature. The parental cells continued to grow for 
approximately 24 h before they entered stationary phase (Figure 4-17 A) where 
they remained for ~ 2 days. In contrast, the LAP-A-dKO parasites continued to grow 
for a further 12 h (36 h in total) before entering stationary phase. 
Both parental and LAP-A-dKO parasites showed the morphology typical for 
starvation with very elongated and thin cell body and reduced motility, analysed 
visually under the microscope. 
The cell cycle stages of the parasites grown under leucine starvation were analysed 
by flow cytometry after 2, 3 and 4 days (Figure 4-17 B). The number of sub-G1 cells 
in the LAP-A-dKO parasite population after 3 and 4 days was slightly increased 
compared to the parental cells despite the observation that the LAP-A-dKO cells 
continued to grow and enter stationary phase at a later time point. Similarly, LAP-A-
overexpressing parasites showed an increased number of sub-G1 cells than controls. 
In fluorescence microscopy, the number of cells with pathological morphology was 
increased in LAP-A-dKO and overexpressing cells. While 18.5 % of the parental cell 
population showed morphological defects, it was 23.2 % in LAP-A-dKO and 24.5 % in 
overexpressing cells. 
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Figure 4-17: Growth and cell cycle analysis under amino acid limitation.  
(A) Growth curve of procyclic parasites in MEM without leucine. KOBH3, 4 and 9 are different LAP-A double 
knockout strains. (B) Cell cycle analysis of procyclic parasites (parental, double knockout and overexpression) 
in MEM without leucine after 2, 3 and 4 days via flow cytometry. (C) Cell cycle analysis of procyclic parasites 
(parental, double knockout and overexpressing cells) grown in MEM without “non-essential amino acids” 
after 3 days via flow cytometry. 
 
When procyclic parasites were grown in MEM in the absence of non-essential 
amino acids, cell division arrested (no increase in the number of cells could be 
observed) and the parasites died rapidly as indicated by cell cycle analysis with flow 
cytometry (Figure 4-17 C), where about half of the parasites were seen as sub-G1 
population after 3 days. LAP-A-overexpressing procyclics had a higher number of 
sub-G1 cells than parental cells, which in turn showed sub-G1 cells than the LAP-A-
dKO. These findings were confirmed by fluorescence microscopy where 50.8 % of 
the parental, 42.3 % of the LAP-A-dKO and 59.0 % of the overexpressing parasites 
showed morphological defects.  
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4.3.10  Subcellular localisation of LAP-A in T. brucei 
Bloodstream and procyclic forms of T. brucei were grown to mid-log phase and 
fixed on poly-lysine coated glass slides. Mitochondria were stained using red 
fluorescent MitoTracker and DNA in the nuclei and kinetoplasts were stained with 
DAPI. TbLAP-A was visualised using the affinity purified rabbit anti-TbLAP-A anti-
serum as described in 4.2.5. Cells were imaged by confocal fluorescence 
microscopy.  
Parental bloodstream form and procyclic T. brucei (Figure 4-18) show a clear TbLAP-
A staining that disappears in RNAi-mediated LAP-A knockdowns and LAP-A-dKO 
cells, thus confirming the result obtained by western blotting. cMyc-tagged LAP-A 
staining (with cMyc-specific antibody) exhibited a similar pattern to that obtained 
using the anti-TbLAP-A antibody in the parental cell line, although in bloodstream 
form parasites overexpressing the cMyc-tagged LAP-A a distribution in foci was 
observed while the untagged LAP-A seems more homogeneous.  
Co-localisation analysis using JACoP in ImageJ (Bolte & Cordelieres, 2006, Schneider 
et al., 2012) gave some indication of partial co-localisation of TbLAP-A with the 
nucleus and the mitochondrion in bloodstream forms and procyclics, when analysed 
with Li’s approach (Li et al., 2004), however, LAP-A’s localisation in the nucleus is 
not supported when images are inspected manually. An example analysis of 
parental bloodstream form cells is shown in Figure 4-19. The distribution of Classical 
intensity correlation coefficient-based (ICCB) methods, like Pearson’s coefficient, 
Costes’ approach (Costes et al., 2004) and Van Steensel’s approach (van Steensel et 
al., 1996), did not give conclusive results. This may be caused by the inherent 
heterogeneity of the LAP-A and MitoTracker signals, background noise and/or 
bleeding of the DAPI channel into FITC, as well as limitations of resolution in the z-
axis of the samples and resulting signal bleeds from lower and higher planes.  
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Figure 4-18: Subcellular localisation of LAP-A in T. brucei. 
Shown are immunofluorescence images of bloodstream form (A) and procyclic (B) T. brucei taken at different 
fluorescence channels. Top rows show parental parasites, middle rows are RNAi (clone 1) of bloodstream 
form parasites with RNAi induced for 4 days before fixation of the cells, or LAP-A-dKO of procyclics, and the 
bottom rows show LAP-A-cMyc overexpressing cells, induced for 2 days before localisation. The Images were 
taken with identical microscope settings (and antibody dilution for parental and RNAi) for comparison of the 
different cell lines. The figure shows a 3D reconstruction of images taken with a Leica TCS SP5 confocal 
microscope at 63x magnification.  
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Figure 4-19: Colocalisation analysis with JACoP using Li’s approach.  
Shown are example analyses of colocalisation of LAP-A with DAPI (A) and MitoTracker (B) in parental 
bloodstream form cells. The value on the x-axis depends on the covariance of the channels that are 
compared, while the y-value reflects the intensities of the channel in question. The upper graphs show the 
graphs for the LAP-A channel, the lower ones for DAPI and MitoTracker respectively. (C) Schematic 
representation of the interpretation of the graphs, with dark grey indicating the distribution in case of 
complete colocalisation and exclusion and the light grey areas showing the expected distribution in case of 
colocalisation in presence of noise or partial colocalisation. 
 
In conclusion, the immunofluorescence analysis indicates LAP-A localisation in the 
cytoplasm in both life cycle stages of the parasites, although the pattern of 
distribution shows differences. So LAP-A in the blood stream form seems more 
heterogeneous and for the cMyc-tagged LAP-A localised to foci, which might be an 
artefact of overexpression, while in procyclic parasites LAP-A distribution is more 
homogeneous. A localisation to the endoplasmic reticulum (ER) would cause a very 
similar pattern and would have to be confirmed by co-localisation studies using ER-
specific and cytosolic marker proteins.  
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4.3.11  Crystallisation of the LAP-As 
TbLAP-A, TcLAP-A and LmLAP-A crystallised in various conditions. TbLAP-A crystals 
in P212121 with six chains in the asymmetric unit grew in citrate-containing 
conditions and comprise apo TbLAP-A, missing the metal ions in the active site 
(Figure 4-20 A). TbLAP-A complexes crystallised under many different conditions, 
preferentially in space group P21 with 6 or 12 chains per asymmetric unit (Figure 
4-20 B). TcLAP-A crystallised only in citrate-containing conditions, resulting in 
crystals in space group R32 with one or both metal ions missing from the active site 
(Figure 4-20 C). No ligand complexes of this protein could be crystallised. LmLAP-A 
crystallised in many different conditions forming hexagonal plate-like crystals, of 
which only two diffracted (Figure 4-20 D). One of these, grown in the presence of 
actinonin, was in space group P321 and diffracted to 2.5 Å.  
 
Figure 4-20: LAP-A crystals.  
(A) apo TbLAP-A crystal, black bar = ~200 μm; (B) TbLAP-A-Mn-bestatin crystal, black bar = ~ 100 μm; (C) 
TcLAP-A-Mn-citrate crystal, black bar = ~50 μm; (D) LmLAP-A-Mn-actinonin crystal, black bar = ~ 50 μm. 
 
4.3.12  TriTryp LAP-A structures 
The structures of the TriTryp LAP-As were solved by molecular replacement and 
show a very high structure similarity to each other and LAPs of other species. The 
structure description will focus on the TbLAP-A with differences in TcLAP-A and 
LmLAP-A indicated where relevant.  
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4.3.12.1 Overall and quaternary structure in the crystals 
TbLAP-A has two domains (N- and C-terminal) each with a mixed / structure 
(Figure 4-21). The smaller N-terminal domain (aa 2-197) shows a six-stranded -
sheet (β1, β6, β5, β2, β4, β3) flanked by five -helices (α2 – α6). At the N-terminus 
there is an -helix (α1), which interacts with the neighbouring protomer in the 
hexamer. The structures of other LAPs in the PDB do not have this N-terminal helix. 
The N-terminal domain is connected to the C-terminal domain by a long -helix 
(α7). The highly conserved C-terminal domain (aa 215-521) is nearly identical to the 
structures of other LAPs in the PDB and is composed of a central eight-stranded -
sheet (β7, β8, β10, β9, β13, β17, β14, β15), which is surrounded by -helices (α8 – 
α17) and a small -sheet (β11, β12, β16).  
 
 
Figure 4-21: TbLAP-A.  
(A) TbLAP-A in complex with Mn
2+
, HCO3
-
 and bestatin. Ligands are shown as spheres coloured by atom type, 
protein is shown as ribbon. The secondary structure elements are numbered from N- to C-terminus.  
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TbLAP-A shows the typical hexameric architecture of the M17 metallopeptidases, 
where six LAP-A protomers form a dimer of trimers (Figure 4-22 A & B). The C-
terminal domain, containing the active site, forms the core of the hexamer, packed 
around the central 3-fold axis with the active sites facing into the central cavity, 
which is secluded from the surrounding bulk solvent. This results in low accessibility 
for substrates as long as the assembly as hexamer persists. 
 
 
Figure 4-22: TbLAP-A quaternary structure.  
Two trimers (A) form a dimer of trimers (hexamer) (B). Protein chains are shown as ribbons coloured by 
chain. The ligands in the active site (bestatin, manganese and HCO3
-
) are shown as spheres coloured by atom 
type. (C) Surface view of the hexamer along the three-fold axis (left) and rotated about 90° (right), coloured 
by chain.  
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4.3.12.2 Comparison of the TriTryp LAP-A structures  
The TriTryp LAP-As have identical core structures with overall RMSDs for TcLAP-A 
and LmLAP-A towards TbLAP-A of 0.31 Å and 0.33 Å respectively with differences 
limited to loop regions and slight changes in the length of secondary structure 
elements (Figure 4-23). For example, the N-terminal helix and -strands β3 and β4 
in the N-terminal domain are slightly shorter than those in TbLAP-A, while β5 and 
β6 are slightly longer. Some loop regions in the N-terminal domain (between α2 and 
β2, β3 and β4, α5 and β5, and α6 and β6) and in the C-terminal domain (between 
β8 and β9 and β10 and α11) show different conformations.  
Structural differences of LmLAP-A compared to TbLAP-A (Figure 4-24) and TcLAP-A 
are mainly in the loop regions. The secondary structure elements and their 
positions in LmLAP-A are nearly identical to those in TbLAP-A with the exception of 
the β1, β3 and β4, which are shortened and α2, which is replaced by a loop region. 
The N-terminus of LmLAP-A is extended and forms a loop before the start of the α1-
helix. The loop regions noted as different for TcLAP-A are extended in LmLAP-A and 
adopt different conformations. Additionally, the loop between β6 and α7 is 
extended, harbouring a small α-helix and helix α11 in the C-terminal domain is 
extended by one turn. 
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Figure 4-23: Comparison of TcLAP-A with TbLAP-A.  
(A) Superposition of TcLAP-A (crimson) and TbLAP-A in complex with manganese, HCO3
-
 and bestatin (ice 
blue). (B) Superposition of the same two proteins coloured by ProSMART (Nicholls et al., 2012) from yellow 
(identical structures) to orange and red (differing parts of the structures) and white indicating the missing 
part of the shortened N-terminal helix in the TcLAP-A structure. Superpositions in this and all subsequent 
figures were made using SSM (Krissinel & Henrick, 2004).  
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Figure 4-24: Comparison of LmLAP-A with TbLAP-A.  
(A) Superposition of LmLAP-A (lemon) and TbLAP-A in complex with manganese, HCO3
-
 and bestatin (dark 
cyan). (B) Superposition of the same two chains coloured by ProSMART (Nicholls et al., 2012) from yellow 
(identical structures) to orange and red (differing parts of the structures) and white indicating the helix 
missing and loop region shortened in the LmLAP-A structure. The proteins are shown as ribbons and the 
ligands as spheres coloured by atom type. 
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All of the TriTryp LAP-As form hexamers in the crystals (Figure 4-25) and analysis 
using PISA (Krissinel & Henrick, 2007) confirmed the hexamer as the likely oligomer 
in solution. All conformational differences seen between the TriTryp LAP-As are at 
the surface of the hexamer and away from the active site and are unlikely to 
influence oligomerisation or enzymatic activity. 
 
 
Figure 4-25: TriTryp LAP-A hexamers.  
(A) TbLAP-A; (B) TcLAP-A; (C) LmLAP-A. The LAP-As are shown in worm-and-tube representation (left) and the 
surfaces are shown coloured by electrostatic potential (right).  
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4.3.12.3 Metal coordination in the active site and apo LAP-A 
The metal-coordinating amino acid residues in the TriTryp LAP-As are conserved 
and identical to those in previously solved LAP structures, Figure 4-26. The two 
metal binding sites are reported to have different binding affinities for the metal 
ions, with site 1 having lower affinity than site 2 (Carpenter & Vahl, 1973, Burley et 
al., 1990). In TbLAP-A, the carboxylate oxygen atoms of D294, E373 and the main 
chain and carboxylate oxygens of D371 coordinate the metal ion in site 1, and the 
carboxylate oxygens of D294, E373 and D312 and the ε-amino group of K289 
coordinate that in site 2. The corresponding residue numbers in TcLAP-A are K288, 
D293, D311, D370 and E372, and in LmLAP-A are K299, D304, D322, D389 and E391.  
 
 
Figure 4-26: Superposition of the metal binding sites.  
The main chains of TbLAP-A (dark cyan) and PfLAP (purple) are shown as ribbons, metal coordinating residues 
are shown as cylinders coloured by atom type with the C atoms coloured by model, TbLAP-A = dark cyan, 
TcLAP-A = crimson, LmLAP-A = lemon, PfLAP = purple. The manganese ions in the TriTryp LAP-A structures 
and the amino acid labelling are coloured by model with blue for TbLAP-A, red for TcLAP-A and yellow/orange 
for LmLAP-A. The coordination contacts between amino acid residues and metals are shown as red dashed 
lines; an additional coordination partner is either a water molecule or ligand and not shown in this figure.  
 
While the unliganded TbLAP-A (crystallised in presence of leucine), TbLAP-A 
complexes and LmLAP-A structures have two metals bound in the active site, the 
TcLAP-A structures show clear density for only one metal ion, in site 1, but no metal 
in site 2. However, the active site residues adopt the same conformations as if two 
metal ions were bound. 
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Most LAP-A crystals grew in the presence of manganese ions. However, LAPs are 
reported to be zinc-dependent enzymes and thus crystals of EDTA-treated TbLAP-A 
were grown in the presence of ZnCl2. However, XRF scans (Figure 4-27) on the 
resulting crystals indicated the presence of manganese ions and subsequent data 
collection at different wavelengths and calculation of anomalous difference maps 
confirmed the absence of Zn2+ ions from both metal binding sites, by the presence 
of anomalous difference peaks at a wavelength above the X-ray absorption edge of 
zinc (1.3052 Å), Figure 4-28.  
 
Figure 4-27: XRF scan of the TbLAP-A-Mn crystal grown in presence of zinc. 
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Figure 4-28: Anomalous difference density in the active site of TbLAP-A.  
(A) Anomalous difference map calculated from data collected at a wavelength of 0.9795 Å, contoured at 5σ. 
(B) Anomalous difference map calculated from data collected at a wavelength of 1.3051 Å, contoured at 5σ.  
 
The structures of LAP-As in their apo form, unliganded and in complex with 
inhibitors are practically identical. However, the active site loop (aa 293-305) of the 
apo TbLAP-A is disordered and no electron density for bound metal ions could be 
detected, most likely due to the high concentration of citrate in the crystallisation 
buffer chelating the metal ions. Apo TcLAP-A as well as the other LAP-A structures 
shows fully formed active sites independent of metal or ligand binding. 
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Figure 4-29: Superposition of apo TbLAP-A and to TbLAP-A-Mn-bestatin.  
(A) Superposition of the A chains and (B) a close-up of the active site region of apo TbLAP-A and TbLAP-A in 
complex with manganese, HCO3
- 
and bestatin with the protein in ribbon representation and the ligands as 
spheres coloured by atom type. Apo TbLAP-A is coloured in lemon, while TbLAP-A complex is coloured by 
ProSMART (Nicholls et al., 2012) from yellow (identical to apo structure) to red (differing to apo structure) 
and white indicating the loop region missing in the apo structure.  
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4.3.12.4 The TbLAP-A-bestatin complex 
TbLAP-A crystallised in the presence of the inhibitor bestatin. The electron density 
of the ligand was well defined in all 12 chains in the asymmetric unit and was 
modelled in the same conformation (Figure 4-30). The bestatin conformation 
mimics the gem-diolate intermediate of the peptide substrate in the process of its 
cleavage.  
 
 
Figure 4-30: Electron density of bestatin bound in chain A of TbLAP-A.  
The weighted electron density maps (2mFo-DFc) and difference maps (mFo-DFc) were calculated using 
REFMAC5 (Murshudov et al., 2011). Bestatin and Mn
2+ 
are shown as ball-and-stick models coloured by atom 
type, mFo-DFc maps contoured at 3σ in green (positive) and red (negative), the 2mFo-DFc maps are contoured 
at 1σ and drawn in blue. (A) Unbiased maps generated before ligand modelling. (B) Maps after refinement 
with bestatin.  
 
The coordination of bestatin (Figure 4-31 A) is facilitated mainly through the Mn2+ 
ions and hydrogen bonding. The Mn2+ ions coordinate the nitrogen atom N2 and 
oxygen atoms O2 and O3. Additionally, N2 is coordinated through hydrogen bonds 
to the side chain oxygens of D294 and D312 as well as the main chain oxygen of 
 213 
T401. The main chain oxygen of D371, and the side chains of K289 and D294 form 
hydrogen bonds to O2, while the side chain of K301 forms a hydrogen bond to O3.  
Furthermore the bound HCO3
- forms a hydrogen bond to the O2 atom. While 
hydrophobic residues surround the phenyl ring of bestatin, its carboxyl group forms 
hydrogen bonds to G404 and R467. The bestatin binding in TbLAP-A is identical to 
that in PfLAP (Figure 4-31 B).  
 
 
Figure 4-31: Bestatin binding in the active site. 
Bestatin, Mn
2+
 and HCO3
-
 are shown as ball-and-stick models and active site residues are shown as cylinders, 
coloured by atom type with C according to model, amino acid numbering according to TbLAP-A. (A) Bestatin 
coordination in the active site of TbLAP-A with hydrogen bonds as black dashed lines and metal coordination 
shown as red dashed lines. (B) Superposition of the active sites of the bestatin complex structures of TbLAP-A 
(dark cyan with ice blue ligand) and PfLAP (3KR4, purple with lilac ligand).  
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A schematic view of the bestatin binding in TbLAP-A is shown in Figure 4-32. 
 
Figure 4-32: Schematic view of bestatin binding in the TbLAP-A active site. 
Shown are bestatin and the residues coordinating it via hydrogen bonds (green labels, hydrogen bonds as 
dashed lines), and hydrophobic interactions (black labels, red half circles). Ligand and hydrogen bonding 
residues are shown as ball and stick models coloured by atom type. Figure made with LigPlot+ (Laskowski & 
Swindells, 2011). 
 
4.3.12.5 The actinonin complexes 
For both TbLAP-A and LmLAP-A the electron density was sufficient to model the 
ligand in its approximate conformations (Figure 4-33 and Figure 4-34). However, its 
occupancy was below 100 % and the limited resolution and quality of the data sets 
does not allow accurate determination of the ligand’s conformation.  
The TbLAP-A complex with actinonin had six molecules in the asymmetric unit, so 
that local NCS could be applied for the protein. The electron density for the 
actinonin on the other hand was only sufficient in four chains and varied slightly, so 
that the ligand was finally modelled in each chain individually. However, the 
electron density of two of the chains (D and F) was very poor, so that these were 
not included in analysis of the binding mode. The actinonin from two of the well-
defined chains with the electron densities of chain A are shown in Figure 4-34. The 
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binding mode of actinonin in TbLAP-A was identical in the four chains (Figure 4-35 
B) and differed only slightly to the one in LmLAP-A (Figure 4-35 C). 
Actinonin in LmLAP-A and TbLAP-A is coordinated by the Mn2+ ions and hydrogen 
bonds. In both structures the two Mn2+ atoms coordinate the oxygen atoms O2 and 
O4 of the ligand. In LmLAP-A the side chains of K299, D304, K311 and D389 form 
hydrogen bonds to O2 and O4, and the main chain oxygen of L420 and the main 
chain nitrogen of G422 form hydrogen bonds to N1 and O13 respectively. The N14 
atom of actinonin coordinates a water molecule. The corresponding residues in 
TbLAP-A are K289, D294, K301, D371, L402 and G404 and additionally, A405 forms a 
hydrogen bond to O27 (in four out of six chains). Because of the poor data quality 
no water molecules were modelled in the TbLAP-A structure with the exception of 
those replacing the HCO3
-. Superposition of the active sites including the actinonin 
molecules (Figure 4-35 C) reveals the high similarity of the conformations actinonin 
adopts, its coordination involving the same amino acid residues. The only difference 
can be observed in the hydroxymethyl-pyrrolidine moiety, which forms a hydrogen 
bond in TbLAP-A but not in LmLAP-A where it is bent away from the corresponding 
residue (A424). 
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Figure 4-33: Electron density of actinonin bound in LmLAP-A.  
The weighted electron density maps (2mFo-DFc) and difference maps (mFo-DFc) were calculated using 
REFMAC5 (Murshudov et al., 2011). (A) Unbiased maps generated before ligand modelling. (B) Maps after 
refinement with actinonin. Actinonin and Mn
2+ 
are shown as ball-and-stick models coloured by atom type, 
mFo-DFc maps contoured at 2σ for (A) and 3σ in (B), in green (positive) and red (negative), the 2mFo-DFc maps 
are contoured at 1σ and drawn in blue.  
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Figure 4-34: Electron density of actinonin bound in TbLAP-A.  
The weighted electron density maps (2mFo-DFc) and difference maps (mFo-DFc) were calculated using 
REFMAC5 (Murshudov et al., 2011). Shown are the actinonin molecules of chain A and E representing the 6 
molecules in the asymmetric unit superposed. (A) Unbiased maps generated before ligand modelling. (B) 
Maps after refinement with actinonin. Actinonin and Mn
2+ 
are shown as ball-and-stick models coloured by 
atom type, mFo-DFc maps contoured at 2σ for (A) and 3σ in (B), in green (positive) and red (negative), the 
2mFo-DFc maps are contoured at 1σ and drawn in blue.  
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Figure 4-35: Actinonin binding sites in LmLAP-A and TbLAP-A. 
(A) LmLAP-A active site with bound actinonin. (B) TbLAP-A active site with bound actinonin. (C) Superposition 
of the active sites of LmLAP-A and TbLAP-A with active site residues numbered after LmLAP-A (orange) and 
TbLAP-A (blue). Actinonin (BB2), Mn
2+
 and HCO3
-
 are shown as ball-and-stick models and active site residues 
are shown as cylinders, coloured by atom type with C according to model, hydrogen bonds as black dashed 
lines and metal coordination shown as red dashed lines.  
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The actinonin interactions in TbLAP-A and LmLAP-A are plotted in Figure 4-36. 
 
 
Figure 4-36: Schematic view of actinonin binding in the active sites of TbLAP-A and LmLAP-A.  
(A) TbLAP-A, (B) LmLAP-A. Shown are actinonin and the residues coordinating it via hydrogen bonds (green 
labels, hydrogen bonds as dashed lines), and hydrophobic interactions (black labels, red half circles). Ligand 
and hydrogen bonding residues are shown as ball and stick models coloured by atom type. Figure made with 
LigPlot+ (Laskowski & Swindells, 2011). 
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4.3.12.6 TcLAP-A in complex with citrate 
TcLAP-A crystallised only in citrate containing conditions, which led to the absence 
of one or both of the Mn2+ ions from the active site and no electron density for the 
inhibitors. However, the structure obtained from co-crystallisation with the 
inhibitor amastatin showed clear density for one partially occupied Mn2+ ion and a 
citrate molecule bound in the active site, but no amastatin (Figure 4-37 A & B).  The 
HCO3
- is replaced by a SO4
2-.  
 
 
Figure 4-37: Citrate binding in TcLAP-A.  
Shown are the weighted electron density maps (2mFo-DFc) and difference maps (mFo-DFc), calculated using 
REFMAC5 (Murshudov et al., 2011): (A) Unbiased maps generated before ligand modelling (but with the 
Mn
2+
). (B) Maps after refinement with citrate (CIT) and SO4
2-
. CIT and SO4
2-
 shown as cylinder coloured by 
atom type, Mn
2+ 
as grey sphere, mFo-DFc maps contoured at 2σ for (A) and 3σ in (B), in green (positive) and 
red (negative), the 2mFo-DFc maps are contoured at 1σ and drawn in blue. (C) Mn
2+
, SO4
2-
 and CIT 
coordination in the active site. CIT, SO4
2-
 and coordinating side chains shown as cylinders coloured by atom 
type with the side chain C atoms in orange Mn
2+ 
as grey sphere, the white sphere indicates the location of the 
empty metal binding site. The metal coordination and hydrogen bonds are drawn as dashed lines in red and 
black respectively.  
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The citrate molecule is coordinated by the Mn2+ and hydrogen bonding (Figure 
4-37 C), with Mn2+ coordinating the oxygen atoms O3 and O4. While K288 forms a 
hydrogen bond to O4, K300 forms hydrogen bonds with O3 and O5. Oxygen atom 
O7 from the citrate forms hydrogen bonds to D311, M308 and a water molecule. 
Main and side chains or R374, G373 and K288 coordinate the SO4
2- molecule. 
 
4.3.13  Oligomeric State in solution 
The TriTryp LAP-As crystallised as hexamers, like in other LAPs structures in the PDB. 
To confirm the hexamer as the oligomeric state in solution, SEC-MALLS analyses of 
all three LAP-As were carried out at a range of protein concentrations. The expected 
molecular masses expected for the different oligomeric states are summarised in 
Table 4-20 and were used to annotate the elution peaks obtained from the SEC-
MALLS data allowing for an error of ± 10 %. An overlay of the differential refractive 
index traces at a protein concentration of 1.0 mg mL-1 with annotated peaks 
according to the oligomeric states corresponding to the molecular masses is shown 
in Figure 4-38.  
 
Table 4-20: Expected molecular masses for different LAP-A oligomers. 
 Monomer [kDa] Dimer  [kDa] Trimer [kDa] Hexamer [kDa] 
TbLAP-A 55.4 110.8 166.2 332.4 
TcLAP-A 55.9 111.8 167.7 335.4 
LmLAP-A 57.1 114.2 171.3 342.6 
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Figure 4-38: Annotated SEC-MALLS data for TbLAP-A, TcLAP-A and LmLAP-A.  
Shown are the overlaid differential refractive index traces of the three LAP-As each at 1 mg mL
-1
. 
 
TbLAP-A (Figure 4-39) analysis in the NaCl-containing buffer showed an asymmetric 
double peak of ~ 270 kDa at one side of the peak and ~ 240 kDa at the other (Table 
4-21). These calculated masses would correspond approximately to a tetrameric 
state of the protein, which is very unlikely when the X-ray structures of this and 
other LAPs are considered. More likely this peak is caused by a dynamic equilibrium 
of hexamers and trimers with the speed of equilibration being faster than the time 
of running the SEC. The asymmetric peak shape indicated the lower molecular mass 
species to be more abundant than the higher. The SEC-MALLS traces were identical 
for all concentrations tested. To investigate whether the buffer composition is 
destabilising the expected hexamer, a different buffer was tested exchanging the 
200 mM NaCl with 100 mM KCl and increasing the Tris concentration from 10 mM 
to 50 mM. Enzymatic activity of TbLAP-A could be shown in the KCl-containing 
buffer (see 4.3.1), but the protein was inactive in the NaCl-containing one (not 
shown). SEC-MALLS analysis of TbLAP-A in the KCl-containing buffer showed a more 
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symmetric double peak with ~ 280 and ~ 270 kDa as molecular masses calculated 
from each side of the peak (Table 4-21). These data also suggest a concentration-
independent mixture of hexamer and trimer, but in contrast to the previous buffer 
the two oligomeric states seem to be present in equal amounts. As the KCl-
containing buffer shows a higher amount of higher molecular mass species and can 
also be used for measurements of the enzymatic activity, it can be assumed that the 
protein is active in the higher oligomeric state. Overall these data demonstrate a 
significant influence of the buffer composition on the stability of the oligomeric 
state of TbLAP-A.  
 
 
Figure 4-39: SEC-MALLS traces of TbLAP-A.  
Shown are the normalised traces of the differential refractive index and at the different protein 
concentrations loaded. Asterisks indicate the data obtained in KCl-containing buffer while the other traces 
are from NaCl-containing buffer. The molecular weights calculated from the peaks are shown as dashed lines 
in the same colours as the corresponding differential refractive index trace. 
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Table 4-21: Mw of the TbLAP-A oligomers obtained from SEC-MALLS.  
The asterisks indicate the samples obtained from KCl-containing buffer, all others obtained with buffer 
containing NaCl. 
Protein Concentration 
[mg mL-1] 
Aggregation 
in sample 
Peak 1 
[kDa] 
Peak 2 
[kDa] 
TbLAP-A 0.3 No* 281.2* 274.3* 
 0.5 No 284.5 246.4 
 1.0 No 273.8 238.8 
 3.0 No 266.6 240.6 
 3.0 No* 274.8* 269.0* 
 5.0 No 264.6 236.5 
 
 
The analysis of TcLAP-A (Figure 4-40) showed the presence of two peaks, one with a 
calculated molecular mass of ~ 320 kDa and the other with ~ 170 kDa (Table 4-22), 
which correspond to the hexamer and trimer, respectively. While the elution 
volume of the hexamer peak was the same at all protein concentrations analysed, 
the peak maxima of the trimer peaks varies due to the influence of the hexamer 
species on the trimer. The higher the proportion of the hexamer compared to the 
trimer, the bigger its influence on the behavior of the trimer. At all concentrations 
analysed the hexameric species was the most abundant and as the concentration 
was lowered the proportion of trimers increased. Unlike the TbLAP-A data, the 
hexameric and trimeric species separate well on the column, so that their masses 
can be determined more accurately. This suggests a slower conversion of the 
hexamer and trimeric TcLAP-A species, than in TbLAP-A. 
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Figure 4-40: SEC-MALLS traces of TcLAP-A.  
Shown are the normalised traces of the differential refractive index and at the different protein 
concentrations loaded. The molecular weights calculated from the peaks are shown as dashed lines in the 
same colours as the corresponding differential refractive index trace. 
 
Table 4-22: Mw of the TcLAP-A oligomers obtained from SEC-MALLS. 
Protein Concentration 
[mg mL-1] 
Aggregation 
in sample 
Peak 1 
[kDa] 
Peak 2 
[kDa] 
TcLAP-A 0.5 No 331.1 162.2 
 1.0 No 318.5 167.4 
 3.0 No 309.9 183.2 
 
 
Analysis of the LmLAP-A (Figure 4-41) revealed three distinct molecular mass 
species plus a considerable amount of aggregation (not shown in the figure). This 
influences the baseline considerably and reduces the accuracy of the molecular 
mass calculations. The three elution peaks have molecular masses of ~ 300 kDa, 
~ 125 kDa and ~ 60 kDa (Table 4-23), which correspond to the hexamer, trimer and 
monomer respectively. All three species present in the sample are well separated 
from each other and the aggregates in the void volume (not shown in the figure). 
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The lower the protein concentration the higher is the proportion of monomers in 
the mixture. Whether the monomers are a result of instability and subsequently 
result in their aggregation or if the monomeric state is physiologically relevant is not 
clear.  
 
 
Figure 4-41: SEC-MALLS traces of LmLAP-A.  
Shown are the normalised traces of the differential refractive index and at the different protein 
concentrations loaded. The molecular weights calculated from the peaks are shown as dashed lines in the 
same colours as the corresponding differential refractive index trace. 
 
Table 4-23: Mw of the LmLAP-A oligomers obtained from SEC-MALLS. 
Protein Concentration 
[mg mL-1] 
Aggregation 
in sample 
Peak 1 
[kDa] 
Peak 2 
[kDa] 
Peak 3 
[kDa] 
LmLAP-A 0.5 Yes 293.1 118.9 59.1 
 1.0 Yes 299.2 109.0 54.8 
 3.0 Yes 310.3 152.2 67.4 
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4.4 Discussion 
4.4.1 LAP-A as potential drug target in T. brucei 
The data obtained indicate that LAP-A is not essential for survival and proliferation 
of bloodstream and procyclic T. brucei brucei parasites under the conditions tested. 
RNAi-mediated depletion in bloodstream parasites and both RNAi-mediated 
depletion and the generation of dKO mutants in procyclics support this conclusion. 
Whether this is the result of redundancy caused by the presence of additional M17 
LAPs, paralogues of the one investigated, requires further research. The LAP-A 
paralogues are predicted to localise to the endoplasmic reticulum and the 
mitochondrion and therefore should have distinct functions from LAP-A, which is 
most likely cytosolic. It is not possible to predict if the paralogues can compensate 
for the loss of LAP-A. The overexpression of LAP-A in procyclics was not toxic. 
However, a decrease in proliferation and increase in sub-G1 cells were observed 
after prolonged induction of LAP-A overexpression in parasites growing in minimal 
media suggesting a reduction in parasite fitness when media resources are limiting.  
Overall the results indicate LAP-A cannot be considered as a drug target in T. brucei, 
unlike in P. falciparum, where its potential has been shown (Stack et al., 2007, 
Harbut et al., 2011). However, its role in vivo remains to be established since LAP-A 
might be required for infectivity, survival of the parasite inside the host or the 
crossing of the blood brain barrier. Due to the profound differences in metabolism 
and life cycle stages between the TriTryps, the results obtained with T. brucei brucei 
parasites do not allow to draw conclusions about LAP-A’s potential as drug target in 
T. cruzi and L. major.  
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4.4.2 Physiological function of the LAP-A 
The establishment of LAP-A’s subcellular localisation could aid in the identification 
of the physiological function. Indeed a cytosolic localisation would suggest functions 
distinct from an enzyme that resides in the endoplasmic reticulum. Thus, while in 
the cytosol LAP-A would perform metabolic or housekeeping functions, in the 
endoplasmic reticulum the enzyme could be involved in the post-translational 
modification of N-terminal signal peptides of specific proteins and therefore 
perform a more regulatory role. In the present study the enzyme appears to be 
mainly cytosolic although colocalisation studies with a marker for endoplasmic 
reticulum have not been performed and the latter cannot be excluded. 
Fluorescence microscopy does not give convincing evidence for the presence of the 
enzyme in the nucleus and hence an involvement in site-specific homologous 
recombination, as in E. coli (Gourlay & Colloms, 2004, Paul & Summers, 2004), is 
unlikely.  
T. brucei parasites do not exhibit a clear and specific phenotype upon depletion or 
overexpression of LAP-A, so that the protein’s physiological function remains 
elusive.  
When procyclic T. brucei are exposed to leucine starvation, parental cells stop 
proliferation and enter a short stationary phase before they show DNA 
fragmentation. LAP-A-dKO parasites on the other hand appear to exhibit a growth 
advantage under these conditions and proliferate further entering the stationary 
phase later. This distinct and somewhat surprising growth behaviour might indicate 
a role of LAP-A in the sensing of amino acid levels and its influence in regulation of 
the growth rate. LAP-A’s involvement in these processes is speculative and its 
connection to the growth behaviour remains to be elucidated.  
One possible mode of regulation would be the participation of LAP-A in the 
trimming of N-termini of specific proteins. These modifications may be essential for 
protein function and sensitive to the levels of leucine. This trimming could be 
triggered by the lack of leucine as direct regulator of LAP-A activity or alternatively 
the proteins whose N-termini are modified sense the lack of leucine. Another 
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possibility is a more indirect role of LAP-A in amino acid sensing, related to the 
overall amino acid level inside the cells. A lack of LAP-A as metabolic enzyme could 
lead to an increased level of di- and tri-peptides and overall lower levels of free 
amino acids in the cells. This could induce an increased expression and activation of 
amino acid transporters, which would in turn increase the amino acid uptake from 
the media. This would lead to better growth initially, but ultimately lead to a faster 
depletion of resources in the media and therefore result in cell starvation after a 
shorter period of time.  
 
4.4.3 Potential use of LAP-A-dKO, RNAi and overexpression 
strains 
The T. brucei LAP-A-dKO, -RNAi and overexpressing strains can be used to study the 
physiological function of the LAP-A and other aminopeptidases. They can serve as 
starting strains for the knockout, knock down or overexpression of other enzymes 
involved in amino acid metabolism to gain insight in these complex processes of 
T. brucei, which might give clues about other potential drug targets. 
 
4.4.4 Structure and oligomeric state of LAP-A and their effects on 
possible physiological substrates 
The TriTryp LAP-As form hexamers in solution and also crystallise as hexamers. 
Although it cannot be ruled out that these are artefacts of the buffer conditions 
used to conduct the experiments, homology to other LAPs indicates this oligomeric 
state to be a key features of this family of enzymes. Analysis of the structure shows 
the active sites of each protomer facing towards the inner cavity, sequestered from 
the bulk solvent. Although access channels allow diffusion into the inner cavity and 
the active sites, the accessibility seems restricted to small, unfolded substrates. This 
favours LAP-A’s function as a mainly metabolic enzyme with housekeeping function 
or trimming of the N-termini of specific unfolded peptides. However, the bacterial 
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M17 family LAPs PepA and PepB were shown to cleave the loosely folded protein 
casein in vitro (Bhosale et al., 2010), indicating the LAP’s potential to process larger 
substrates.  
 
4.4.5  The physiological metal ion in the active site of LAP-A 
While early studies on the bovine lens LAP showed Zn2+ to be the physiological 
metal ion in the active site of the M17 family LAPs (Carpenter & Vahl, 1973), the 
enzyme was also active with other divalent metal ions (Kim & Lipscomb, 1993, Kim 
et al., 1993, Jia et al., 2010, Morty & Morehead, 2002, Cadavid-Restrepo et al., 
2011). It was noted before (Kale et al., 2010) that PpLAP produced in E. coli has 
Mn2+ in its active site. It was shown that substrate specificity is influenced by the 
metal identity in the active site (Cappiello et al., 2006), with sulfhydryl-containing 
substrates only being accepted by Mn2+-containing LAPs but not by Zn2+-containing 
ones.  
Within this work, the best crystals of the TriTryp LAP-As grew in the presence of 
Mn2+. Indeed, crystals grown in Zn2+-containing conditions also had Mn2+ in the 
active site. This might implicate Mn2+ to be the physiological metal co-purified with 
the enzyme expressed in E. coli or, but more likely, indicates Mn2+ contamination of 
one or multiple solutions used throughout the process. The high degree of identity 
of the active site residues of the TriTryp LAP-As with those from other characterised 
species, suggests similar characteristics and Zn2+ to be the physiological metal.  
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4.5  Summary and future work  
The structures of the TriTryp LAP-As were solved in different ligand complexes, 
which gives insight into ligand binding and confirm the homology to other family 
members. The parasitological data presented in this thesis show LAP-A not to be 
essential in T. brucei brucei when cultured in vitro. However, LAP-A might still be 
indispensible for infectivity, immune evasion or crossing of the blood brain barrier, 
which remains to be investigated. The experiments in T. brucei do not allow 
conclusions to be drawn about LAP-A’s essentiality in T. cruzi and Leishmania spp.  
LAP-A’s physiological function within T. brucei parasites remains elusive and further 
studies are necessary to confirm its localisation to the cytoplasm and to determine 
whether its function is metabolic or regulative and can be compensated for by the 
presence of its paralogues. In future investigations, kinetic characterisation of the 
peptidase activity would be useful for determining the physiological metal ion and 
substrates, as well as the possible regulation of its function by leucine or other 
amino acids.  Examination of the paralogues LAP-B and LAP-N and their potential to 
compensate for the loss of LAP-A will expand the understanding of amino acid 
metabolism in these parasites and potentially aid identification of novel targets for 
rational drug design. 
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Chapter 5 Summary and Conclusions 
The TriTryps cause a set of devastating diseases, mainly in the developing world.  In 
addition, the poverty of the effected population led to general neglect by the 
pharmaceutical industry. However, in recent years neglected tropical diseases have 
been addressed more extensively.  
The Trypobase project was one of the initiatives aimed to identify lead compounds 
for drug development against the TriTryps using both classical pharmacology with 
phenotypic assays and a target-based drug design approach. The targets included 
TbAK, and the TKs and TMPKs from all three species. In this thesis the structures of 
TbAK, LmTK and TbTK were solved to aid the process of rational drug design. With 
the exception of cordycepin binding to TbAK, no lead compound was identified for 
these targets during the limited time of the Trypobase project. However, the 
structures obtained can aid future drug discovery projects. 
Extensive phenotypic screening of compounds for trypanocidal activity identified a 
compound active against T. cruzi. Initial metabolomic studies investigating the 
possible biological target indicated leucyl aminopeptidase to be effected. Based on 
this hypothesis the LAP-A was added to the target list and in scope of this work, the 
structures of LAP-A from all three species were solved. Later, assays carried out by 
collaborators revealed the lead compound not to act on LAP-A. Hence, within this 
work, LAP-A’s potential as a drug target was evaluated in T. brucei parasites. 
Neither RNAi-mediated LAP-A depletion nor dKO nor LAP-A overexpression were 
lethal to the bloodstream and procyclic form parasites, which does not support LAP-
A as potential drug target. Nevertheless, the parasite strains generated can be used 
to shed light on the complex interactions within amino acid metabolism in T. brucei, 
which might lead to the identification of novel drug targets. The data do not allow 
conclusions about LAP-A’s potential as drug target in T. cruzi and L. major, which 
requires further investigation. 
Taken together, my results highlight the difficulties of classical pharmacology and 
target-based drug design. The classical pharmacology approach identifies 
compounds, whose mechanism of action (MOA) is not known, and identification of 
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the biological targets is challenging with a high risk of false positives. An unknown 
MOA results in difficulties with optimisation of the pharmacokinetic properties and 
reduction of off-target effects, which prolongs the process of drug development 
considerably. The target-based approach on the other hand struggles with 
identification of ligands for known targets. Screening carried out in vitro often does 
not reflect the physiological binding situation and especially weak-binding 
compounds might not be identified as potential candidates. However, crystal 
structures aid the process of compound optimisation by identifying features that 
can be used to increase specificity or to suggest modifications to facilitate 
resistance to degradation by other enzymes, as seen clearly in case of 2-
fluorocordycepin (Vodnala et al., 2013). 
Many drug discovery processes suffer from short funding periods, which do not 
leave much room for adaptations of the strategy after obtaining initial results.   
 
Appendices 
A.1 Expression, purification, and crystallisation of 
thymidylate kinases  
A.1.1 Introduction 
Thymidylate kinases (TMPKs) catalyse the phosphorylation of dTMP to dTDP 
(EC 2.7.4.9) with the preferred phosphate donor being ATP. TMPKs have been 
extensively studied for their ability to phosphorylate cytotoxic nucleoside analogues 
and as potential drug targets, e.g. in P. falciparum, causative agent of malaria 
(Kandeel et al., 2009). Several structures have been solved (Figure A.1-1) and 
discussed with respect to mechanism, substrate specificity and suitability as drug 
target (Whittingham et al., 2010, Choi et al., 2012, Leibly et al., 2011). TMPKs are 
approximately 25 kDa in size and form homodimers in solution. Each subunit 
contains a five-stranded parallel β-sheet surrounded by 7-11 α-helices. Each subunit 
forms its own active site, composed of a so-called critical loop with the DR(Y/H) 
motif, containing the catalytically important aspartic acid and arginine residues 
(Reynes et al., 1996), the P-loop, responsible for binding of the α- and β-phosphates 
of the phosphate donor and their orientation (Saraste et al., 1990) and a LID region, 
a flexible loop which closes upon substrate binding.  
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Figure A.1-1: Structure of P. falciparum TMPK (PfTMPK). 
 (A) PfTMPK (PDB ID: 2wwh, Whittingham et al., 2010) protomer shown in ribbon representation with P-loop 
in lawn green, critical loop in pale crimson and LID region in blue, AP5dT in cylinder representation coloured 
by atom type. (B) PfTMPK dimer shown as ribbon with AP5dT atoms represented as spheres. Figure made 
with CCP4mg (McNicholas et al., 2011). 
 
There are two types of TMPK, distinguished by the presence (type I) or absence 
(type II) of an additional basic residue in the P-loop. Depending on species the 
details of the catalytic mechanism differ slightly, e.g. in movements of P-loop and lid 
during catalysis or orientation of specific side chains to stabilise the transition state. 
The phosphoryltransfer reaction of mouse TMPK and the homologous guanylate 
(GMPK) and adenylate kinases (AMPK) have been determined to be random bi-bi 
mechanisms with both substrates (NMP and phosphate donor) binding 
independently of each other (Cheng & Prusoff, 1973, Li et al., 1996). It has been 
analysed in great detail for the human enzyme using structural data for complexes 
with substrates, products and transition state mimics (Figure A.1-2, Ostermann et 
al., 2000). In brief, upon substrate binding the P-loop, adenosine-binding loop and 
LID region close into their active conformation orienting the substrates (Figure A.1-2 
A). The γ-phosphate is essential for adoption of the active conformations of 
substrates and the active site residues of the TMPK. The correct conformations 
allow the dTMP phosphate, held in place by the catalytic arginine (R97 in human 
TMPK), to make a nucleophilic attack on the γ-phosphate of the phosphate donor 
forming a transition state, looking similar to the dTMP-AlF3-ADP complex in Figure 
A.1-2 B (green). After the reaction is completed the product moves into a 
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conformation unfavourable for the back reaction (Figure A.1-2 C and D). The 
products are released thereafter.  
 
 
Figure A.1-2: Mechanism of human TMPK based on X-ray structures.  
(A) Overlay of TMPK complexes with dTMP-ADP (grey) and dTMP-AppNHp (yellow); (B) dTMP-AppNHp 
(yellow) and dTMP-AlF3-ADP (green); (C) dTMP-AlF3-ADP (green) and Ap5dT (blue); (D) Ap5dT (blue) and dTDP-
ADP (red); more details are given in the text. Figure modified from (Ostermann et al., 2000). 
 
A.1.1.1 TMPKs in drug development 
TMPKs, while playing a crucial role in activation of cytotoxic nucleoside analogues, 
are known to be essential enzymes and therefore potential targets in gram-positive 
bacteria like Staphylococcus aureus (Choi et al., 2012). Additionally, it was shown 
that inhibition of human TMPK improves the efficiency of anticancer drugs like 
doxorubicin (Hu & Chang, 2008). 
 
A.1.1.2 Thymidylate Kinases from the TriTryps 
The TriTryp TMPKs are much bigger than those of other species with masses of 
40.1, 39.5 and 39.4 kDa for L. major, T. brucei and T. cruzi respectively, due to the 
presence of an extra N-terminal domain of unknown function. This domain of 
approximately 130 amino acid residues has no homologues outside the 
kinetoplastida and is predicted to contain 4-5 β-strands and 4 α-helices by the 
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PSIPRED and PHD servers (Buchan et al., 2013, Rost et al., 2004). An alignment of 
TMPK sequences, whose X-ray structures are known, is shown in Figure A.1-3. As 
expected, the catalytically important regions, P-loop and the critical loop, are highly 
conserved among different species. Besides the N-terminal extension, TriTryp 
TMPKs have an additional helix inserted between the critical loop and lid domain. 
To date no kinetic or biophysical data have been published for any kinetoplastid 
TMPK.   
 
Figure A.1-3: Sequence alignment of TMPKs.  
Similar residues highlighted in yellow, identical residues shown in red. Secondary structure was predicted for 
LmTMPK using the PHD server (Rost et al., 2004) and is shown above the sequences with α-helices as spirals 
and β-sheets as dashed lines (confidence of the prediction < 90%) or arrows (confidence >90%). Important 
structural features determined in the PfTMPK structure are highlighted below the sequences: P-loop region 
(green bar), critical loop (red stars) and lid region (blue bar). Figure was made in ESPript 3.0 (Gouet et al., 
2003). 
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A.1.2 Experimental 
A.1.2.1 Cloning and Expression of TMPKs in the baculovirus system 
Previous expression tests of a number of TMPK constructs in E. coli failed to 
produce soluble and stable protein. Therefore, 18 constructs were cloned and 
tested for expression with the baculovirus system at OPPF, Table A.1-1. The SDS-
PAGE analysis of the expression test is shown in Figure A.1-4. 
 
Table A.1-1: TMPK constructs for expression with the baculovirus system. 
Cloning performed in 96 well plate format; “well” gives location in the 96 plate, OPPF number was given for 
identification of the process in the OPPF database. 
Well Gene name Amino acid 
range 
Mr of expected protein 
(+ tag) [Dalton] 
Vector 
pOPIN 
OPPF No. 
G04 TbTMPK 2-345 39383.7 (+2158) F 11350 
H04 TbTMPK 120-345 26180.6 (+2158) F 11353 
A05 TbTMPK 2-345 39383.7 (+1274) I 11348 
B05 TbTMPK 120-345 26180.6 (+1274) I 11351 
C05 TbTMPK 2-345 39383.7 (+969) E 11349 
D05 TbTMPK 120-345 26180.6 (+969) E 11352 
E05 TcTMPK 2-351 39302.1 (+2158) F 11362 
F05 TcTMPK 122-351 26447.1 (+2158) F 11365 
G05 TcTMPK 2-351 39302.1 (+1274) I 11360 
H05 TcTMPK 122-351 26447.1 (+1274) I 11363 
A06 TcTMPK 2-351 39302.1 (+969) E 11361 
B06 TcTMPK 122-351 26447.1 (+969) E 11364 
C06 LmTMPK 2-363 39952.8 (+2158) F 11356 
D06 LmTMPK 131-363 26034.3 (+2158) F 11359 
E06 LmTMPK 2-363 39952.8 (+1274) I 11354 
F06 LmTMPK 131-363 26034.3 (+1274) I 11357 
G06 LmTMPK 2-363 39952.8 (+969) E 11355 
H06 LmTMPK 131-363 26034.3 (+969) E 11358 
 
 239 
 
Figure A.1-4: SDS-PAGE of TMPK expression tests in the baculovirus system. 
First and last lanes are protein standards. Each other lane contains a NiNTA purified expression test sample 
from the baculovirus expression test. Lane labelling corresponds to the well numbers in Table A.1-1. 
Performed by Louise Bird and Joanne Nettleship at OPPF. 
 
 
A.1.2.2 Purification of LmTMPK 
Cells from 1 L Sf9 cultures expressing LmTMPK were resuspended in 40 mL lysis 
buffer (50 mM Tris pH 8.0, 500 mM NaCl, 25 mM imidazole, 1 mM DTT, 1 mM EDTA, 
100 μM PMSF and 25-29 U Benzonase) and lysed by sonication. Cell debris was 
removed by centrifugation (5000 rcf, 30 min, 4°C). The supernatant was loaded 
onto a pre-equilibrated 5 mL HisTrap crude FF column for 1 h in a loop on ice. After 
washing with 10 mL lysis buffer the column was connected to an AKTA FPLC and 
washed with 15 mL lysis buffer. The protein was eluted with an imidazole gradient 
from 25 mM to 500 mM. The protein-containing fractions, identified by SDS-PAGE 
analysis, were pooled and concentrated to ~250 μL in the presence of 1 mM MgCl2, 
1 mM dTMP and 1 mM AppNHp. The stable protein was loaded onto an 
equilibrated Superdex 200 column in SEC buffer (10 mM Tris pH 8.0, 200 mM NaCl, 
1 mM DTT).  After SDS-PAGE analysis the protein-containing fractions were pooled 
and concentrated to 5.2 mg mL-1 in the presence of 1 mM MgCl2, 1 mM dTMP and 
1 mM AppNHp. The protein was aliquoted, flash frozen in liquid nitrogen and stored 
at -80°C. 
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A.1.2.3 Crystallisation of LmTMPK 
The initial screen (JCSG + Index) was carried out in sitting-drop vapour diffusion 
format with 150 nL protein solution mixed with an equal amount of precipitant, 
using a Mosquito robot (TTP Labtech, UK). Additionally, seeding experiments were 
set up as described for TbTK in 3.2.8 using seed stocks prepared from initial hits as 
well as LmTK 11320 crystals for cross-seeding. Crystals grew within two months and 
were optimised in hanging-drop and sitting drop vapour diffusion format with 1 μL 
or 0.5 μL protein solution respectively plus an equal volume of precipitant.  
After mounting and vitrification of optimised LmTMPK crystals, no diffraction was 
obtained. Therefore, the small microcrystals found in the initial screens were tested 
for diffraction in situ at beamline I04-1 of the DLS.  
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A.1.3 Results 
A.1.3.1 Expression, purification and crystallisation 
Expression in Sf9 cells did yield soluble protein for the construct 11357, which 
encodes LmTMPK in which the first 130 amino acids have been deleted (spanning 
amino acids 131-363), fused to an N-terminal non-cleavable Histag. None of the 
other constructs tested produced soluble protein. Purification of LmTMPK 11357 
was successful using nickel affinity and size exclusion chromatography (Figure A.1-5) 
and the protein could be stabilised by addition of dTMP and AppNHp. 
 
 
Figure A.1-5: LmTMPK purification.  
(A) Size exclusion trace (absorption at 280 nm) of LmTK 11357. The black bar indicated the fractions 
containing LmTMPK, identified by SDS-PAGE analysis (B).  
 
The best crystals grew in following conditions: 
- 0.2 M (NH4)2SO4, 0.1 M Bis-Tris pH 5.5, 25 % (w/v) PEG 3350, in sitting drop 
format, with seeding (Figure A.1-6 A). 
- 0.2 M Li2SO4, 0.1 M Bis-Tris pH 5.5, 25 % (w/v) PEG 3350 in sitting drop 
format, with seeding (Figure A.1-6 B). 
- 0.2 M Li2SO4, 0.1 M Bis-Tris pH 5.5, 20 % (w/v) PEG 3350 in hanging drop 
format, (no seeding) (Figure A.1-6 C). 
- 0.2 M Li2SO4, 0.1 M Bis-Tris pH 6.5, 19 % (w/v) PEG 3350 in hanging drop 
format, with seeding (Figure A.1-6 D). 
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LmTMPK formed small bi-pyramidal crystals (Figure A.1-6 A & B) after 2 months. 
After optimisation and seeding experiments the resulting crystals (Figure A.1-6 C & 
D) mounted and vitrified did not diffract. In situ exposure at the I04-1 beamline of 
the DLS revealed the initial crystals (not optimised) also to be non-diffracting. 
 
 
Figure A.1-6: Crystals of LmTMPK.  
(A) Crystals grown after 2 months with seeding in 0.2 M (NH4)2SO4, 0.1 M Bis-Tris pH 5.5, 25 % (w/v) PEG3350, 
black bar ~ 100 μm. (B) Crystals grown after 2 months with seeding in 0.2 M Li2SO4, 0.1 M Bis-Tris pH5.5, 25 % 
(w/v) PEG 3350; black bar ~ 100 μm. (C) Crystals grown in 0.2 M Li2SO4, 0.1 M Bis-Tris pH 5.5, 20% (w/v) PEG 
3350, black bar ~ 50 μm. (D) Crystals grown with seeding in 0.2 M Li2SO4, 0.1 M Bis-Tris pH 6.5, 19% (w/v) PEG 
3350, black bar ~ 50 μm. 
 
A.1.4 Discussion 
Expression and stabilisation of the TriTryp TMPKs turned out to be very difficult. 
With the baculovirus expression system it was possible to obtain soluble and stable 
N-terminally truncated LmTMPK, but all attempts to express full-length LmTMPK or 
any construct of TbTMPK and TcTMPK failed. This truncated LmTMPK was purified 
and stabilised by addition of TMP and AppNHp. Unfortunately, LmTMPK did not 
form diffracting crystals, so that no structural information could be obtained to help 
rational drug design. 
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A.2  Sequences and plasmid maps 
A.2.1 Protein sequences 
The full-length protein sequences from the databases are shown below with the 
amino acid range seen in the crystal structures in bold. 
>TbAK (Tb427.06.2360) 
MSSAPLRVYVQCNPLLDVSAHVSDEFLVKYGLERGTAILLSERQKGIFDDIEKMPNVRYVPGGSGLNV
ARVAQWMQQAYKGKFVTYVGCIADDRYGKVLKEAAEHEGIVMAVEHTTKAGSGACAVCITGKERTLVA
DLGAANHLSSEHMRSPAVVRAMDESRIFYFSGFTLTVDVNHVLQACRKAREVDGLFMINLSAPFIMQF
FSAQLGEVLPYTDIIVANRHEAKEFANMMKWDTDCVEEIARRAVSEVPYTGTKGRVVVFTRDIESTVL
ATKDGVETVPVPQLDQDKVIDMNGAGDAFMGGFLSAYAVGKDLRRCCETGHYTAQEVIQRDGCSFPEK
PSFSP 
 
>LmTK (LmjF.21.1210) 
MFRGRIELIIGPMFAGKTTELMRRVKREIHARRSCFVIKYSKDTRYDEHNVASHDQLMLRAQAAVSQL
TEVRDTWKRFDVLAIDEGQFFSDLVDFCNTAADAGKVVMVSALDGDYRRKPGQICELVPYCEAVDKLT
AVCMMCHEQPACFTRRTVNVEQQELIGGADMYIATCRECYSKQQLPSIEEMRTQRMAIKEVEKRYLGL
SDKRATASPQTPEKPAGGWCTKAGVATLPTMVKEGAASSGASAGMKSGRGLCEMQAFTTETPKYQRVE
PACTASAASSE 
 
>TbTK (Tb427.10.880) 
MHDGDGNIELIIGPMFAGKTTELMRRVQRHKHAQRSCYIINYSRNSYQNQRLSTHDQLSLTANVSIAK
LSEVCDEWRDYDVIAVDNGQFFPDVVGFCARAANEGKTVIVSALDVDCRETPFDEVCRLVPRAESVLK
LSAVCMECHEHDAFLTYRTIESNERELYGGADMYLAVCRWCYKQLTMSHVDAQKTSASTAAVVPNGAH
GRIELIIGPMFAGKTTELMRRVQRHKHAQRSCYIIKYTGDTRYSEGAITSHDQRALTANVSVSNLHDV
GDEWRKYDVIAVDEGQFFPGVAAFCSKAADSGKVVIVSALDADYLQEPFEEICLLVSRADSVVKLSAV
CMECHNRKASFTYRTVKSDERKLVGGSDMYMSVCRSCYETKRNMVQTEKYIYSCVGINEGSYSECSPG
PSERSSAGTSGVQTSVKVDEQNCTEPNTEAKKMPLKRKRNQMAVDTT 
 
>TcTK (TCSILVIO_009141) 
MFASHTSTCTLKLRYAEDQRNFRLAFGFCASSIQQLFADISLQMMLENESHGHIELIIGPMFAGKTTE
LMRRVRRELFAKRSCYVIKHSRDARYSRESVSSHDKLLLGATAAVAELREVGDAWRPFDVVAVDEGQF
FPDIVGFCNTAADAGKTVIVSALDGDYRRQPFDGICRLIPLAESVKKLTAVCMECHCRSASFTYRTVS
SEKRELIGGADMYIAACRTCFVTKSKKRAEMEAKGSVQTVDKCSDTPAAEKQKGEQREVEEDPITPPT
TIAAAETPLSASAARKRPVDVDENVPTDAERCKSKARLECH 
 
 
>LmLAP-A (LmjF.11.0630)  
MSAMKRPRSNSIVEETAVSAYVQTCTNFKSNVTFTDISKVSCVAPHVLLVGALEQLRDNSLKSVLFYC
PAVAEALQRVKAGSTVKTLAEVPGRKGYTEVMVTALPATTSRTNCPYRADSMSEAVAAACGSVEEGEV
LDVYVCAPAGSETAVANAVARAAPHSYTAKAGQATKAYMKQAMSLNVVMSSRAAFTQELVRGKSVCVA
ELEAICTSVQLCQRLVDTPPCMLDTVVYAEIAAAYAAELGVDMTVIKGDELREKGYGGIYAVGKCAQY
PAHLVTLRYRNPNAAEGAKNIAMVGKGVYDCGGLALKPAAHMTNMKTDMGGSAGVFCAFIAVVRSMKM
QRTHFSHIANISVTLCLAENAIGPHSYRNDDVVVMKSGKSVEVMNTDAEGRIVLGDGVYYATGEQDFV
PDVLIDMATLTGAQGVATGSKHAGVYASDAEAEKDMISAGLQSGDLCYPVLYCPEYHEEVYKSPCADM
RNIANSSSSAGSSCGGYFVEQHLSERFRGPFVHVDMAYPTSNTAGATGYGVTLVFEFLRQH 
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>TbLAP-A (Tb427tmp.02.4440)   
MPTLPKAEAKELSAFVQSCVEYKTNVCFTDVAAYESNQKGVLSSGLAVLVGTHKQLRDPAVQRLPFYN
PAVAEAIERVKEGGTYGVLVEGLANAAGSKFVRVVVGEVPTKASRNNCPARPDVVTXLVTAALDEVKE
PNTTVDVFVLSNAVLPIAAAVARCGKHNFSAKDGAAAAAYNSGKVSRLQVVFPEPPAIPPKDLEAVAT
STQLCQRLVDAPPNLLTTATFTEIAQGYAKALGFDVDVICGDDLCERGYGGIYSVGKAAFEAPRLVTL
LYTPKGTPVKKVSLVGKGIVYDCGGLALKPADYMKLMKHDMGGAAAVFCGFLTAVRLQQPVQLSCTLC
LAENAIGPKSYRNDDIIVMKSGKTVEVINTDAEGRIVLGDGVFHATNELSFTPDVVIDMATLTGAQGI
ATGRHHAGLYVNEEGAEAAMLRAGRESGETCFPVLYCPEYHEPEFKSNHADMTNLMERRDNAGVSCAG
YFITTHLSPKFTGAHIHVDLAYPVFNSNGATGFGPALLTEYFRKL 
 
>TcLAP-A (Tc00.1047053508799.240)   
MNRPPATDSGASEFVRSCVNFKTNVEFTDVDAYKKTHTAGLASTFVVILGTHAQLREDALKELPFCPA
VAEAIQRVKKGETYAVLAEGVKNEANERFVRVLVGEVPSEASRTNCSARPDVVVSLLSAALEEIKGPE
TKVDVFVCSTAALAIAVAAARSAKRNFTAKEGLAARGYCDNCVRLTVVFPTAPNPSPSELVVVATSTQ
LCQRLVDAPTNLLNTATFAEVAQSYAKELGCAVDVICGEELRERGYGGIYSVGKCAAEAPRLVTLSYK
PKDETRKKVALVGKGIVYDSGGLSLKPTNFMTGMKRDMGGAAAVFCGFLTAVRLQMPIELSCTLCLAE
NAIGPDAYRNDDILTLKSGKTVEVNNTDAEGRLVLGDGVFHATHEISFKPDVLVDMATLTGAQGIATG
HRHAGIFVNDEEEELSFLKAGRVSGETCFPVLYCPEYHVTEFRSPVADMRNSVKQVNNASVSCAGHFV
ANHLSPDFKGKHIHVDMAFPAFENDKATGFGPALLMEYLRNLR 
 
 
 
 
A.2.2 Nucleotide sequences of TbLAP-A RNAi fragment and UTRs 
for double KO 
TbLAP-A RNAi fragment (reverse complement) 
TACCCAAGGCCGAAGCAAAAGAGCTTTCTGCGTTCGTCCAGTCGTGCGTCGAATACAAAACCAATGTT
TGCTTCACCGATGTCGCCGCCTACGAAAGCAACCAGAAGGGTGTACTGTCCTCAGGACTCGCTGTTCT
TGTTGGAACTCATAAGCAACTCCGTGACCCCGCCGTCCAGCGTTTACCATTTTACAATCCCGCTGTTG
CTGAAGCTATTGAGCGGGTGAAGGAAGGTGGGACGTACGGCGTTTTGGTGGAGGGACTTGCGAATGCG
GCAGGCTCAAAGTTCGTGCGCGTTGTCGTTGGTGAGGTGCCCACGAAGGCATCTCGCAACAACTGCCC
TGCCCGACCGGATGTTGTGACTGCNCTTGTAACTGCTGCATTGGACGAAGTTAAAGAGCCTAATACAA
CGGTGGATGTCTTTGTGCTTTCCAATGCTGTCCTTCCCATCGCTGCTGCTGTAGCACG 
 
 
 
5'-UTR (reverse complement) 
GGGAGGCGGTAATGACAAGTCGCCCGCAGGATGGATAAAATTTACGGGCCAAACAAGTGCTAAATCAG
GAGACAGGTCGTACTTTTATTATTATTATTATTATCATTATCACCCTTACTGCTGTTTTTAATGTTTC
TTTGTCCCTTTCTCTGTTTCTACGCTTCCACTGTTGCGTTGACGGAAGAAATGGGGTAACTTTGTCTT
TGTCTTTTTTTTTTTTTGAAAGGCAAAAAAATTCTTAAACTTGACAGATACCAAGGCTCTCACACCCT
TGATACCAATATGCGGTCACTCCTGCGCCTCTATTTTCTCCTTTTTTTTCTTCTTGCCATGGAAAAGC
AAATCTCGACTTTTTTTTTTGAAAGGAGTACGTTCGAACTTCACCGGTATATCGCCATTGAGTTGCTA
ACAACCGAAGTACATATCAGTTGACAGAAGTGCAATATTTCTTGCTTGGGACTTACGTTAGCAGGAAT
TTGTTAAAAAGGGAGTGTAGCAACAACAATAAGAGATAAGGTGCATAAGGGGACCTGAAGC 
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3'-UTR (reverse complement) 
GGCGTGCAAGTATCGGTTCCCGAATTTGGAAAATCGTTGTAGGGGAAACGAATGTGAATGAAGGGTCT
TGACTGCCCATGTTGGAGATTTCTTCTACATGATTTCCTTAACCTGCTCTCTTGGGGTTTGTGTAGGC
GCGGATTGGGATGAGGTCGTGGAGGAAAAAGGGAGAACACATACACACACACTCATCCACCCACTCAC
AAGGGGAACTGCGGGAAAGGGGAAGGGAAGGAAAATAAATACATGGTGAATTCTTCTTTGTTTTTGAA
AAAAAAATCCGAAAATCATTCGGCTTCCTTTTATTTATTTATGTACTTCCTGCAGTCTTCGTCATCGT
TACTGCTGTCACTTGCTACTGCAGCCGTTGTGGTTGCGGGGTTCATTTATGCCTCTCTAGGTAACCCT
AACGGTCATCGCTATGCCCAGTGTGCGGTGTTTTGTGAGTTTACTCGTTTACTCGCTAC 
 
 
 
A.2.3 Primer sequences 
Constructs of adenosine and thymidine kinases were cloned using the primers listed 
in Table A.2-1. The primer sequences used to clone the pOPIN constructs at OPPF 
are not listed here. Other constructs tested for expression were cloned by Dr. Glyn 
Hemsworth and Cristina Bosch. 
 
Table A.2-1: Primer sequences for the kinases for E. coli expression vectors.  
Name Vector 
backbone 
Sequence 5' --> 3'  
(Restriction enzyme site/overhang for cloning) 
Restriction 
enzyme/ 
Overhang  
TbAK-LIC-F YSBLIC CACCACCACCACATGTCATCCGCTCCTCTGAGG Overhang 
TbAK-3C-F YSBLIC3C CCAGGGACCAGCAATGTCATCCGCTCCTCTGAGG Overhang 
TbAK-Rev YSBLIC, 
YSBLIC3C 
GAGGAGAAGGCGCGTTATCAAGGAGAAAAACTGGGCTTC
TC 
Overhang 
LmTK-F_3C_F S LI  C AGGGACCAGCAATGTTCCGCGGTCGTATAGAGC Overhang 
LmTK-F_3C_R YSBLIC3C GAGGAGAAGGCGCGTTATCACTCTGAGGATGCAGC Overhang 
TcTK-F_3C_F-1 YSBLIC3C CCAGGGACCAGCAATGTTTGCCTCCCACACG Overhang 
TcTK-F_3C_F-2 YSBLIC3C CCAGGGACCAGCAATGCTGGAGAACGAATCG Overhang 
TcTK-F_3C_R YSBLIC3C GAGGAGAAGGCGCGTTATTAGTGACACTCCAGCCG Overhang 
TKs-3C_M_F pMAL-C2 ACTGGAATTCATGGGCAGCAGCCATCAT EcoR1 
LmTK-F_M_R pMAL-C2 CAGTGTCGACTCACTCTGAGGATGCAGC Sal1 
LmTK-dC_M_R pMAL-C2 CAGTGTCGACTCACTTCGAGTAGCACTCGC Sal1 
TbTK-F_M_R pMAL-C2 CAGTGTCGACCTAAGTAGTATCAACGGCC Sal1 
TcTK_M_R pMAL-C2 CAGTGTCGACTTAGTGACACTCCAGCCG Sal1 
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Primer sequences used to clone the TriTryp LAP-A constructs and the vectors used 
for T. brucei parasitology are listed in Table A.2-2. 
 
Table A.2-2: Primer sequences for the TriTryp LAP-As. 
Name Vector 
backbone 
Sequence 5' --> 3'  
(Restriction enzyme site/overhang for cloning) 
Restriction 
enzyme/ 
Overhang  
Overexpression in E. coli: 
TbLAP_3Cfor YSBLIC3C CCAGGGACCAGCAATGCCTACTTTACCCAAGGCC Overhang 
TbLAP_3Crev YSBLIC3C GAGGAGAAGGCGCGTTACTACAATTTTCGGAAGTACTCGG Overhang 
TcLAP_3Cfor YSBLIC3C CCAGGGACCAGCAATGAACAGACCTCCTGCTACAGATTCA
GG 
Overhang 
TcLAP_3Crev YSBLIC3C AGGAGAAGGCGCGTTATTATCGTAAATTACGAAGATATT
CCGTCAGC 
Overhang 
LmLAP_3Cfor YSBLIC3C AGGGACCAGCAATGTCCGCGATGAAGCGCCCG Overhang 
LmLAP_3Crev YSBLIC3C GAGGAGAAGGCGCGTTACTAGTGCTGGCGCAGAAACTCG
AAC 
Overhang 
Parasitology: 
ECCFor pGRV23 GCCATATGATGCCTACTTTACCCAAGGCC Nde1 
ECCRev pGRV23 GCGGATCCCTACAATTTTCGGAAGTACTCGG BamH1 
cmycFor pGRV33 GCCATATGATGCCTACTTTACCCAAGGCC Nde1 
cmycRev pGRV33 GCGTTAACCTACAATTTTCGGAAGTACTCGG Hpa1 
RNAiFor pGR19 GCGGATCCAAGCTTTACCCAAGGCCGAAGCAAAA BamH1, 
HindIII RNAiRev pGR19 GCGTTAACGGGCCCCGTGCTACAGCAGCAGCGAT pa1, Apa1  
5UTRFor pHD887 CGCGGCCGCGGGAGGCGGTAATGACAAGTC Not1 
5UTRRev pHD887 GCCTCGAGGCTTCAGGTCCCCTTATGCAC Xho1 
3UTRFor pHD887 GCAGGCCTGGCGTGCAAGTATCGGTTCCC Stu1 
3UTRRev pHD887 GGCTAGCGCGGCCGCGTAGCGAGTAAACGAGTAAACTCAC Nhe1, Not1 
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A.2.3 List of constructs 
Table A.2-3: List of constructs for protein production. 
OE-Ec = overexpression in E. coli, OE-Bv = overexpression with the baculovirus system. Constructs marked 
with an asterisk (*) were cloned by Dr. Glyn Hemsworth, constructs marked with two asterisks (**) were 
cloned by Cristina Bosch. 
Name 
 
Protein Amino acid range Vector backbone Application 
Adenosine kinase (Chapter 2) 
TbAK-LIC TbAK 2-345 YSBLIC OE-Ec 
TbAK-3C TbAK 2-345 YSBLIC3C OE-Ec 
Thymidine kinases (Chapter 3) 
LmTK-F_3C LmTK 2-284 YSBLIC3C OE-Ec 
TcTK-A_3C TcTK 2-313 YSBLIC3C OE-Ec 
TcTK-B_3C TcTK 45-313 YSBLIC3C OE-Ec 
LmTK-F_M LmTK 2-284 pMAL-C2 OE-Ec 
LmTK-dC_M LmTK 2-178 pMAL-C2 OE-Ec 
TbTK-F_M TbTK 2-455 pMAL-C2 OE-Ec 
TcTK_M TcTK 45-313 pMAL-C2 OE-Ec 
LmTK-F_28** LmTK 2-284 pET28 OE-Ec 
LmTKdC_3C* LmTK 2-178 YSBLIC3C OE-Ec 
LmTKdC_LIC* LmTK 2-178 YSBLIC OE-Ec 
TbTK-F_3C* TbTK 2-455 YSBLIC3C OE-Ec 
TbTK-F_LIC* TbTK 2-455 YSBLIC OE-Ec 
TbTKdC_3C* TbTK 2-382 YSBLIC3C OE-Ec 
TbTKdC_LIC* TbTK 2-382 YSBLIC OE-Ec 
TbTK-D1_3C* TbTK 2-179 YSBLIC3C OE-Ec 
TbTK-D1_LIC* TbTK 2-179 YSBLIC OE-Ec 
TbTK-D2_3C* TbTK 198-382 YSBLIC3C OE-Ec 
TbTK-D2_LIC* TbTK 198-382 YSBLIC OE-Ec 
TcTK-A_28** TcTK 2-313 pET28 OE-Ec 
TcTK-TdC_3C* TcTK 87-225 YSBLIC3C OE-Ec 
TcTK-TdC_LIC* TcTK 87-225 YSBLIC OE-Ec 
Leucyl aminopeptidases (Chapter 4) 
TbLAP_LIC TbLAP-A 2-521 YSBLIC OE-Ec 
TbLAP_3C TbLAP-A 2-521 YSBLIC3C OE-Ec 
TcLAP_3C TcLAP-A 2-520 YSBLIC3C OE-Ec 
LmLAP_3C LmLAP-A 2-538 YSBLIC3C OE-Ec 
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Table A.2-4: List of constructs for protein production, continued. 
OE-Bv = overexpression with the baculovirus system. 
Name 
 
Protein Amino acid range Vector backbone Application 
Thymidine kinases (Chapter 3) 
11318 LmTK 2-284 pOPIN-E OE-Bv 
11319 LmTK 2-185 pOPIN-E OE-Bv 
11320 LmTK 2-185 pOPIN-F OE-Bv 
11435 TcTK 2-313 pOPIN-F OE-Bv 
11438 TcTK 2-228 pOPIN-F OE-Bv 
11441 TcTK 45-313 pOPIN-F OE-Bv 
11444 TcTK 45-228 pOPIN-F OE-Bv 
11433 TcTK 2-313 pOPIN-I OE-Bv 
11436 TcTK 2-228 pOPIN-I OE-Bv 
11439 TcTK 45-313 pOPIN-I OE-Bv 
11442 TcTK 45-228 pOPIN-I OE-Bv 
11434 TcTK 2-313 pOPIN-E OE-Bv 
11437 TcTK 2-228 pOPIN-E OE-Bv 
11440 TcTK 45-313 pOPIN-E OE-Bv 
11443 TcTK 45-228 pOPIN-E OE-Bv 
11335 TbTK 2-455 pOPIN-F OE-Bv 
11338 TbTK 2-382 pOPIN-F OE-Bv 
11341 TbTK 2-180 pOPIN-F OE-Bv 
11344 TbTK 198-455 pOPIN-F OE-Bv 
11347 TbTK 198-382 pOPIN-F OE-Bv 
11333 TbTK 2-455 pOPIN-I OE-Bv 
11336 TbTK 2-382 pOPIN-I OE-Bv 
11339 TbTK 2-180 pOPIN-I OE-Bv 
11342 TbTK 198-455 pOPIN-I OE-Bv 
11345 TbTK 198-382 pOPIN-I OE-Bv 
11334 TbTK 2-455 pOPIN-E OE-Bv 
11337 TbTK 2-382 pOPIN-E OE-Bv 
11340 TbTK 2-180 pOPIN-E OE-Bv 
11343 TbTK 198-455 pOPIN-E OE-Bv 
11346 TbTK 198-382 pOPIN-E OE-Bv 
Thymidylate kinases (Appendix A1) 
11350 TbTMPK 2-345 pOPIN-F OE-Bv 
11353 TbTMPK 120-345 pOPIN-F OE-Bv 
11348 TbTMPK 2-345 pOPIN-I OE-Bv 
11351 TbTMPK 120-345 pOPIN-I OE-Bv 
11349 TbTMPK 2-345 pOPIN-E OE-Bv 
11352 TbTMPK 120-345 pOPIN-E OE-Bv 
11362 TcTMPK 2-351 pOPIN-F OE-Bv 
11365 TcTMPK 122-351 pOPIN-F OE-Bv 
11360 TcTMPK 2-351 pOPIN-I OE-Bv 
11363 TcTMPK 122-351 pOPIN-I OE-Bv 
11361 TcTMPK 2-351 pOPIN-E OE-Bv 
11364 TcTMPK 122-351 pOPIN-E OE-Bv 
11356 LmTMPK 2-363 pOPIN-F OE-Bv 
11359 LmTMPK 131-363 pOPIN-F OE-Bv 
11354 LmTMPK 2-363 pOPIN-I OE-Bv 
11357 LmTMPK 131-363 pOPIN-I OE-Bv 
11355 LmTMPK 2-363 pOPIN-E OE-Bv 
11358 LmTMPK 131-363 pOPIN-E OE-Bv 
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Table A.2-5: List of constructs for parasitological work. 
KO = knockout in T.  brucei, RNAi = RNA interfecerence in T. brucei, OE-Tb = overexpression in T. brucei, OE-
myc-Tb = overexpression of cMyc-tagged protein in T. brucei. 
Name 
 
Protein Amino acid/ base 
pair range 
Vector backbone Application 
Leucyl aminopeptidase (Chapter 4) 
ECC TbLAP-A 2-521 pGRV23 OE-Tb 
cmyc TbLAP-A 2-521 pGRV33 OE-myc-Tb 
RNAi (TbLAP-A) bp 10-475 pGR19 RNAi 
5UTR - bp -598 - -62 pHD887B KO 
3UTR - bp +7 - +473 pHD887H KO2 
 
A.2.4 Plasmid maps 
A.2.4.1 YSBLIC and YSBLIC3C 
For overexpression in E. coli the sequences of the proteins of interest (POI) were 
cloned into YSBLIC and YSBLIC3C vectors between the LIC-for and LIC-rev sites.  
 
Figure A.2-1: Plasmid map of YSBLIC3C vector. 
This and all subsequent plasmid maps were drawn using Serial cloner (version 2.6.1, from RealBasic). KanR = 
Kanamycin resistance.  
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A.2.4.2 pOPIN-I, -E and –F 
The pOPIN vectors (plasmids for OPPF In-fusion, (Berrow et al., 2007) are ampicillin 
resistant plasmids with identical backbones, their only differences being the 
different tags fused t the protein of interest (POI). The three pOPIN vectors used for 
thymidine kinase baculovirus generation are shown below.  
 
 
Figure A.2-2: Plasmid map (linearised) of the pOPIN vector family. 
The three pOPIN vectors used for the thymidine and thymidylate kinases were pOIPNF, pOPINI and pOPINE. 
AmpR= Ampicillin resistance. 
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A.2.4.3 pGRV23b-TbLAP-A and pGRV33b-TbLAP-A 
The vectors pGRV23b-TbLAP-A and pGRV33-TbLAP-A for overexpression of LAP-A 
and cMyc-tagged LAP-A in T. brucei parasites are very similar to each other. The 
major difference is the presence of the cMyc-tag fused to the C-terminal end of 
TbLAP-A in pGRV33-TbLAP-A (missing in pGRV23b-TbLAP-A).  
 
 
Figure A.2-3: Plasmid map of pGRV23b-TbLAP-A. 
AmpR= Ampicillin resistance. PuromycinR = puromycin resistance. 
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A.2.4.4 pGR19-TbLAP 
The vector for LAP-A RNAi in T. brucei parasites encodes the same TbLAP-A 
fragment in opposite orientation, separated by a DNA linker.  
 
 
Figure A.2-4: Plasmid map of pGR19-TbLAP-A-RNAi.  
The RNAi fragment was cloned into the vector in two different orientations, indicated by the red arrows. 
HygroR = hygromycin resistance marker, AmpR= Ampicillin resistance. 
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A.2.4.5 pH887B/UTRs and pH887H/UTRs 
For generation of LAP-A double knockouts in T. brucei parasites.  
 
Figure A.2-5: Plasmid map of pHD887B-TbLAP-A-UTRs. 
AmpR= Ampicillin resistance, the BSD cassette facilitated blasticidin resistance. 
 
 
Figure A.2-6: Plasmid map of pHD887H-TbLAP-A-UTRs. 
AmpR= Ampicillin resistance, HygroR = hygromycin resistance marker. 
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A.3 Media composition for T. brucei parasite cultures 
Table A.3-1: Media composition.  
MEM = minimal essential media, MEM –Leu = MEM without leucine, MEM –neaa = MEM without the “Non-
essential amino acids”. In this and the following table: *Compounds added in form of “Non-essential amino 
acids” (100x, Sigma M7145). ** Compounds added in form of “MEM Vitamins” (100x, Sigma M6895). 
Concentrations are given in mg L
-1
 unless stated otherwise. 
 HMI-9 SDM-79 MEM MEM -Leu MEM -neaa 
Salts, etc.      
HEPES 5960 8000 714 714 714 
MOPS - 5000 - - - 
CaCl2  2H2O 165 180 301 301 301 
Fe(NO3)3  H2O - 0.14 - - - 
KCl 330 360 402 402 402 
KH2PO4 - - 2** 2** 2** 
KNO3 0.076 - - - - 
MgSO4 98 - - - - 
MgSO4  7H2O - 180 200 200 200 
NaCl 4500 6120 760 760 760 
NaHCO3 3020 2000 - - - 
Na2HPO4  H2O - - 12** 12** 12** 
NaH2PO4  H2O 125 126 211 211 211 
Na2SeO3  5H2O 0.017 - - - - 
Mercaptoethnol 15 - - - - 
Bathocuproline disulfonate 
 Na2 
28 - - - - 
Amino acids      
DL-Alanine 25 200 9* 9* - 
L-Arginine  HCl 84 215  126 126 126 
L-Asparagine 25 8 15* 15* - 
L-Aspartic acid 30 14 13* 13* - 
L-Cysteine 182 0.02 - - - 
L-Cystine 91 29 24 24 24 
L-Glutamine 584 320  292 292 292 
L-Glutamic acid 75 24 15* 15* - 
Glycine 30 15 8* 8* - 
L-Histidine  HCl  H2O 42 38 42 42 42 
Hydroxyproline - 2 - - - 
L-Isoleucine 105 46 52 52 52 
L-Leucine 105 54 26 - 26 
L-Lysine  HCl 146 72 73 73 73 
DL-Methionine 30 85  16 16 16 
L-Phenylalanine 66 111  100 100 100 
L-Proline 40 615   612* 612* 600 
DL-Serine 42 71  11* 11* - 
Taurine - 160  - - - 
DL-Threonine 95 394  48 48 48 
L-Tryptophan 16 10 10 10 10 
L-Tyrosine 104 150  100 100 100 
L-Valine 94 42 47 47 47 
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Table A.3-2: Media composition continued. 
*** Dialysed FBS was replaced by non-dialysed FBS for the standard culture media HMI-9 and SDM-79 used 
initially and the MEM for the stepwise adaptation to glucose-free MEM.  
 HMI-9 SDM-79 MEM MEM -Leu MEM -neaa 
Vitamins etc.      
p-aminobenzoic acid - 2.01 - - - 
Ascorbic acid - 0.01 - - - 
DL-alpha-tocopherol-
Na2PO4 
- 0.002 
- - - 
Vitamin B-12 0.013 - - - - 
Biotin 0.013 0.2 - - - 
Choline chloride 4 0.8 1.0** 1.0** 1.0** 
Calciferol  0.02 - - - 
D-Pantothenic Acid ½Ca 4 0.7 1.0** 1.0** 1.0** 
Folic acid 4 4.7 1.0** 1.0** 1.0** 
L-glutathione (reduced) - 0.01 - - - 
Menadione - 0.002 - - - 
myo-Inositol 7.2 1.41 2.0** 2.0** 2.0** 
Niacine - 0.005 - - - 
Niacinamide 4 0.705 1.0** 1.0** 1.0** 
Pyridoxal  HCl 4 0.705 1.0** 1.0** 1.0** 
Pyridoxine  HCl - 0.005 - - - 
Riboflavin 0.4 0.072 0.1** 0.1** 0.1** 
Thiamine  HCl 4 0.702 1.0** 1.0** 1.0** 
Vitamin A acetate - 0.028 - - - 
Other compounds      
Sodium acetate - 10 - - - 
Pyruvate  Na 114 100 - - - 
Adenine  2 - - - 
Adenosine  10 12.22 12.22 12.22 
AMP  H2O  0.04 - - - 
ATP Na2  2H2O  0.2 - - - 
Guanine HCl  2H2O  0.06 - - - 
Guanosine  10 - - - 
Hypoxanthine 136 0.06 - - - 
Ornithine  HCl   10.00 10.00 10.00 
Thymine  0.06 - - - 
Uracil 10 0.06 - - - 
Cytosine 10  - - - 
Xanthine Na  0.06 - - - 
Cholesterol  0.04 - - - 
Tween 80  4 - - - 
Phenol red Na 15 11 10.00 10.00 10.00 
Glucose 4500 1000 - - - 
Glucosamine  HCl - 50 - - - 
D-ribose - 0.1 - - - 
Deoxy-D-ribose - 0.1 - - - 
Haemin [μg mL
-1
] - 7.5 7.5 7.5 7.5 
FBS (non-dialysed) - - 1 % 1 % 1 % 
dialysed FBS*** 10 % 10 % 9 % 9 % 9 % 
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Table A.3-3: Composition of “Non-essential amino acids”. 
(100x, Sigma M7145), in g L
-1
. 
L-Alanine (free base) 0.89 
L-Asparagine (free base) 1.5 
L-Aspartic acid (anhyd.) 1.33 
L-Glutamic acid 1.47 
Glycine 0.75 
L-Proline 1.15 
L-Serine 1.05 
 
Table A.3-4: Composition of “MEM Vitamins”  
(100x, Sigma M6895), in g L
-1
. 
Choline chloride 0.1 
Folic acid 0.1 
Myo-Inositol 0.2 
Niacinamide 0.1 
D-Pantothenic Acid ½Ca 0.1 
Pyridoxal  HCl 0.1 
Riboflavin 0.01 
Thiamine  HCl 0.1 
KCl 0.2 
KH2PO4 0.2 
NaCl 8.0 
Na2HPO4 1.15 
 
HMI-9 and SDM-79 media were obtained from the central facilities of the Instituto 
de Parasitologia y Biomedicina “Lopez-Neyra”, Granada, Spain. The MEM media 
were prepared manually. 
List of Abbreviations 
aa  Amino acid residue 
AcMNPV Autographa californica multiple nuclear polyhydrosis virus 
ADA  Adenosine deaminase 
Ado  Adenosine 
ADP  Adenosine diphophate 
AK  Adenosine kinase 
AMC  4-methyl-7-coumarinylamide/7-amido-4-methylcoumarin 
AMPK  Adenylate kinase 
AppNHp β,γ-imidoadenosine 5’-triphosphate 
AP5A  Adenosine (5’) pentaphospho (5’) adenosine 
AP4dT    P1-(5'-adenosyl)-P5-(5'-thymidyl) tetraphosphate  
AP5dT  P1-(5'-adenosyl)-P5-(5'-thymidyl) pentaphosphate 
ATP  Adenosine tryphosphate 
AU  Asymmetric unit 
AZT  3’-azido-3’deoxythymidine 
BB2  Actinonin  
BES  Bestatin 
BF  Bloodstream form (T. brucei) 
BME   β-mercapto-ethanol 
bp  Base pairs 
BSD  Gene for blasticidin deaminase 
CIT  Citrate 
CL  Cutaneous Leishmaniasis 
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CNS  Central nervous system 
Cyt  Cytosine 
Da  Dalton 
dAdo  Deoxyadenosine 
DAPI  4’,6-diamidino-2-phenylindole 
dC  Deoxycytosine 
dG  Deoxyguanosine 
dIno  Deoxyinosine 
DLS  Dynamic light scattering or Diamond light source 
dKO  Double knockout 
DNA  Deoxyribonucleic acid 
dNTP  Deoxyribonucleotide triphosphate 
Dox  Doxycycline 
dThd  Thymidine 
dTMP  Thymidine monophosphate 
DTT  Dithiothreitol  
dTTP  Thymidine triphosphate 
DTU  Discrete typing units 
dUrd  Deoxyuridine 
dUTPase Deoxyuridine triphosphate nucleotidohydrolase 
ECC  Ectopic copy control 
EDTA  Ethylenediaminetetraacetic acid 
ER  Endoplasmic reticulum 
ESI-MS  Electrospray ionisation mass spectrometry 
FBS  Foetal bovine serum 
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Guo  Guanosine 
HAT  Human African trypanosomiasis 
HRP  Horseradish peroxidase 
HygroR Hygromycin resistance protein 
ICCB  Intensity correlation coefficient-based 
IPTG  Isopropyl thio-β-D-galactoside 
KRM  4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine 
LAP  Leucyl aminopeptidase 
LB  Luria-Bertani media 
LIC  Ligation-independent cloning 
Lm  Leishmania major 
MCL  Mucocutaneous Leishmaniasis 
MEM  Minimal essential media 
MOA  Mechanism of action 
MPD  2-Methyl-2,4-pentanediol 
MW  Molecular weight 
NCS  Non-crystallographic symmetry 
NTDs  Neglected tropical diseases 
OE  Overexpression 
OPPF  Oxford protein production facility 
ORF  Open reading frame 
PBS  Phosphate buffered saline 
PDB  Protein data bank 
PEG  Polyethylene glycol 
PF   Procyclic form (T. brucei) 
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pI  Isoelectric point 
PKDL  Post-kala-azar dermal leishmaniasis 
PMSF   Phenylmethanesulfonylfluoride 
POI  Protein of interest 
rcf  Relative centrifugal force 
RMSD  Root mean square deviation 
RNA  Ribonucleic acid 
RNAi  RNA interference 
rpm  Revolutions per minute 
SDS-PAGE Sodium dodecylsulfate polyacrylamide gel electrophoresis 
SEC-MALLS  Size exclusion chromatography multi angle laser light scattering 
sKO  Single knockout 
SMT  Sterol C-24-methyltransferase 
SSM  Secondary structure matching 
Tb  Trypanosoma brucei 
Tc  Trypanosoma cruzi 
TMPK  Thymidylate kinase 
TK  Thymidine kinase 
TriTryps The three trypanosomatids T. brucei, T. cruzi and Leishmania spp. 
Urd  Uridine 
UTR  Un-translated region (upstream (5’) and downstream (3’) of a gene) 
VAT  Variant antigenic type 
VL  Visceral Leishmaniasis 
VSG  Variable surface glycoprotein 
WHO  World Health Organisation 
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